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CHAPTER 1 
1.1 Background 
 
Since the first case report of syncope during initiation of quinidine therapy in the 
1920s 1 until the most recent reports of drug withdrawals, drug-induced arrhythmias 
have been high on the agenda of the pharmaceutical industry, regulatory agencies, 
healthcare professionals, and patients. Up until today, 14 drugs have been 
withdrawn from the market due to this deleterious side-effect (Table 1). In 1997,    
a pivotal case report 2 triggered public awareness regarding the risks associated with 
drug-induced arrhythmia. In this publication, a 59 year-old man, who was otherwise 
healthy presented to the emergency department after complaining of dizziness and 
shortness of breath whilst playing handball. When the patient’s electrocardiogram 
was recorded, episodes of ‘torsades de pointes’ (TdP) were found to underlie his 
symptoms. The patient had been taking the antihistamine, terfenadine, the previous 
day for nasal congestion due to hay fever. During clinical evaluation, the possibilities 
that the arrhythmia were caused by liver disease, ischemia, myocardial infarction or 
electrolyte imbalances were ruled out, and it was considered likely that terfenadine, 
a drug available without prescription and taken without concomitant other drugs, 
was the likely trigger for the arrhythmia. In early 1998, terfenadine was withdrawn 
from the market due to its potential to lead to TdP-type arrhythmias.   
 
Terfenadine was not the first marketed drug to be withdrawn due to cardiovascular 
safety concerns (see Table 1), but its story has become extremely important        
for drug development. It illustrated that compounds with even small risks of very 
serious side-effects, such as drug-induced TdP, could upset the risk-benefit balance 
of any new chemical entity. Recent work has discussed the possibilities that 
terfenadine-induced dysrhythmias may be due to its ability to cause ventricular 
fibrillation rather than TdP 3. 
 
Safety pharmacology studies play a significant role in guiding the pharmaceutical 
industry in preventing unsafe agents, such as terfenadine, to reach the patient 
population. In addition, this discipline is involved in providing valuable insights into 
the mechanisms of potential adverse effects of drug candidates. Although the term 
‘safety pharmacology’ was used prior to the inception of the ICH S7A document in 
2001, where the core battery studies of safety pharmacology are described, it was  
in this document that the term was defined. These guidelines provide a basis for the 
preclinical safety studies, in three major areas (cardiovascular, respiratory and      
the central nervous system), that need to be performed before a new chemical entity 
can be tested in human studies.   
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Table 1 
Drug 
Year of 
Introduction 
Therapeutic Area 
Year of 
Withdrawal 
    
Prenylamine 1960s Antianginal 1988 
Lidoflazine # 1979 Antianginal 1989 
Terodiline 1986 Antianginal / Urinary incontinence 1991 
Terfenadine 1982 Antihistamine 1998 
Sertindole * 1996 Antipsychotic 1998 
Astemizole 1986 Antihistamine 1999 
Grepafloxacin 1997 Antibiotic 1999 
Cisapride 1988 Gastric prokinetic 2000 
Droperidol 1960s Tranquillizer / Analgesic 2001 
Levacetylmethadol 1997 Methadone substitution 2001 
Dofetilide # 1999 Class-III antiarrhythmic drug for 
atrial fibrillation 
2003 
Thioridazine 1960s Antipsychotic 2005 
Clobutinol 1960s Antitussive 2007 
Dextropropoxyphene ** 1960s Opioid analgesic 2009 
 
* Re-introduced later following re-evaluation of risk–benefit; ** In addition to QT-liability, 
safety in overdose was also an issue. # Withdrawn by the sponsor for commercial reasons, 
European market. 
 
Table 1: Drugs withdrawn from the major markets of the world as a result of their potential 
for QT prolongation and/or TdP (Courtesy of Dr Rashmi R Shah 4). 
 
 
Drug attrition rates remain high, and this is one of the major reasons why the costs 
of drug development are astronomical. The major reasons for drug attrition are 
illustrated in Figure 1 as was initially shown in a study of Kola and Landis 5.  Whilst 
efficacy of compounds at drug targets has increased over the years, as have 
pharmacokinetic and bioavailability issues, attrition due to safety is actually becoming 
more of an issue. Therefore, a large unmet need clearly exists for the improvement 
of these safety issues at the early phases of the drug discovery process. 
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Figure 1: Reasons for drug attrition in 1991 and 2000. PK, Pharmacokinetics. Modified from 
Kola and Landis, 2004. Over the 10-year period safety, both non-clinical toxicology and 
clinical, remain a major cause of drug attrition accounting for approximately 30% of all drug 
discontinuation (Adapted from Laverty et al.; 2011) 6. 
 
From the three major areas that are studied under the auspices of the ICH S7A 
guidelines, cardiovascular risk, and particularly arrhythmogenic risk, remains one    
of the major reasons for halting of preclinical programs as well as withdrawal of 
compounds from the market. Figure 2 illustrates the prevalence and occurrence    
of safety liabilities relating to the major organ systems at all stages of the drug 
development process. Interestingly, the only stage of this process where 
cardiovascular events are not the major cause of attrition is during phase 1,      
where healthy subjects are exposed to the new chemical entity. One of the major 
reasons for this could be the fact that cardiac side-effects are more likely to show up 
in diseased hearts that have undergone remodelling, e.g., due to pressure or volume 
overload. Patients showing these characteristics are more likely to show up later on 
in the drug development process, and ultimately may be the desired target 
population. This underscores the importance of screening compounds for cardiac 
side-effects in disease models (see section 1.3). Figure 3 shows the major adverse 
events in the cardiovascular field that have been reported to the Food and Drug 
Administration (FDA) since 1969. Although the incidence of arrhythmia may be 
relatively high due to increased scrutiny of drug-induced arrhythmias over the last 
decade, these data illustrate the importance of arrhythmia as an unwanted 
cardiovascular side-effect. In addition, according to the data of Shah (2006) 7, QT 
prolongation was the reason for about one-third of all drug withdrawals between 
1990 and 2006. Despite the fact that prolongation of the QT interval in itself is not a 
safety issue, it is currently the most widely used risk marker for TdP arrhythmias.   
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Figure 2: Prevalence of safety liabilities relating to the major organ systems. At nearly all 
stages of drug development, cardiovascular liability causes the highest risk of safety issues 
(From Redfern et al.; 2010) 8. 
In 2005, the ICH introduced an additional guideline, ICH S7B, specifically addressing 
the issues of non-clinical evaluation of human pharmaceuticals on ventricular 
repolarization. In this guideline various recommendations were made, including an 
in-vitro screen to evaluate the effects of the compound on the rapid component of 
the delayed rectifier potassium current (IKr) besides an in-vivo QT study. Later that 
same year, the clinical counterpart to ICH S7B, ICH E14, was also introduced.  This 
guideline advocates the use of a thorough QT study in a randomized, double-blinded 
manner in healthy volunteers for all new chemical entities. 
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Figure 3: Cumulative cardiac adverse events (AEs) reported to the US Food and Drug 
Administration (FDA) Adverse Event Reporting System (AERS) since 1969. Cardiac 
arrhythmias remain the most reported adverse effect in the cardiovascular field (From Laverty 
et al.; 2011) 5. 
The limitations of these guidelines are widely recognized. Among these, QT 
prolongation per se does not necessarily lead to arrhythmias 9, 10 (see section 1.3). 
Moreover, arrhythmia initiation is not a static process and many factors interact, 
some of which remain unknown to date. With regard to the IKr channel, when          
a compound blocks this channel, the same compound may not cause TdP in vivo. 
Thus, it is very likely that efficacious compounds are discarded early in the drug-
development process due to inhibitory effects on IKr, whereas simultaneous actions 
on other ion channels or proteins may offset the IKr effects, rendering the 
compounds safe for in-vivo use. Alternatively, there are examples of compounds that 
may cause arrhythmias without having major effects on IKr (e.g., JNJ303 11), and 
compounds that can increase repolarization duration while having minimal effects on 
IKr (e.g., alfusozin 12).  
 
As attrition rates and cardiac side-effects remain relatively high, there is a pressing 
need for better understanding of the mechanisms involved in TdP. Once these 
mechanisms are uncovered, this will allow for better prediction (via more predictive 
(surrogate) markers) and prevention (via novel targets) of this arrhythmia. 
 
1.2 The Ventricular Action Potential and Arrhythmogenesis 
To understand the mechanisms of arrhythmogenesis, it is important to comprehend 
the complexity of the normal electrical activity of the heart and single cardiac cells. 
Each normal heart beat is initiated by an electrical impulse that originates in special 
pacemaker cells in the sinus node. From here, electrical activity spreads via the atria 
and conduction system, ultimately activating the ventricular myocytes.  
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Activation of these cells leads to an action potential configuration as shown in 
Figure 4. Since the first recordings of action potentials in canine Purkinje fibres      
in the 1950’s by Draper and Weidmann 13, we have come to understand the ionic 
basis of the cardiac action potential in great detail. The ventricular action potential is 
made up of complex interactions between both inward and outward ion movements 
across the membrane of myocytes causing both depolarization and repolarization. In 
phase 0 there is an inward movement of sodium ions (INa), which leads to rapid 
depolarization of the cell. During phase 1 rapid repolarization occurs via the transient 
outward potassium current (ITO). In some species, calcium-activated chloride current 
(ICl(Ca)) also contributes. Following this, there is a tightly controlled balance of both 
inward and outward currents that determines the duration of the plateau phase of 
the action potential (phase 2). During this time period, the outward currents are 
carried by a number of potassium channels, including the rapid and slow delayed 
rectifier currents (IKr and IKs, respectively) and the sodium-potassium pump (INaK). 
Inward current is mainly carried through the L-type calcium channel (ICaL) and 
(depending on the membrane potential and local sodium and calcium concentrations) 
on the sodium-calcium exchanger (INaCa). It is the entry of calcium during this      
time frame that causes activation of the ryanodine receptors and release of calcium 
from the sarcoplasmic reticulum (SR). This process of calcium-induced calcium 
release is essential for excitation-contraction coupling and enables each action 
potential to be transduced into a mechanical event, allowing blood to be pumped 
around the body 14. 
 
Following on from the plateau phase, inactivation of the calcium channels combined 
with increases in the outward potassium current lead to terminal repolarization 
(phase 3). Finally, outward potassium and pump currents are responsible for the 
maintenance of the resting membrane potential (phase 4).  
 
As it can be seen from Figure 4, there are species differences in the morphology of 
these action potentials. For example, IKs is much larger in guinea pigs when 
compared to canine or human cells and ICl(Ca) does not seem to play a role in phase-1 
repolarization in human or guinea-pig cells. However, the general principles remain 
the same for the three species shown. This is not the case in rat and mouse, where 
the action potentials are of very short duration due to the fact that the major 
repolarizing current is ITO. For this reason, it is not recommended that these     
species are used for the assessment of compounds on action-potential properties in 
safety-pharmacology studies. 
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Figure 4: Representation of the inward and outward currents that contribute to the 
ventricular action potential in 3 different species. In addition, the cytoplasmic calcium 
transient is shown.  Current amplitudes are relative to one another and were generated using 
3 different computer models of the cardiac action potential 15 – 17. Phases 0-4 are noted for 
each action potential. (Courtesy of Jordi Heijman, PhD).  
In addition to the species differences that are noted in Figure 4, there are also 
regional differences in the expression of the various ion channels throughout the 
heart, and this can contribute to different action-potential characteristics. In dog 18, 
human 19 and guinea-pig 20, the action potential of epicardial myocytes is shorter in 
duration than that of endocardial cells. In addition, the spike-and-dome configuration 
is more prominent in the epicardium than the endocardium. There is also regional 
heterogeneity in calcium-handling proteins 21 and recent work has demonstrated 
transmural heterogeneity of excitation-contraction coupling and calcium handling    
in human hearts 22. Various studies 23, 24 have also illustrated that cells from the 
mid-myocardium have a longer action-potential duration than those from              
the endocardium and are more susceptible to prolongation, e.g., by blockade of IKr 25. 
However, the functional and clinical relevance of these ‘M cells’ is still under     
debate 26, 27. Finally, there are also large interventricular differences in ion currents 
that contribute to dispersion of repolarization 28. These regional electrical gradients 
caused by the differences in action-potential duration are responsible for the T wave 
on the electrocardiogram 29, 30. Under various pathological conditions, exaggerated 
dispersion of repolarization creates the substrate for reentrant arrhythmias 31.   
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In 1998, the term “repolarization reserve” was introduced by Roden 32. According to 
this concept, the inhibition or functional impairment of one transmembrane ion 
channel does not automatically result in excessive repolarization changes due to the 
fact that other currents that are normally redundant can compensate for the current 
that is reduced. This “reserve” can be augmented by various factors, including 
sympathetic tone, diet (e.g. grapefruit juice 33) and disease (e.g. diabetes 34; see 
recent review by Varro et al.  35). In certain circumstances, however, the “reserve” is 
not sufficient to compensate for the challenge that is imposed upon it. Clinically, 
among conditions in which the repolarization reserve can be challenged are the 
congenital long-QT syndromes (LQTS), with a prevalence of around 1 in 2500 live 
births 36. In long-QT patients the duration of repolarization, as measured on the ECG 
as the time interval between the beginning of the Q wave and the end of the T 
wave, is prolonged. The two most common LQT syndromes are caused by mutations 
in the KCNQ1 gene (encoding for the ?-subunit of the IKs channel) or in hERG 
(encoding for the ?-subunit of the IKr channel), although at the time of this writing 
there have been 13 LQT syndromes described 37 - 39. Symptomatic patients with these 
syndromes can present with syncope or cardiac arrest, often as the result of TdP 
arrhythmia, and it is thought that the mechanisms of arrhythmogenesis in these 
patients are also operative in patients with drug-induced TdP. 
 
Afterdepolarizations are among the mechanisms that are thought to be involved in 
arrhythmogenesis in both drug-induced TdP and congenital LQT (Figure 5). These 
oscillations can lead to either triggered activity 40 and/or functional block which may 
encourage re-entry circuits. These phenomena can be detected from the single cell 
to the tissue and can even be observed in the intact heart when monophasic action 
potentials are recorded 41. They are defined as depolarizations of the cardiac action 
potential that can occur in phase 2, 3 or 4 of the action potential 42. Normally if   
they occur in phase 4 they are called delayed afterdepolarizations (DADs) and if they 
occur earlier on the action potential then they are termed early afterdepolarizations 
(EADs). There is now a general consensus that DADs are a result of a transient 
inward current (ITI) activated by intracellular Ca2+ 43. This transient inward current is 
mainly due to activation of the electrogenic Na+-Ca2+ exchanger (NCX), with the 
Ca2+-activated Cl- current (ICl(Ca)) contributing in some species 44, 45. The mechanisms 
underlying EADs are much less clear cut however, and remain a topic of debate. 
Early evidence suggested EADs were caused as a result of reactivation of ICaL due to 
the prolonged plateau phase of the action potential 46, 47. However, there is other 
experimental evidence that suggests that EADs may also be caused as a result of ITI 
activation by intracellular Ca2+, especially under conditions of Ca2+ overload 48 - 50. 
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Figure 5: Representative examples of afterdepolarizations occurring in the single canine 
myocyte. Figure shows both membrane potentials and contraction for each situation. Left 
??????? ???? ???? ???????? ??? ???? ?-adrenergic agonist isoproterenol (ISO); the middle panel 
illustrates an EAD (#) induced by augmentation of the late sodium current, using ATX-II; the 
right panel illustrates that under certain conditions both types of afterdepolarizations can be 
seen in the same action potential. In this particular example, blockade of IKs ?????-adrenergic 
stimulation are the proarrhythmic treatment and it can be seen that an early aftercontraction 
initiates prior to the upstroke of the EAD.  
1.3 Proarrhythmic Models and Markers 
As TdP arrhythmias themselves are fortunately rare, strong surrogate markers are of 
crucial importance for the pharmaceutical industry for proarrhythmic risk assessment 
of novel chemical entities. In addition, various proarrhythmia models, both in-vivo 
and in-vitro, have been developed. These models share the characteristic of a 
reduced repolarization reserve, by different inciting mechanisms, which primes them 
for arrhythmia. 
 
In clinical reality, many patients with TdP do not have a ‘perfect’ unremodeled heart, 
which illustrates the importance of checking for proarrhythmic activity in disease 
models. The dog with chronic complete atrioventricular block (CAVB) is one such    
in-vivo model. It has been used for over a century 51 and since 1995 52 has received 
much attention as a model of TdP. After ablation of the atrioventricular node, 
electrical conduction from the atria to the ventricles is interrupted, resulting in a 
slower idioventricular rhythm to determine the heart rate. Due to this, cardiac output 
is initially reduced and over a period of 2-5 weeks ventricular hypertrophy occurs as 
a compensatory mechanism 53.  At the cellular level, the delayed rectifier K+ current 
IKs is reduced 54, whereas sarcoplasmic reticulum Ca2+ release and INaCa are  
enhanced 55. Taken together, these alterations predispose to TdP arrhythmias, 
making the CAVB dog a sensitive model for TdP detection. Another in-vivo model 
used to detect the proarrhythmic potential of new compounds is the methoxamine-
18 
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sensitized rabbit 56. This model was first described in the early 1990s 57. Even today 
the exact mechanisms of ?-adrenoreceptor sensitization for TdP in this model are still 
unclear, however altered Ca2+ handling is likely to play a role.   
 
Over recent years, various newer animal ?????????????????????????????-adrenergic 
????????? ????? stimulation with isoproterenol (ISO) reproducibly produced TdP in 
anesthetized dogs with a reduced repolarization reserve caused by selective IKs 
blockade 58, 59. Interestingly under these conditions, aftercontractions were observed 
on the left-ventricular-pressure (LVP) signal prior to TdP induction, suggesting that 
abnormal Ca2+ handling plays a pivotal arrhythmogenic role. A combination of IKr  
and IKs blockade has also been shown to induce TdP in conscious dogs and   
anaesthetized rabbits 60. Finally, in guinea pigs, adrenaline has been used to reveal 
the torsadogenic potential of a combination of E-4031 (IKr blocker) and               
HMR1556 (IKs blocker) 61. 
 
In addition to the in-vivo models mentioned above, there are also a number of       
in-vitro models, as reviewed by Lawrence et al. 62. Perhaps the most widely studied     
in-vitro model is the perfused and paced Langendorff-mounted rabbit heart. Many 
drugs with clinical proarrhythmic properties can be detected in this model 9, 63, 64. 
 
As already noted above, the most commonly used surrogate marker for TdP liability 
is the QT interval of the ECG. Although this biomarker has been adopted by 
regulatory agencies, in both preclinical and clinical studies, the link between            
a prolonged QT interval and arrhythmia is not watertight by any means. Numerous 
studies have indicated a discordance between QT prolongation and TdP induction. 
For example, Carlsson et al. 65 showed that QT prolongation alone could not 
discriminate between methoxamine-sensitized rabbits that showed TdP and those 
that did not. In this particular study, the IKr blocker almokalant was infused            
at different rates. In the animals subjected to a high rate of infusion of the 
compound, TdP was seen in 9 out of 10 rabbits and this was accompanied by an 
increase in QT of 30%. Interestingly in the rabbits receiving a lower rate infusion,  
an increase in  QT time of 42% was seen, however TdP was only seen in 1 out of 8 
animals.  In the clinical setting, in patients with acquired prolongation of the QT 
interval, Gilmour et al. (1997) 66 showed that QT-interval prolongation alone was 
insufficient to account for the initiation of TdP, suggesting that other arrhythmogenic 
factors are more relevant.  
 
Over recent years, more direct markers of TdP prediction have been proposed. 
Among them are: TRIaD, beat-to-beat variability of repolarization (BVR) and the 
electromechanical window (EMW).  
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In a study of Hondeghem et al. of 2001 9, the investigators characterized 702 
chemical entities in Langendorff-perfused rabbit hearts, and then measured various 
determinants, collectively known as TRIad. Triangulation (‘T’) of the action potential 
(taken as the repolarization time from APD30 to APD90), reverse-use dependence 
(‘R’), temporal instability of the action potential duration (‘I’), and dispersion of 
repolarization (spatial and temporal, ‘D’) were all measured. In these experiments, 
the instability was quantified by means of a so-called “instability index”. This index 
was computed as the difference between the upper and lower quartiles of APD60 
during the last 60 beats during drug perfusion.  However, this parameter does not 
take into account the consecutiveness of the beat-to-beat repolarization instability. 
Hondeghem and his colleagues then went on to plot the instability index against APD 
prolongation. In this setting, a number of chemical entities induced considerable 
repolarization instability while producing only minimal lengthening of the APD. TdP-
like polymorphic ventricular tachyarrhythmias were often seen under these 
conditions. Vice versa, there were also compounds that lengthened the APD 
considerably but left temporal instability minimally altered. These compounds 
showed no or hardly any arrhythmogenic activity. In addition to TRIaD, more 
recently Hondeghem also ????????? ????????????? ??? ???????? ??????????? ???? ??? ???
additional risk marker 67. Cardiac wavelength is the product of the effective refractory 
period and the conduction velocity and therefore takes into account additional factors 
that appear to influence arrhythmogenic outcome but otherwise would not be 
considered for arrhythmia risk. These data further question the utility of QT times 
alone as a proarrhythmic marker. 
 
Beat-to-beat variability of repolarization (BVR) takes into account the 
consecutiveness of variability. As dispersion of repolarization seems to play an 
important role in arrhythmogenesis, it is likely that the consecutiveness of 
repolarization duration is also vital. For example, if the repolarization duration 
increases by the same increment throughout the heart then it is unlikely that 
arrhythmia will ensue, as there is only a minimal risk of functional conduction block.  
In 2004, Thomsen et al. 10 quantified BVR as short-term variability (STV). This 
parameter was quantified as being the mean orthogonal distance from the line of 
identity to the most distant points of the Poincaré plot. These data can be derived by 
????????????????????????????????????????n+1 – Dn|/[nbeats?????????????????????????
the duration of repolarization. This marker has been most extensively studied in the 
CAVB dog where D is derived from endocardial monophasic-action-potential 
recordings. In this model, multiple compounds have been tested and BVR has been 
assessed 53. Interestingly, whereas BVR increases by the administration of many 
proarrhythmic agents, it can also be reduced when an anti-arrhythmic agent is 
applied 68, 69.  Since its inception, the concept of BVR has been applied in multiple 
animal models 58, 70 and also to the clinical situation 71 - 74 and, in the majority of 
conditions, it does seem to be a more reliable marker of arrhythmogenic risk 
compared to QT prolongation alone. 
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Finally, the latest surrogate marker to be described for TdP risk is the EMW, which 
was recently characterized in dogs by van der Linde et al. 59. Under normal 
conditions, the QT interval is shorter than the duration of the LVP (QLVPend), 
providing a positive EMW.  Interestingly, atrial pacing, atropine or body temperature 
changes had no major effects on the EMW, whereas changes in the QT duration 
were considerable. However, during IKs blockade in dogs, ????stimulation with ISO 
led to a large negative EMW and this was very often accompanied by TdP. 
Prevention of TdP by atenolol or verapamil was associated with a (much) less-
negative EMW. On the other hand mexiletine, a class-1B antiarrhythmic drug 
sometimes used to treat LQT3 patients, did not affect the EMW or prevent TdP 
induction. These initial data indicate that mismatches between the electrical and 
mechanical activity of the heart may be better indicators of arrhythmogenesis than 
electrical activity alone. 
 
 
1.4 Aims and Outline of this Thesis  
 
Based on the above, a greater understanding of the underlying mechanisms behind 
drug-induced TdP is required, not in the least to aid the pharmaceutical industry     
to develop safer compounds and to avoid that efficacious compounds are discarded 
on false assumptions. Hence, the main objective of the work presented in this thesis 
was to study the mechanisms involved in TdP arrhythmogenesis, focusing on the 
cellular aspects that underlie BVR, one of the newer surrogate markers thought      
to have utility in predicting this arrhythmia. Particular attention was paid to how BVR 
is altered under various proarrhythmic conditions and how this can contribute to 
arrhythmia formation.   
 
In Chapter 2, we describe a protocol for isolating canine cardiac myocytes and then 
assessing changes in AP duration in canine ventricular myocytes utilizing optical 
imaging techniques. This technique is then validated by using various test 
compounds. In addition, a protocol is described that allows for the assessment of 
BVR in single canine myocytes. The protocols described in Chapter 2 were then 
applied in the studies underlying Chapters 3 and 4. In Chapter 3, isolated 
myocytes were used to investigate the impor???????????? stimulation in the rescue 
of excessive increases in BVR following IKr blockade and augmented late INa. In 
addition, the effects of IKs inhibition on BVR were investigated in the presence and 
abse?????????? stimulation. These studies were important in defining the influence 
that alterations in the repolarization reserve could have on BVR and enable us to 
begin to delineate ionic mechanisms of BVR. In Chapter 4 additional cellular 
mechanisms of BVR are described. Here, we investigated the relationship between 
spontaneous Ca2+ releases and BVR using a combined experimental and 
?????????????? ????????? ?????? ??????????? ??? ???? ??? ????????? ????? ???? ???????? ?Ks 
blockade. In addition a mechanism for this relationship is proposed.  This chapter 
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delves further into the ionic mechanisms of BVR and provides important insights into 
mechanisms behind TdP arrhythmias as well as aiding in the development of anti-
arrhythmic agents. Chapter 5 investigates interventricular differences in the 
regulation of cyclic AMP levels by phosphodiasterases (PDE), and how this can have 
differential effects on the ion channels that are regulated under this pathway, which 
may ultimately affect dispersion of repolarization and have arrhythmogenic 
consequences. In Chapter 6 we move from the single cell to the whole animal. In 
this study, the effect of a novel combined ion-channel blocker, AZD1305, was 
assessed for proarrhythmic liability in the CAVB dog, where repolarization reserve is 
already challenged by the remodeling process making these animals much more 
susceptible to TdP arrhythmia. In addition, BVR was monitored throughout these 
studies to further establish this parameter as a superior surrogate marker for TdP 
induction. In the studies for Chapter 7, we investigated the utility of the EMW in the 
anesthetized guinea-pig model after challenging these animals with known 
torsadogenic reference compounds. Finally, in Chapter 8 the findings of all chapters 
are discussed in an integrated manner and ideas for further research are outlined. 
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Abstract 
 
Proarrhythmic side effects are a major limitation during the drug development 
process for cardiac and non-cardiac compounds. Because changes in cardiac action 
potential (AP) are undesirable, the evaluation of the effects of test compounds       
on the AP is essential before advancing new compounds to clinical testing. However, 
an increase in repolarization duration alone is not always proarrhythmic, and newer 
surrogate markers have been suggested to better predict the occurrence of 
arrhythmia. Described in this chapter is a protocol for assessing changes in AP 
duration in canine ventricular myocytes utilizing optical imaging techniques. This 
protocol can be used at an early stage of drug discovery due to its relatively fast 
throughput. Additionally, a protocol is presented for assessing the occurrence of 
after-depolarizations, as well as a novel parameter for proarrhythmic risk, beat-to-
beat variability of repolarization. This protocol can be used at a later stage of the 
drug discovery process to assess proarrhythmic potential. 
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2.1 Introduction 
 
Regulatory guidance documents 1, 2 rely on prolongation of the QT interval as a 
biomarker for predicting the risk of compound-induced Torsades de Pointes (TdP). As 
changes in cardiac action potential (AP) are undesirable, the evaluation of the effects 
of test compounds on the AP is essential before advancing new chemical entities 
(NCEs) to human testing. Compound throughput in the single myocyte assay is much 
greater than with conventional APD models, and animal use is reduced. However, 
the technical difficulties associated with making sharp-electrode (SE) recordings in 
these cells limit the number of test compounds that can be assessed. Hence, cell 
lines expressing key cardiac ion channels (IC), and the advent of automated 
electrophysiology, have made it possible to “molecularise” the AP as a means of early 
QT risk assessment. Nevertheless, no matter how comprehensive the panel of ICs 
becomes, there is always the need to assess test compounds in an integrated system 
(e.g., myocyte, whole animal). Accordingly, a new method employing a fast voltage-
sensitive dye (e.g., di-4-ANEPPS) to record APs in left ventricular midmyocardial 
myocytes (LVMMs) and which is technically less challenging has been developed in 
our laboratories. Because of these attributes, it provides an experimental AP duration 
(APD) assay with high throughput, making it possible to more quickly identify and 
discard at an earlier stage of the drug discovery process NCEs that may potentially 
modify APD 3.  
   
A prolonged QT interval cannot reliably predict the pro-arrhythmic potential of a test 
compound 4, 5. As a result, rather than simply assessing the QT interval prolongation 
risk, efforts are being made to identify more reliable preclinical proarrhythmic 
markers that correlate with the incidence of TdP, such as beat-to-beat variability of 
repolarization (BVR), which is quantified as short-term variability (STV(APD)) in 
LVMM cells 4, 6, 7. Because one of the limitations to optical measurements from LVMM 
cells using di-4-ANEPPS is the need to limit measurements to finite time periods to 
avoid phototoxic effects of the dye, measurement of the putative proarrhythmic 
markers STV(APD), early after-depolarizations (EADs) and delayed after-
depolarizations (DADs), could only occur using SE methodology. Therefore, the latter 
methodology can be used to assess the proarrhythmic potential of a test compound 
in LVMM cells at a late phase of the drug discovery process.  
 
Detailed below is a method for studying APs in isolated canine LVMM cells. The  
focus is measurement of changes in the AP parameters induced by superfusion with 
a test compound (Basic Protocol) using di-4-ANEPPS. In addition, a protocol is 
described for investigating the arrhythmogenic effects of a test compound on 
temporal STV(APD) and the occurrence of EADs and DADs using the SE technique 
??????????? ????????? ???? ??? ?-adrenergic receptor (???? stimulation is an important 
contributor to arrhythmogenesis under conditions where repolarization is impaired by 
a reduction in the slow activated potassium current (IKs), as occurs in association 
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with either inherited or acquired long QT1 syndrome 7, 8, a second alternate protocol 
is included that makes possible an investigation of the effects of a test compound in 
combination with isoproterenol (ISO)??????? agonist. 
 
NOTE: All protocols using live animals must first be reviewed and approved by an 
Institutional Animal Care and Use Committee (IACUC) or must conform to 
governmental regulations regarding the care and use of laboratory animals. 
 
2.2 Basic Protocol: Measurement of Test Compound-Induced 
Changes in Action Potential Parameters in the Dog Midmyocardial 
Myocytes 
 
Described in this protocol is a procedure for recording APs in isolated dog LVMMs and 
measuring changes in AP parameters induced by a test compound. Measurement of 
the AP is accomplished using di-4-ANEPPS, a voltage-sensitive dye. 
 
2.2.1 Materials 
 
? ???????????????????????????-35 months) 
? Normal Tyrode’s solution (see recipe)  
? Calcium-free and containing 0.2 and 1.8 mM CaCl2 
? Bovine albumin serum (BSA, Sigma) 
? Pentobarbitone 
? 1 M CaCl2 
? Collagenase A (Roche Diagnostics) 
? 70% and 100% (v/v) ethanol (in water) 
? Di-4-ANEPPS (Sigma) 
? Test compound 
? Reference compound (e.g., dofetilide, a class III antiarrhythmic agent) 
? Dimethyl sulfoxide (DMSO; Sigma) 
 
Equipment and supplies for myocyte isolation (Figure 1, left panel) plus: Micro-
osmometer (e.g., Advanced Instruments model 3300) 
? pH meter (e.g., SevenMulti, Mettler Toledo) 
? 1-liter sterile Schott Duran bottles (LabPlanet, IL, USA) 
? Gassing system to deliver medical O2 (99.5%, type F cylinder) 
? Oxygenating bubbler 
? Surgical scissors, straight, S/S, 105 mm (4-1/8 in.) 
? Mayo dissection scissors, straight, B/B, 140 mm (5-1/2 in.) 
? Medium dissecting forceps, straight, 160 mm (6.30 in.) 
? Aesculap Iris dissection forceps (Ted Pella) 
? 100-, 200-, and 500-ml Beakers 
? Sewing needle and thread 
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? Waste tissue bag 
? 50-ml BD Plastika syringe and Polyethylene tubing 
? Heating coil (Radnoti) 
? DC50-B5 heating circulator (HAAKE, Thermo Fisher Scientific) 
? Perfusion system  
? (R3603, Tygon, Saint-Gobain Performance Plastics Corporation) 
? Cannula (vessel dilator 1.65 × 0.53 mm; Cordis, J&J Company) 
? 10-ml Syringes 
? 130-mm Dissection dishes without rubber silicone base 
? Cell dissociation sieve tissue grinder kit (Sigma) with Screens for               
CD-1(100-???????? 
? Inverted microscope (e.g., Nikon Eclipse TS100) 
 
Equipment and supplies for recording optical AP (Figure 2), including: 
? Antivibration table (Scientifica) and Faraday cage (Type II, Scientifica), 
covered with materials that prevent entry of light 
? Inverted microscope (e.g., Nikon Eclipse TE200) with 40× oil objective (1.30 
NA, Nikon) 
? FHD microscope chamber system (IonOptix) 
? Cell MicroControls mTCII temperature controller and heater (IonOptix, Dublin, 
Ireland) 
? CF-8vs valve assembly and  cFlow controller (IonOptix) 
? Immersion oil for fluorescence and general microscopy (Cargille Laboratories) 
? Long-pass (>700 nm) and narrow band-pass (540-580 and 600-640 nm) 
filters 
? Chromatic reflectors (<590 and <700 nm) 
? Dual-emission photometry system with two photomultiplier tubes (PMTs), 
each with an amplifier and high-voltage power supply (Cairn Research) 
? Xenon arc lamp power supply associated with arc lamp + housing (Cairn 
Research) 
? Cairn shutter supply associated with xenon arc lamp + housing (Cairn 
Research) 
? TH-10Kmp-thermistor probe (Cell MicroControls) 
? Bath-mounted platinum wire electrodes 
? Infrared camera (Watec) and Vista 14-inch monitor (Norbain SD) 
? HSE stimulator P (Hugo Sachs Elektronik) or MyoPacer Field Stimulator 
(IonOptix) 
? MultiClamp 700A amplifier and Digidata 1322A digitizer (Molecular Devices) 
? Computer with pClamp 10 software (Molecular Devices) for acquisition and 
analysis of electrical signal 
? Corning cover glass (no. 1, 25-mm sq; Corning Life Sciences) 
? Vacuum pump (Rena Air 200, Planet Rena) 
? Lens cleaning tissue (Thermo Fisher Scientific) 
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Figure 1: Isolation of canine LVMMs. The left panel shows the apparatus used for isolating 
LVMM cells from a canine heart. Photographic and schematic showing cannulation (C.) of the 
left anterior descending (LAD) coronary artery for perfusion of the left ventricle during the 
isolation procedure (top right). The catheter is placed through the aorta into the LAD (E.) and 
a photo of a single isolated LVMM (F.). A. indicates the solution reservoir; B. the heated coil; 
C. the cannula; D. the heart. 
 
2.2.2 Pre-surgery preparation 
 
1.    The day before isolation prepare the following: 
1 liter normal Tyrode’s solution containing 0.2 mM CaCl2, 
9 liters normal Tyrode’s solution containing 1.8 mM CaCl2, 
5 liters calcium-free Tyrode’s solution. 
2.  Check the pH (7.38-7.42) and osmolarity (275-315 mOsm) of the normal 
Tyrode’s solutions. Adjust pH as needed with 1 M NaOH or HCl. 
If the osmolarity of the solution is not within this range, discard and prepare 
fresh solution.  
3. Fill two 1-liter Schott Duran bottles with calcium-free Tyrode’s solution and 
place in the refrigerator (4°C). 
4.  On the day of myocyte isolation, but before obtaining the heart, place the two 
Schott Duran bottles of calcium-free Tyrode’s solution on ice and begin 
bubbling continuously with medical O2 (99.5%). 
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5.  Set up the work space with the following items: 
105-mm surgical scissors, straight, S/S, 
140-mm Mayo dissection scissors, straight, B/B, 
160-mm medium dissecting forceps, straight, 
Aesculap Iris dissection forceps, 
Sewing needle and thread, 
100-, 200-, and 500-ml beakers, 
Waste tissue bag. 
6.  Connect a 50-ml Plastika syringe via polyethylene tubing to the heating coil. 
Fill the syringe with bubbled, room-temperature, calcium-free Tyrode’s 
solution. Remove bubbles from the tubing connected to the heating coil. 
7.  Set the perfusion rate at ?20 ml/min. 
This should produce a steady stream from the cannula. 
8.  Fill two 10-ml syringes with cold calcium-free Tyrode’s solution and keep at 
4°C in a refrigerator. 
9.  Dissolve 150 mg BSA in 300 ml room-temperature calcium-free Tyrode’s 
solution (fin????????????????????????????????????????????2. 
10.  Activate the DC50-B5 heating water circulator for 15 min before sacrificing 
the animal. Adjust the “set” temperature of the heating coil to 37°C. 
 
2.2.3 Obtain LVMMs 
 
11.  Induce anesthesia in a dog using ?45 mg/kg pentobarbitone and 
supplementary anaesthetic as necessary until there are no pedal or pupil 
reflexes. Open the chest via left thoracotomy, remove the heart, and 
immediately place it in cold, oxygenated calcium-free Tyrode’s solution. Rinse 
the heart three times using more of the same solution. 
12.  Remove some of the tissue around the aorta and shorten it slightly (by 3 to 5 
mm), leaving sufficient length for the thread and clamp (?5 mm; Figure 1, 
top center). 
13.  Cannulate the left anterior descending coronary artery through the aorta  
(Figure 1, top center, top right) and infuse ?10 ml cold calcium-free 
Tyrode’s solution through the cannula using a syringe from step 8. 
14.  Use needle and thread to secure the cannula and then attach the cannula to 
the isolation setup (Figure 1, top center). 
15.  Perfuse for 5-10 min with room temperature, oxygenated calcium-free 
Tyrode’s solution at 20 ml/min. 
16.  During perfusion, dissolve collagenase A at 1.1 mg/ml into the Tyrode’s 
solution containing BSA. Continue bubbling with oxygen. 
17. Perfuse the heart with Tyrode’s solution containing BSA and collagenase A for 
20 min at 20 ml/min. 
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The initial cold perfusion protects the heart muscle from damage during the period 
before it is attached to the isolation setup. BSA is used to improve survival and 
recovery of LVMMs. Perfusion of warm solution and addition of calcium optimize the 
activity of collagenase A. 
 
18.  Perfuse the heart with room temperature, oxygenated normal Tyrode’s 
solution containing 0.2 mM CaCl2 for 5-10 min at 20 ml/min. 
19.  Remove the heart from the perfusion apparatus and dissect 1-cm chunks 
from the midmyocardial region of the left ventricular wall (Figure 1, bottom 
right). Place them in a 50-mm dissecting dish containing 50 ml normal 
Tyrode’s solution with 0.2 mM CaCl2, swirl to rinse, and allow to settle for ?10 
min. 
20.  Decant supernatant, rinse LVMM cells in 10 ml normal Tyrode’s solution 
containing 0.2 mM CaCl2, and filter through a cell dissociation sieve using 
100-?????????????????-1. 
21. Prepare 90 ml of a 5 mg/ml BSA solution in normal Tyrode’s solution 
containing 1.8 mM CaCl2. 
22. Wash LVMM cells in 90 ml normal Tyrode’s solution containing 0.2 mM CaCl2 
and allow them to settle for ?10 min. 
23. Discard supernatant, rinse LVMM cells in 45 ml normal Tyrode’s solution 
containing 1.8 mM CaCl2 and 5 mg/ml BSA, and then allow to settle for ?10 
min. Repeat. 
24.  Replace supernatant with 90 ml normal Tyrode’s solution containing 1.8 mM 
CaCl2 and examine the cells under an inverted microscope. 
 
Healthy LVMMs should be quiescent rod-shaped cells with clear cross-striations 
(Figure  1F). Although quantification is not required for the purpose of this work, 
one can expect a yield of ?9 × 10 6 cells. 
 
25.  Wash the perfusion setup twice with 70% ethanol, then twice with deionized, 
distilled water. 
 
2.2.4 Prepare Vehicle, di-4-ANEPPS, and Test and Reference Compounds 
 
26.  Dissolve 5 mg di-4-ANEPPS in 100% ethanol at a concentration of 10 mM. 
Dilute this stock solution in ethanol to a concentration of 1 mM, and then 
???????????????? this solution in 1 liter of normal Tyrode’s solution containing 
1.8 mM CaCl2 to yield ???????????????????????????? 
 
IMPORTANT: Minimize exposure of all solutions containing di-4-ANEPPS to light by 
wrapping in tin foil and, if necessary, placing a tin foil lid over the top. 
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27.  Dissolve ?25 mg test compound in DMSO at a concentration of 100 mM. 
Dilute this solution serially with DMSO to produce three more DMSO stocks 
(e.g., 10, 1, and 0.1 mM). Finally, dilute each test compound stock 1000-fold 
?????????????????????? ????????????????????????????????????????????? 
28.  Dissolve ?25 mg reference compound (e.g., dofetilide) in DMSO at a 
concentration of 1 mM. Dilute this 1000-????? ??? ???? ?? dye solution (final       
?? ?? reference compound). The reference compound should be tested in 
preliminary experiments to determine the optimal concentration for response. 
This applies to dofetilide or any other reference compound. 
29.  Dilute DMSO 1000-????????????????????????????????????a 0.1% DMSO vehicle 
solution. 
 
2.2.5 Prepare Experimental Setup 
 
30.  Turn on the arc lamp power supply, followed by the computer, stand-alone 
power supply for the Cairn shutter, dual-emission photometry system with 
amplifiers, 2×PMT power supply modules, monitor, microscope light, vacuum, 
HSE simulator, and Multiclamp 700A. Set both PMT power supply modules at 
920 V. 
 
The Multiclamp 700A is not used, but must be turned on to ensure that the pCLAMP 
protocol sequencing operates without querying the telegraphed settings within 
pCLAMP. 
 
31.  Clean the microscope objective and place a drop of oil on it. 
32.  Place a cover glass in the FHD microscope chamber, clip the chamber in 
place, and make contact between the objective and cover glass so that the 
LVMMs can be seen. 
33.  Fill and prime each channel of the CF-8vs valve assembly with 50 ml of each 
vehicle, reference, and test solution until the perfusion flow is constant and 
without bubbles. Attach the inflow tube of the Cell MicroControls mTCII 
temperature heater to the FHD microscope chamber system. 
34. ?????????????????????????????????????????????????-4-ANEPPS dye solution 
at 3 ml/min until flow is constant. Switch off perfusion and disconnect 
suction.  
 
2.2.6 Dye-Load Cells and Record APs 
 
35.  ???????????????????????????????????????????????????2 × 10 5 cells) into a 
foil-wrapped vial. Leave for ?10 min at room temperature. 
36.  Using a pipet, transfer 1 ml dye-loaded cells to the FHD microscope chamber 
and allow to settle for ?3 min to ensure that cells are not washed away when 
perfusion starts. 
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37.  Set the temperature of the Cell MicroControls mTCII temperature controller to 
37°C, ????????? ???? ???????? ???????? ???? ????????? ???? ???????? ???? ??? ????
solution for 10 min at 3 ml/min. 
 
 
Figure 2: Optical experimental setup and tissue bath. Epifluorescence recordings are made 
from LVMM cells as previously described (Hardy et al., 2009). The setup includes a Faraday 
cage (A.), HSE stimulator P (B.), Cairn shutter (C.), cFlow controller (D.), Vista 14-inch 
monitor (E.),dual-emission photometry system (F.), MultiClamp 700A (G.), Digidata 1322A 
(H.), antivibration table (I.), vacuum waste bottle (J.), inverted microscope (K.), long-pass 
filter (L, >700 nm), CF-8vs valve assembly (M.), superfusion tubing (N.), connection to     
iris (xenon arc lamp, O.), narrow bandpass filters (P, 540-580 and 600-640 nm), infrared 
camera (Q.), chromatic reflectors (R, <590 and <700 nm), temperature controller (S.), 
outflow (T.), thermistor (U.), chamber (V.), oil objective (W.), inflow (X.), electrodes (Y.), 
and heater (Z.). 
38.  Using protocol A in Table 1, apply continuous electrical field stimulation at 
1Hz (i.e., 60 pulses/min) for 4 msec duration using a constant-voltage 
isolated MyoPacer field stimulator through bath-mounted platinum wire 
electrodes (FHD microscope chamber; Figure 2). Increase the stimulator 
voltage amplitude (generally 4-6 V) until some LVMMs begin to contract in 
time with the stimulus. Select a healthy rod-shaped cell that has visible 
striations (Figure 1F), is not in contact with any other cells, and contracts in 
time with the stimulus. Move this LVMM to the center of the microscope field 
of view. Use a diaphragm placed before the PMTs to limit the view around the 
cell and ensure that light emitted from neighboring cells does not interfere 
40 
 ACTION POTENTIAL RECORDINGS IN CANINE VENTRICULAR MYOCYTES 
 
with recordings. Close the rig doors. Determine the stimulation voltage (?10-
20% above the minimum threshold) that will evoke a contraction in the cell. 
Stimulation is controlled via protocols written in Clampex, the data acquisition 
module of pClamp. Protocol A allows for continued stimulation of LVMMs 
without exposure to excitation light (to avoid di-4-ANEPPS phototoxicity) and 
with the PMTs gated (to maintain greater stability). This ensures that a valid 
optical AP signal is evoked. 
39. Once a valid optical AP signal has been obtained, use protocol B (Table 1) to 
acquire an optical AP signal for 5 sec every 4 min. In protocol B, continuous 
stimulation of LVMMs is maintained at 1 Hz, but the cells are exposed to 
excitation light and the PMTs are not gated (to allow for quantitative 
detection of the two different emitted wavelengths).  
40.  Just before initiating superfusion with the test compound, record APs during 
exposure to the 0.1% DMSO vehicle solution. Use this AP as the control. 
41.  Initiate superfusion with each concentration of test compound by opening the 
appropriate valve of the CF-8vs valve assembly using the cFlow controller. 
42. If the test compound has an effect on the AP (e.g., prolongation or 
shortening), apply 0.1% DMSO to test the reversibility of the effect. 
43.  If the test compound has no effect on the AP, apply the reference compound 
to test whether the LVMM cell is capable of responding to an active 
compound. 
44.  Upon completion of the experiment, switch off perfusion and heater, 
disconnect suction, stop stimulation, and push the lever of the microscope 
away and remove the filter. 
45.  Clean all equipment between experiments. Flush the FHD microscope 
chamber with ethanol followed by water and then dry thoroughly. Lower the 
objective, remove the glass cover, clean under the chamber with a tissue, 
and clean the objective with a lens cleaning tissue. Place sufficient drops of 
oil on the objective, place a new glass cover in the FHD microscope chamber, 
and then raise the lens so that a clear image can be seen through the oil via 
the eyepieces on the microscope when viewing any part of the FHD 
microscope chamber upon which LVMM cells may be placed.  
46.  Perform additional experiments to obtain data from at least four additional 
cells.  
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Table 1 
 
“Step 44 protocol” “Step 45 protocol” 
Digidata 
1322A 
input/output 
Stimulus 5 V 5 V Digital OUT 3 
Shutter control 0 V 5 V Digital OUT 2 
PMT gating 5 V  
(which “Gates” the PMT) 
0 V Digital OUT 1 
560 nm PMT 
detection Yes Yes Analogue IN14 
620 nm PMT 
detection Yes Yes Analogue IN15 
Math signal No IN14/IN15 Not applicable 
 
Table 1: Protocols used in Clampex 10 software for detection of emitted light. 
In both protocols, the acquisition mode is episodic, the sweep duration is 1 sec, and the data 
acquisition is at 10 kHz. However, protocol B will only run for 5 sweeps, whereas protocol A 
will run for 235 sweeps. 
 
2.2.7 Analyze Data 
 
47.  Using pClamp software, measure AP parameters (Figure 3A) from on-line 
acquired data and save the relevant information for additional off-line 
analysis. 
48.  Perform off-line analysis using Clampfit (a module of pClamp) and a custom-
made optical AP myocyte macro 3 to smooth the optical trace data as follows: 
a. Calculate a baseline by taking the mean of the first 10 msec                 
(100 data points). 
b. Subtract this value from all data points. 
c. Collect every tenth data point from the baseline data and smooth using 
cubic splines. 
d. Normalize smoothed and baseline data with respect to the maximum value 
of the AP “dome” peak. 
49. Quantify test compound effects relative to data collected in the presence of 
the first perfusion with 0.1% DMSO. Data for each experimental condition are 
the average of five APs at 1 Hz, collected every 4 min. 
50.  If appropriate, produce a graph plotting the concentration-effect of the test 
compound on a given AP parameter (Figure 4). 
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Figure 3: Measurement of changes in the AP during superfusion with reference compounds. 
A. Representative optical AP of a canine LVMM cell and parameters measured during the 
experiment. APD50, APD70, and APD90: action potential duration optically measured at 50%, 
70%, and 90% repolarization. B-D. Representative optical APs recorded using di-4-ANEPPS-
based method with vehicle solution (0.1% DMSO) and in the presence of dofetilide (class III 
???????????????? ?? ????? ?????????? ?????????? ???? ???????? ????????? ???? ???? ??? ????? ????
terfenadine (multiple ion channel blocker; 0.1 and ?????????-D reprinted from Hardy et al., 
2009 with permission from Elsevier 3. 
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Figure 4: Effects of nine reference compounds on optically measured APD. Graphs show 
mean % change in APD50 and APD90 induced by A. dofetilide (n=?????????? ???????????????   
B. E4031 (class III antiarrhythmic; n=????????????C. D-sotalol (class III antiarrhythmic; n = 8   
????????????????????????????????????????????????????????????????? for E4031 during second set), 
D. ATX-II (agonist of late INa; n=????????????E. cisapride (n=????????????F. terfenadine (n=5 
??????????G. alfuzosin (multiple ion channel blocker; n=??????????and n=?????????????????-II 
for experiments in which D-sotalol did not have an effect on optically measured APD),         
H. diltiazem (inhibitor of ICaL; n??????????????????I. pinacidil (opener of IKATP; n=????????????
at a pacing frequency of 1 Hz. Data expressed as mean±SEM. *P < 0.05, $P < 0.01, and    
#P < 0.001 compared to values from 0.1% DMSO. Statistical analysis is to be ‘within cell’, 
with each concentration of each reference compound within each cell compared to vehicle 
(0.1% DMSO). Change from vehicle analyzed and the geometric mean change (%) from 
vehicle is to be reported, together with 95% confidence limits for the mean change. Effects 
are to be reported as statistically significant if P < 0.05. Increases or decreases are to be 
considered equally likely, leading to a two-sided testing approach. The data are log 
transformed prior to analysis and each parameter is analyzed separately. All comparisons are 
with the vehicle group. Reprinted from Hardy et al. with permission from Elsevier 3. 
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2.3 Arrhythmogenic Effects of a Test Compound on Beat-To-Beat 
Variability of Repolarization and Occurrence of Early and Delayed 
After-Depolarizations 
 
Described in this protocol is a procedure for assessing the arrhythmogenic effects of 
a test compound on the beat-to-beat variability of APs in LVMMs and the occurrence 
of early after-depolarizations (EADs) and delayed after-depolarizations (DADs). The 
conventional microelectrode (sharp-electrode or SE) technique is employed to 
measure the AP. This technique allows direct measurement of the transmembrane 
potential over a prolonged period of time. 
 
2.3.1 Materials  
 
? Isolated LVMMs (see Basic Protocol) 
? Normal Tyrode’s solution (see recipe) containing 1.8 mM CaCl2 
? Test compound 
? Reference compound (e.g., dofetilide, a class III antiarrhythmic agent) 
? Dimethyl sulfoxide (DMSO; Sigma) 
? 3 M KCl 
 
Equipment and supplies for microelectrode recording of AP (Figure 5), consisting 
of: 
  
? Antivibration table and Faraday cage (e.g., TMC) 
? Inverted microscope (e.g., Nikon Eclipse TE200) with 10× eyepieces and 40× 
oil objective 
? Perfusion chamber for myocytes (e.g., BT-1[-???????????????????????? 
? Perfusion system with water-jacketed heat exchanger for inflow of 
superfusate to myocyte chamber (e.g., Radnoti) 
? Micromanipulator for coarse and fine positioning of microelectrodes (e.g., 
Narishige) 
? Headstage with microelectrode holder (e.g., Molecular Devices) 
? Glass microelectrodes 
? Fiber optic light source (e.g., Schott KL1500, Schott) 
? Programmable stimulator and computer with software for driving stimulator 
(e.g., Tabor pulse generator, Tabor Electronics) 
? MultiClamp 700A or Axoclamp 2B amplifier, Digidata 1322A digitizer 
(Molecular Devices) 
? Computer with pClamp 10 software (Molecular Devices) for acquisition and 
analysis of electrical signal 
? Video camera and monitor (e.g., Pulnix TM-640, JAI, and CEM-12A-II, CBC) 
? Video edge-motion detector (e.g., Crescent Electronics VED-105) 
? 3-ml Syringe and 22-G spindle needle (World Precision Instruments, 
Germany) 
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Figure 5: Sharp-electrode experimental setup. The center panel is a schematic drawing of 
the assembly of components in the outer photographs, including inverted microscope (A.), 
microscope table with perfusion chamber (B.), perfusion system with water-jacketed heat 
exchanger for inflow of superfusate (C.), fiber-optic light source (D.), micromanipulators for 
coarse and fine positioning of microelectrodes (E.), video camera (F.), headstage 
(preamplifier) with holder and microelectrode (G.), vibration-isolated work station (H.), 
stimulator (I.), microelectrode amplifiers (J.), video edge-motion detector (K.), analog-to-
digital converter (L.), and computer (M.) with pCLAMP 10 software for automated waveform 
control and data acquisition. 
2.3.2 Prepare Vehicle and Test and Reference Compounds 
 
1.  Dissolve ?25 mg test compound in DMSO at a concentration of 100 mM. 
Serially dilute this solution with DMSO to produce three more stocks at 10, 1, 
and 0.1 mM. 
2.  Dilute the DMSO stocks 1000-fold in normal Tyrode’s solution containing 1.8 
mM CaCl2 to give final conc??????????? ??? ????? ???? ??? ???? ???? ??? ?????
compound. 
3.  At room temperature, dissolve ?25 mg reference compound (e.g., dofetilide) 
in DMSO at a concentration of 1 mM. Dilute this stock in normal Tyrode’s 
solution containing 1.8mMCaCl2 to yield a final conc?????????? ??? ?? ?? 
reference compound. 
 
The reference compound should be tested in preliminary experiments to determine 
the optimal concentration for response. This applies to dofetilide or any other 
reference compound. 
 
4. At room temperature, dilute DMSO 1000-fold in normal Tyrode’s solution 
containing 1.8 mM CaCl2 to yield a 0.1% DMSO vehicle solution. Prepare 
experimental setup and record APs. 
46 
 ACTION POTENTIAL RECORDINGS IN CANINE VENTRICULAR MYOCYTES 
 
5.  Turn on microscope, light source, computer for data acquisition, stimulator, 
video edge system, and monitor. 
6.  Set temperature to 37°C, activate the heater, connect the suction, and start 
perfusion of normal Tyrode’s solution containing 1.8 mM CaCl2 at 3 ml/min. 
Leave for 10 min to reach target temperature. 
7.  Turn off perfusion and place ?1 ml of LVMMs into the perfusion chamber.  
Leave for 5 to 10 min to allow cells to adhere to the bottom of the chamber. 
8.  Resume perfusion at 3 ml/min, 37°C. 
9. Fill a glass microelectrode with 3 M KCl using a 3-ml syringe and a 22-G 
spindle needle. 
 
The glass microelectrodes are made from filamented capillary tubes (World Precision 
Instruments) using a single-barreled microelectrode puller (e.g., DMZ universal 
puller, Zeitz-Instruments Vertriebs). The resistance should be 30-?????? 
 
10.  Insert the filled microelectrode into the microelectrode holder attached to the 
micromanipulator. 
11.  Place the tip of the microelectrode into the superfusion bath using the 
micromanipulator and under microscopic guidance. Zero the amplifier using 
the acquisition software and start recording. 
12.  Select a single undamaged rod-shaped cell with visible striations that is not in 
contact with any other cells and bring to the center of the microscopic view. 
13.  Using the micromanipulator, gently move the microelectrode so it is above 
the center of the cell of interest (without touching it). 
14.  Check that the amplifier is still at 0 mV and readjust, if necessary. 
15. Gently lower the microelectrode onto the cell of interest. Once contact is 
made, record the membrane voltage of the cell. 
 
?????????????????????????????????????????????????????????????????????????????????
?????? ????????????????? ??? ?????????????????????????????? ??????????????????? ??????
min, apply a hyperpolarizing pulse of 20 to 40 mV to help seal the microelectrode 
around the cell. After several minutes, remove the hyperpolarizing pulse and monitor 
the cell for a stable resting membrane potential. If the resting membrane potential is 
not stable, locate and impale another cell. 
 
16.  Once a stable resting membrane potential of ar???????????????????????????????
the stimulator at a pacing frequency of 1 Hz (1000-msec cycle length) with a 
stimulus duration of 5 msec.  
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This should initiate a cardiac AP. If no AP is observed, increase the stimulation 
duration or amplitude. If the AP morphology is suboptimal (e.g., no spike, dome 
shape characteristics) locate another cell and impale it. See Fig 6 for examples of 
optimal SE APs. 
 
17.  Move the markers of the video edge detection to the end of the cell to 
facilitate recording of the contractions. 
18. After a 5- to 10-min stabilization period, decrease the pacing frequency to 0.5 
Hz. Allow another stabilization period of ?5 min, then increase the pacing 
frequency to 2 Hz. 
 
This will make it possible to determine any rate dependence of the test compound. 
 
19.  Just before initiating superfusion with the test compound, record APs during 
exposure to the 0.1% DMSO vehicle solution, and continue until a stable 
recording is obtained at each cycle length. Use these APs as the controls. 
20.  Initiate superfusion with each concentration of the test compound and record 
APs at each of the three pacing frequencies. 
21.  If there is an effect of the test compound on the AP, apply 0.1% DMSO to 
test the reversibility of the effect after examining all concentrations of the test 
compound. 
22.  If the test compound has no effect on the AP, apply a reference compound to 
test whether the LVMM is capable of responding to an active compound. If 
the study is designed to assess the potential of the test compound to prolong 
the QT interval, use dofetilide as the reference compound. 
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Figure 6: Effects of test compounds on APs recorded from a canine LVMM using the SE 
technique. Effects of (A.) HMR1556 (inhibitor of IKs?? ???? ????? ?B.) dofetilide (class III 
antiarrhythmic; ????????????C.) ATX-II (augmenter of late INa; ??????????????????????????
at 1 Hz pacing frequency. Representative AP recordings showing the minimum, maximum, 
and median beats are shown foreach condition. Poincaré plots for each condition are also 
shown. Reprinted from Johnson et al., 2010 with permission from Elsevier 7.
23. At the end of the experiment, turn off the perfusion, stimulator, and heater. 
24.  Clean all equipment between experiments. Rinse the microscope chamber 
and perfusion tubing with 100% ethanol and distilled water to prevent 
contamination and remove residual myocytes. 
25. Begin next series of experiments to obtain data from at least four additional 
cells. 
Analyze Data 
26.  Using pClamp software, measure AP parameters from on-line acquired data 
and save the relevant information for additional off-line analysis. 
27.  Perform additional off-line analysis using Clampfit 7, 9. 
28.  Quantify test compound effects relative to the 0.1% DMSO vehicle data and, 
if appropriate, produce a graph plotting the concentration-effect of the test 
compound for a given AP parameter (Figure 4). Data for each experimental 
condition are the mean of 30 action potentials at each pacing frequency at 
steady state. 
29.  Calculate the BVR of these same beats using the following formula: 
 
???????????????????????????????????2) 
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Poincaré graphs, plotting the APD ???????????????????????????Figures 6 and 7), 
can also be made to visualize these data. If EADs are observed with the test 
compound, BVR should be assessed before the first one is noted. 
 
30.  Count the number of EADs or DADs that are seen in a 30-beat segment, and 
 then calculate the percentage of beats showing these abnormalities. 
 
The number of EADs and DADs under the various conditions provides an additional 
proarrhythmic marker, as EADs have been shown to play a role in arrhythmogenesis 
(Figure 7). 
 
2.4 Arrhythmogenic Effects of a Test Compound on Beat-To-Beat 
Variability of Repolarization Under Conditions that Mimic Long QT1 
????????????????????-Adrenergic Stimulation 
 
Described below is a procedure for assessing the arrhythmogenic effects of a test 
compound on the beat-to-beat variability of APs in LVMMs and occurrence of EADs 
??????????????????????????????? stimulation using ISO. ISO is recommended due to 
its high sele???????? ?????-adrenergic versus ?-adrenergic receptors, and because the 
majority of currently available data has been obtained using ISO. The microelectrode 
technique is employed for measuring the AP. 
 
Additional Materials (also see Alternate Protocol 1). 
 
10 mM ISO ????????????????????????????????????????? ???????????????? 
use and store in the dark at 4°C). 
 
NOTE: Stock and working solutions of ISO should be wrapped in tin foil and 
kept closed whenever possible to prevent degradation. 
 
1.  Place 150 ml normal Tyrode’s solution containing 1.8 mM CaCl2 into each of 
two 200-ml flasks at room temperature. 
2. Dissolve a DMSO stock of test compound at 1000-fold in one flask. In the 
other, dissolve the same concentration of test compound plus 100 nM ISO. 
3.  At room temperature, dilute DMSO 1000-fold in normal Tyrode’s solution 
containing 1.8 mM CaCl2 to yield a 0.1% DMSO vehicle solution. 
4. Prepare electrophysiological equipment and establish recordings of the resting 
membrane potential as described in Alternate Protocol 1 (steps 5 to 18). 
5.  Just before initiating superfusion with the test compound, record APs during 
exposure to 0.1% DMSO vehicle solution. Use this AP as the control. 
6. Initiate superfusion with the test compound and record APs at each of the 
three pacing frequencies. 
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7.  Once steady-state recordings have been made with the test compound at 0.5, 
1, and 2 Hz, begin superfusion with test compound plus 100 nM ISO while 
stimulating the cell at 1 Hz. 
 
This should lead to an increase in cell contraction. If no increase is seen, prepare a 
new ISO solution and repeat. If this still does not lead to an increase in contraction, 
repeat the protocol with a new cell. 
 
8.  Wait until a steady-state recording has been achieved (5-10 min) and record 
APs at 0.5 Hz followed by 2 Hz. Be sure to wait until a steady state is 
achieved at each pacing frequency. 
9.  At the end of the experiment, turn off the perfusion, stimulator, and heater. 
10.  Clean all equipment between experiments. Rinse the microscope chamber 
and perfusion tubing with 100% ethanol and distilled water to prevent 
contamination and remove residual myocytes. 
 
APs can be analyzed as described in Alternate Protocol 1 (steps 26-29). An example 
of the effects of ISO after blockade of the IKs channel with the reference compound 
HMR1556 is shown in Figure 7. 
 
11.  Begin next series of experiments to obtain data from at least four additional 
cells. 
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Figure 7: ????????????? stimulation on a canine LVMM after blockade of IKs current with 0.5 
??? ????????? Upper panel shows consecutively paced APs at 500 ms CL, together with 
????????? ?????? ??????? ???????? ?????????? ??? ????????? ????????? ??? ???? ??? ???????? ???????????  
APD and BVR before DADs are seen (2nd panel from above). The occurrence of DADs 
(3rd panel) increases APD and BVR further, and DAD triggered APs and EADs are 
subsequently observed (4th panel). Arrows indicate timings of paced beats, and * indicate 
EADs. Low amplitude EADs are also generated under these conditions.Reprinted from 
Johnson et al., 2010 with permission from Elsevier 7. 
REAGENTS AND SOLUTIONS 
Use deionized, distilled water (Millipore) in all recipes and protocol steps. 
 
Normal Tyrode’s solution 
 
? 10 mM HEPES, pH 7.38-7.42. 
? 145 mM NaCl. 
? 4 mM KCl. 
? 1 mM MgCl2. 
? 0, 0.2, or 1.8 mM CaCl2 (as specified). 
? 11.1 mM glucose. 
? Filter sterilize (e.g., Millipore Steritop). 
? Store up to 1 week at room temperature. 
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The pH and osmolarity of these solutions should be between 7.38-7.42 (can be 
adjusted with 1 M NaOH or 1 M HCl) and 275-315 mOsm. If the osmolarity is not 
within these limits, the solutions should be discarded. These values must be checked 
each day before the solutions are used. 
 
2.5 Commentary 
 
2.5.1 Background Information 
 
Compounds that induce TdP have been a major focus of regulatory agencies and the 
pharmaceutical industry since the mid-1990s 10, 11, leading to the adoption of ICH 
S7B and ICH E14 guidance documents 1, 2. Both of these directives rely on 
prolongation of the QT interval as a biomarker to predict the risk that a test agent 
may produce TdP 12. As the distribution of ion channel proteins and ionic currents 
that determine AP shape and duration are similar in both canine and human 
ventricles 13, the beagle dog is a commonly used preclinical species for testing the 
effects of compounds on cardiac repolarization 14. Additionally, as repolarization of 
LVMMs usually determines the end of the T-wave 5, data derived from these cells are 
thought to be good predictors of possible effects on the human QT interval. This unit 
describes a di-4-ANEPPS dye-based method (Basic Protocol) for assessing the effects 
of test compounds on the AP in canine LVMM cells that can be used to more 
efficiently generate APD data 3. This makes it possible to discard at an earlier stage 
in the drug discovery process those test agents that may affect the QT. Because 
scientists have sought to study the AP at the molecular level by implementing 
medium-throughput electrophysiological techniques (e.g., IonWorks 15- 17), and 
because the di-4-ANEPPS-based method can generate APD data more easily, this 
????????????????????????????? ??????????? ???????????????????? ??????????????????????
process than has been possible in the past. In addition to APD assessment, the direct 
effects of test compounds on cardiac contractility and calcium transients can be 
detected in canine LVMM cells. Although significant advances have been made in 
developing in vitro tools to identify the functional effects associated with test 
compounds, in vitro screens for test compounds that are directly cytotoxic to the 
heart have not been established. Therefore, canine LVMM cells can also be used to 
develop in vitro ‘black box’ assays to predict cardiotoxicity at an earlier stage of a 
drug discovery program. An additional protocol included in this unit describes           
a method for investigating the arrhythmogenic effects of a test compound on 
temporal BVR quantified as STV, as well as the occurrence of EADs and DADs after 
application of various test compounds (Alternate Protocol 1). This approach is 
expanded in Alternate Prot??????????????????????? stimulation, which is a particularly 
important issue when a test compound may have the propensity to block the IKs 
current. That is, blockade of the IKs channel alone may not, by itself, lead to 
repolarization pro??????????????????????? stimulation during IKs blockade can lead to 
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development of EADs and DADs, both of which have been implicated in the 
generation of arrhythmias 7, 18. Hence, when assessing the properties of a test agent 
that may block the IKs current, it is critical to examine its effects in the presence and 
absence of sympathetic stimulation. Although the compound throughput of these 
alternate protocols is less than with the optical recordings, they provide critical 
information that cannot be gathered from optical or ion channel screening. For a 
number of years QT prolongation has been employed as a surrogate for 
tachyarrhythmia, TdP. However, it is now appreciated that QT prolongation per se 
does not predict the occurrence of this type of arrhythmia 6, 19, 20. Hence, there is a 
need for other markers for drug-induced arrhythmias. Beat-to-beat variability of 
repolarization (BVR) has been proposed as one such marker for TdP 6. Although the 
mechanisms responsible for increasing BVR are unknown, it appears they are 
generated, at least in part, in the cardiac myocyte. Moreover, cellular BVR has been 
shown to discriminate compounds that are proarrhythmic from those that may safely 
prolong repolarization 7, 21. The alternate protocols presented here allow for 
assessment of the effects of test compounds on this parameter as an indicator to 
how they may influence the temporal variability of repolarization in vivo. 
 
2.5.2 Critical Parameters 
 
Preparation of LVMMs 
 
Careful preparation of LVMMs is the most critical step when measuring APs in 
isolated myocytes. Although the placement of the heart in ice-cold oxygenated 
calcium-free Tyrode’s solution helps preserve it from injury, irreversible damage can 
be caused by taking too long to cannulate the LAD coronary artery and mount the 
heart before beginning perfusion of warmed, oxygenated normal Tyrode’s solution 
without CaCl2 (Figure 1). Additionally, although calcium-free normal Tyrode’s 
solution containing collagenase A and BSA is perfused for ?20 min through a beagle 
dog heart of “normal” size (80-120 g) to accurately digest the perfused area of the 
left ventricular wall, the time of digestion must be tailored to the size of the heart if it 
is abnormally large or small. If the size of the heart is not carefully assessed after its 
removal, the cardiac tissue is likely to be under- or over-digested, yielding cells of 
lower quality for testing. 
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Pacing frequency 
 
A crucial parameter is the pacing frequency applied to the cardiac myocytes, as 
described in Alternate Protocols 1 and 2. Many compounds that cause ventricular 
arrhythmias show reverse rate dependence. That is, they have a greater effect at 
slower pacing frequencies. To test for this, compounds are examined at multiple 
pacing frequencies. Caution must be exercised at every stage of recording to ensure 
that a steady state is attained. Initial pacing of the cell under control conditions 
should last at least 5 to 10 min to allow for stabilization with the microelectrode in 
place. After changing the pacing rate, at least 5 min should be allowed to achieve 
steady state. 
 
Choice of test compound concentrations 
 
At a relatively early stage of drug discovery, the concentration range employed for 
testing a compound should be based on its effects on five key ventricular ion 
channels expressed in cell lines: hNav1.5 (mimicking the hINa current), hCav1.2 
(mimicking the hICaL current), Kv4.3-hKChIP2.2 (mimicking the hITo current), hKv7.1-
hKCNE1 (mimicking the hIKs current), and hKv11.1 (mimicking the hIKr current). 
These values are obtained in preliminary functional assessments using either 
conventional or automated electrophysiology. There needs to be consensus on how 
to use these data to understand APD/QT risk, particularly when a compound modifies 
a range of mutually compensatory electrophysiological processes, hence the 
requirement for assessment of a novel compound in an integrated AP system. Thus, 
there would be considerable value in being able to make full use of the early ion 
channel potencies with optical AP data that can be used to prioritize compounds 
early in the drug discovery process (Lead Identification and Lead Optimization) and 
before substantial resources have been invested. The microelectrode AP study can 
be used to assess the proarrhythmic potential of one to two lead compounds before 
they are selected for preclinical development. Other considerations are the solubility 
of the test compound in the normal Tyrode’s solution containing 1.8 mM CaCl2 and 
the necessity of having the lowest test concentration approximate the predicted free 
Cmax in humans. The concentrations must be spaced at either half or full log10 
intervals to provide a high resolution concentration-effect curve in the event that 
effects are noted (Figure 4 and Table 2). 
 
Troubleshooting 
 
Table 3 details some common problems encountered while obtaining optical and SE 
measurements of cardiac APs in isolated LVMM cells. Possible causes and remedies 
are also discussed. 
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Table 2 
Compound N 
(animals) 
Pacing Parameter Baseline Nominal concentrations tested 
Dofetilide     ???????? ??????? ?????? ???? 
         
 4-6 (2) 1.0 Hz APD90 (ms) 377±18 0.4±2% 15±6%* 46±12%* 37±12%* 
   
STV(APD90) 
(ms) 
12±2 11±2 27±13 51 ± 15* 33 ± 5* 
   Triangulation 1.19±0.03 1.18±0.02 1.17±0.02 1.19±0.02 1.16±0.02 
  0.5 Hz APD90 (ms) 436±25 -3±2% 11±5%* 36±13%* 74±20%* 
   
STV(APD90) 
(ms) 
16±4 15±3 21±5 38±8* 92±19* $ 
   Triangulation 1.16±0.03 1.15±0.02 1.13±0.02 1.13±0.02 1.11±0.01 
D-sotalol     ???? ????? ????? ?????? 
         
 4 (3) 1.0 Hz APD90 (ms) 364±18 -4±2% 12±3%* 14±4%* 28±3%# 
   
STV(APD90) 
(ms) 
8±1 7±1 13±1* 13±1* 20±2# 
   Triangulation 1.20±0.04 1.18±0.03 1.21±0.05 1.21±0.04 1.22±0.06 
  0.5 Hz APD90 (ms) 427±27 -9±4% 2±1% 22±7%* 37±6%# 
   
STV(APD90) 
(ms) 
12±1 10±2 13±3 22±4* $ 33±7* 
   Triangulation 1.26±0.1 1.18±0.02 1.18±0.03 1.19±0.05 1.16±0.05 
DL-sotalol     ???? ????? ????? ?????? 
         
 7 (1) 1.0 Hz APD90 (ms) 348±12 -3±1% 4±3% 5±3% 15±5%* 
   
STV(APD90) 
(ms) 
7±1 6±1 8±2 7±1 12±4 
   Triangulation 1.30±0.06 1.26±0.05 1.25±0.04 1.24±0.04 1.24±0.04 
  0.5 Hz APD90 (ms) 400±12 -5±2% -1±2% 4±4% 18±9%* 
   
STV(APD90) 
(ms) 
9±2 8±2 10±1 12±2 13±2 
   Triangulation 1.30±0.07 1.26±0.05 1.23±0.05 1.23±0.04 1.22±0.05 
Cisapride     ??????? ?????? ???? ????? 
         
 4-10 (2) 1.0 Hz APD90 (ms) 360±15 3±3% 37±11%# 23±5%# -12±6% 
   
STV(APD90) 
(ms) 
7±1 8±1 31±13* 10±2 5±1 
   Triangulation 1.22±0.04 1.22±0.05 1.28±0.07 1.29±0.07 1.47±0.10* 
  0.5 Hz APD90 (ms) 380±19 7±2%* 46±8%# 69±19%* $ -16±6% 
   
STV(APD90) 
(ms) 
7±2 12±2 26±5* 42±20* 17±9 
   Triangulation 1.14±0.01$ 1.14±0.01 1.15±0.01 1.22±0.04 1.36±0.09* 
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Compound N 
(animals) 
Pacing Parameter Baseline Nominal concentrations tested 
Terfenadine     ??????? ?????? ???? ????? 
         
 8-10 (2) 1.0 Hz APD90 (ms) 369±16 -1±1% 5±2%# -34±6%# -74±2%# 
   
STV(APD90) 
(ms) 
8±1 8±1 8±1 10±2 9±5 
   Triangulation 1.15±0.01 1.15±0.01 1.17±0.02 1.27±0.04* 1.36±0.05# 
  0.5 Hz APD90 (ms) 424±25 -0.7±1% 6±2%# -17±6%* $ -67±3%# 
   
STV(APD90) 
(ms) 
10±2 15±5 15±5 6±2 3±1# 
   Triangulation 1.15±0.01 1.15±0.01 1.15±0.01 1.20±0.04 1.36±0.04# 
Pinacidil     ???? ???? ????? ????? 
         
 3-7 (1) 1.0 Hz APD90 (ms) 397±18 -8±2%# -9±2%* -51±3%# -86±1%# 
   
STV(APD90) 
(ms) 
10±1 9±1 8±1 10±1 2±0.2# 
   Triangulation 1.18±0.03 1.19±0.03 1.14±0.01 1.45±0.07* 2.57±0.25* 
  0.5 Hz APD90 (ms) 457±37 -10±2%# -4±2% -47±6%# -86±2%# 
   
STV(APD90) 
(ms) 
22±8 13±2 9±1 8±1 2±0.4* 
   Triangulation 1.17±0.03 1.18±0.03 1.13±0.01 1.39±0.04# 2.59±0.29* 
Diltiazem     ???? ???? ????? ????? 
         
 4-5 (2) 1.0 Hz APD90 (ms) 368±30 -4±1% -4±5% -25±6%* -41±4%# 
   
STV(APD90) 
(ms) 
5±1 5±1 5±1 7±2 6±1 
   Triangulation 1.18±0.02 1.18±0.01 1.18±0.02 1.24±0.03 1.37±0.08* 
  0.5 Hz APD90 (ms) 422±41 -7±1% -2±1% -18±6%* -34±5%# 
   
STV(APD90) 
(ms) 
6±1 7±3 5±1 4±1 4±1* 
   Triangulation 1.17±0.01 1.16±0.01 1.16±0.02 1.20±0.02 1.36±0.09* 
 
Table 2: Effects of reference compounds on STV(APD90) and triangulation (Ratio of 
APD90/APD50) as a function of change in APD90 in canine LVMMs. Data are expressed as 
mean±SEM. Changes in APD90, STV (APD90) and triangulation were measured in (i) 
dofetilide-, d-sotalol- and cisapride-treated cells with (before first EAD) and without (once 
steady state was achieved) EADs and (ii) DL-sotalol-, terfenadine-, pinacidil- and diltiazem-
treated cells once steady state was achieved. Differences were tested for statistical 
significance using the paired (two sample for means; same cardiac preparation) and unpaired 
(two sample assuming unequal variances; one preparation versus another) Student’s t-test.  
A value of P<0.05 was considered significant. *P<0.05 and #P<0.01 versus values from 
vehicle; $ P<0.05 versus values at 1.0 Hz. Table 2 adapted from Abi-Gerges et al., 2010 with 
permission from Wiley-Blackwell 21. 
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Table 3 
Problem Possible cause Solution 
Cell does not respond to the voltage 
stimulus or stops visibly contracting when 
di-4-ANEPPS-based method is employed  
for measuring the AP 
 
The magnitude of the 
voltage-stimulus below the 
excitability threshold of the 
LVMM cell 
 
During perfusion with a 
compound 
 
 
Break in stimulating electrode 
 
 
HSE stimulator faulty 
Temperature of the FHD 
microscope chamber system  
not adequate 
 
 
 
 
 
 
 
 
 
 
Cell MicroControls mTCII 
temperature controller & 
Heater faulty 
 
AP morphology is not optimal 
 
LVMM cell not healthy 
Increase the magnitude 
(amplitude and/or duration) 
of the voltage- stimulus 
 
 
Increase the magnitude 
(amplitude and/or duration) 
of the voltage- stimulus 
 
Re-solder the stimulation 
electrode 
 
Replace the stimulator 
Verify temperature and 
adjust it if necessary 
 
Check the vacuum pump and 
clean the outflow 
 
If broken, remove Corning 
Cover Glass, clean the oil 
objective / re-immersed with 
oil for fluorescence and put a 
new cover glass   
 
 
Replace the controller & 
heater 
 
 
Try a new LVMM cell 
 
Try a new LVMM cell 
Cell contracts and looses striations upon 
contact with the microelectrode 
  
Microelecrode itself is not a 
good shape 
Check the resistance of the 
microelectrode before 
touching cell and if necessary 
adjust microelectrode 
fabrication settings 
  
Cell contact was made too 
quickly 
 
Try a new LVMM cell 
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Problem Possible cause Solution 
Recordings show electrical instability Earthing of setup is not 
optimal 
Check earthing of set-up and 
change if necessary 
  
Air bubbles in microelectrode 
 
Ensure the microelectrode is 
free of air bubble before 
placing into electrode holder 
  
Grounding electrode is not in 
solution 
 
Ensure the grounding 
electrode is covered by 
solution in the bath 
   
AP morphology is not optimal or there is   
no AP on stimulation 
The magnitude of the 
voltage-stimulus is below the 
excitability threshold of the 
LVMM cell 
 
Increase the magnitude 
(amplitude and/or duration) 
of the voltage- stimulus 
 
 The temperature  of the bath 
solution is not at 37 öC 
Verify temperature and 
adjust it if necessary  
 
 Perfusion is not at an optimal 
rate 
Verify flow of perfusate is 
running correctly and adjust 
if appropriate 
 
Table 3:  Troubleshooting guide for the recording of APs in the isolated canine LVMMs. 
 
2.5.3 Anticipated Results 
 
Figure 4 illustrates results of a Basic Protocol study evaluating the electro-
physiological effects of reference compounds on the AP of isolated canine LVMMs. 
The reference compounds selected for the optical APD validation study consisted of 
three selective IKr blockers (dofetilide, D-sotalol, and E-4031), three multiple ion 
channel blockers (terfenadine, cisapride, and alfuzosin; IKr inhibitors with additional 
actions on other cardiac ion channels), an agonist of the late INa (anemone toxin II 
[ATX-??????????????????????????????????????????????+ current, IKATP (pinacidil), and an 
inhibitor of the L-type calcium current, ICaL (diltiazem). APD data obtained with these 
nine compounds were as expected, except (1) D-sotalol-induced increases in 
duration were smaller than those caused by other class III antiarrhythmics, and (2) 
increases in APD were not detected using low concentrations of terfenadine.To 
investigate whether a test compound has a proarrhythmic potential, the procedure 
described in Alternate Protocol 1 should be employed. APD data obtained with 
dofetilide, D-sotalol, cisapride, terfenadine, pinacidil, and diltiazem were as expected 
(Table 2). Additionally, LVMMs exhibited a proarrhythmic response to IKr blockers 
and ATX-II (Table 2 and Figure 6). Incidence of EADs was not related to 
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differences in AP prolongation, but corresponded to BVR, quantified as STV (APD) 
(Table 2 and Figure 6. 7, 21). Moreover, assessment of changes in the AP shape 
(e.g., triangulation 19), in addition to changes in APD and STV (APD), may also be 
helpful for assessing the arrythmogenic risk of a test compound (Table 2). Blockade 
of the IKs current with HMR1556 caused very little change in APD when compared to 
baseline conditions (Figure 6), but predisposed the myocyte to increased BVR 
??????? ??? stimulation, especially at fast rates and during the window of DAD 
occurrence (Figure 7). DADs were generated in all cells and EADs in most cells 
(Figure 7 7). In summary, LVMMs provide a suitable preclinical model to frontload 
the effects of new drugs on optically measured APD and also yield information about 
putative indicators of proarrhythmia (BVR, EADs, and DADs) that add value to an 
integrated QT/TdP risk assessment before a compound enters preclinical 
development. 
 
2.5.4 Time Considerations 
 
For the Basic Protocol, 30 min are needed to prepare LVMM cells (Figure 1), 
followed by 1 hr of stabilization at room temperature in normal Tyrode’s solution 
containing 1.8 mM CaCl2. The stabilization period can be used to prepare the optical 
experimental setup and test compound solutions. Thereafter, ?30 min are needed to 
load the cells with di-4-ANEPPS. Performing one experiment evaluating the effects of 
a test compound at four ascending concentrations on the AP of an isolated LVMM cell 
requires 30 min. To conduct a study, an additional 2-3 hr are required for data 
acquisition and to take recordings from four additional LVMM cells, and 10 min are 
needed for additional off-line analysis (including statistics). Cleaning between 
experiments takes 5 min, with the loading of new cells beginning 10 min prior to the 
completion of the experiment in progress. If the LVMM does not respond to field 
stimulation, or if the recorded AP is not valid for initiation of the experimental 
protocol, a new cell can immediately be selected from the FHD microscope chamber 
system (Figure 2, bottom left) without the need for a new stabilization period. Some 
20 min are needed at the end of the experimental day to thoroughly clean the FHD 
microscope chamber system and superfusion tubing (Figure 2, top right and bottom 
left). To perform one of the experiments detailed in Alternate Protocols 1 and 2, 30-
60 min are required after the myocytes have been isolated and stabilized, although 
obtaining a healthy cell with acceptable AP characteristics can take anywhere from a 
few minutes to a few hours. Around 10 min are needed at the end of the day for 
thorough cleaning of the perfusion system and bath. In general, cells can be used for 
recording for up to 36 hr after isolation. 
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Abstract 
 
In vivo studies have suggested that increased beat-to-beat variability of ventricular 
repolarization duration (BVR) is a better predictor of drug-induced torsades de 
pointes than repolarization prolongation alone. Cellular BVR and its dynamics before 
proarrhythmic events are poorly understood. We investigated differential responses 
of BVR in single myocytes during IKs blockade versus IKr blockade and late-INa 
?????????????? ?????? ???? ?????????? ??? ?-adrenergic receptor ????? stimulation. 
Transmembrane action potentials were recorded from isolated canine left-ventricular 
midmyocytes at various pacing rates. IKs was blocked by HMR1556, IKr by dofetilide. 
Late INa was augmented by sea anemone toxin-II. Isoproterenol was added for          
??? stimulation. BAPTA-AM buffered intracellular Ca2+. SEA0400 partially inhibited 
the Na+-Ca2+ exchanger. BVR was quantified as variability of action-potential 
??????????????????????????????????????????? ???????????????????????????????????????
consecutive action potentials. Baseline BVR was significantly increased by IKr 
blockade and late-INa augmentation, especially at ?????????????????????? stimulation 
restabilized these BVR changes. In contrast, IKs blockade caused very little change in 
repolarization when compared to baseline conditions, but predisposed the myocyte 
to i????????? ???? ??????? ??? stimulation, especially at fast rates. BAPTA-AM and 
SEA0400 reduced this excessive BVR and eliminated early afterdepolarizations. In 
c?????????????? stimulation exaggerates BVR during IKs blockade, indicating a BVR-
stabilizing role of ?-adrenergic-sensitive IKs. Loss of IKs plus overriding of Ca2+-
dependent membrane currents, including inward Na+-Ca2+-exchange current, 
conspire to proarrhythmic BVR under these conditions. 
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3.1 Introduction 
 
Beat-to-beat variability of ventricular repolarization duration (BVR) occurs as an 
apparently random alteration of the repolarization duration (measured from 
transmembrane or monophasic action potentials (APs), local activation-recovery 
intervals or QT intervals) in consecutive heart beats at stable rates. Proarrhythmic 
conditions caused by IKr blockade 1 - 3, IKr-plus-IKs blockade 3 and late-INa 
augmentation 4 are characterized by significant increases of BVR. When increased, 
BVR is a better predictor of drug-induced torsades de pointes (TdP) than 
repolarization prolongation alone, at least in canine and rabbit models 1 - 3, and in 
selected human patients 5.  
 
In the case of selective IKs inhibition in vivo, BVR remains unchanged despite mild  
QT prolongation 3, 6. However, upon the additi??? ??? ???????? ?-adrenergic receptor 
?????? ??? ???????? pronounced repolarization instability occurs, as evident from 
amplified BVR, and this precedes the triggering of early afterdepolarizations (EADs), 
ventricular extrasystoles and TdP 6. Various antiarrhythmic interventions (e.g., 
intravenous KCl administration, IK,ATP activation, steady-state ventricular pacing) that 
prevent TdP are characterized by stabilization of BVR when often the QT interval is 
still prolonged 7. Collectively, these data indicate that a prominent rise of BVR heralds 
torsadogenic instability of the heart, whereas its decline is an expression of 
restabilization of electrical activity. 
 
Cellular studies have revealed that the mechanisms underlying BVR reside, at least 
partly, in the cardiac myocyte. Under baseline conditions at fixed-rate pacing, 
isolated ventricular myocytes express temporal (i.e., beat-to-beat) variability of the 
action-potential duration (APD) 1, 8. A direct relationship exists between rate-
dependent APD and BVR, even during random changes in pacing rate 9. 
Pharmacological interventions to influence ion channels that operate during the AP 
plateau can markedly alter baseline BVR. IKr blockade 1, 8, 10 not only increases the 
cellular APD, but also BVR, whilst promoting the generation of EADs. Similar effects 
were noted for late-INa augmentation with sea anemone toxin-II (ATX-II) 11.  
Conversely, the blockade of late-INa with tetrodotoxin 8 or ranolazine 11, 12 largely 
suppresses these proarrhythmic repolarization changes. Finally, intracellular Ca2+ 
chelation with EGTA reduces BVR in myocytes 8. 
 
In contrast, little is known about the contribution of the potassium current IKs to BVR 
stability in cardiac myocytes. IKs function is prominent during ??????? ??????? when it 
promotes AP shortening by increased protein-kinase-A-dependent activation, and 
during IKr block when it limits AP prolongation by time-dependent activation 10, 13, 14, 
thus providing critical “repolarization reserve” when other repolarizing currents are 
impaired 15, 16. BVR exaggerates significantly when IKs is inhibited after AP 
preprolongation with the IKr blocker almokalant 10. 
67 
CHAPTER 3 
In this study we investigated the properties of BVR in single canine left-ventricular 
(LV) myocytes during superfusion with standard buffer containing physiological 
concentrations of ions (baseline) and the differential responses of BVR during 
selective IKs blockade versus IKr blockade and late-INa augmentation, in the absence 
or presence o?? ???? ??? ???????. Our findings indicate a protective role of IKs in 
preventing excessive B??? ???? ???? ??????????? ??????? ???? ??? ???????, and a 
mechanistic contribution of inward Na+-Ca2+ exchange to these proarrhythmic 
sequelae. 
 
 
3.2 Materials and Methods 
 
This investigation conformed with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). Animal handling was in accordance with the European Directive for 
the Protection of Vertebrate Animals Used for Experimental and Other Scientific 
Purposes (86/609/EU). 
 
3.2.1 Cell-Isolation Procedure 
 
Twenty three adult female beagle dogs weighing 12.8±0.3 kg (range: 10.5-15.0 kg; 
9-31 months of age) were used for the myocyte isolations. Anesthesia was induced 
with 45 mg/kg pentobarbital. Once full anesthesia was reached, the chest was 
opened via a left thoracotomy and the heart was excised and placed in an O2-gassed 
Ca2+-free standard buffer solution at approximately 4°C. The cell-isolation procedure 
was the same as previously described 17. Briefly, the left anterior descending 
coronary artery was cannulated and perfused. After ~20 min of collagenase 
perfusion and subsequent washout of the enzyme, the epicardial surface layer was 
??????????????????????????????????????????????????????????????????????????????
samples were collected from the midmyocardial layer underneath while 
contamination with the endocardium was avoided. Samples were gently agitated, 
filtered and washed. LV midmyocytes were stored at room temperature in standard 
buffer solution and only quiescent rod-shaped cells with clear cross-striations were 
used for the experiments. 
  
3.2.2 Cellular Recordings 
 
Transmembrane APs were recorded at 37°C bath temperature using high-resistance 
(30-?????) glass microelectrodes filled with 3 M KCl. Intracellular pacing was done 
at various cycle lengths (CLs) and only cells that showed a spike-and-dome AP 
morphology were accepted for the experiments. Myocyte contractions were recorded 
with a video edge motion detector (Crescent Electronics, Sandy, UT, USA). 
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3.2.3 Solutions and Agents 
 
The standard buffer solution used for the experiments was composed of (in mM): 
NaCl 145, KCl 4.0, CaCl2 1.8, MgCl2 1.0, glucose 11 and HEPES 10, pH 7.4 with 
NaOH at 37°C. HMR1556 ((3R,4S)-(+)-N-[3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluoro-
butoxy)-chroman-4-???-N-methylmethanesulfonamide) was used to block IKs. At    
500 nM it blocks the current completely 10, while exerting minimal, if any, effects on 
IKr and other ion currents 6, 18, 19. IKr was selectively blocked by 1 μM dofetilide (Apin 
Chemicals, Abingdon, United Kingdom). Late INa was augmented by 20 nM ATX-II 
(Sigma, Zwijndrecht, The Netherlands). Intracellular Ca2+ was buffered with 5 μM 
BAPTA-AM (Invitrogen, Breda, The Netherlands). The Na+-Ca2+ exchanger was 
inhibited by 300 nM or 1 μM SEA0400. At these concentrations SEA0400 has little 
effect on ICaL, the cytosolic Ca2+ transient or contraction of canine ventricular 
myocytes, whereas it blocks Na+-Ca2+ exchange by 28-80% (reverse mode > 
forward mode) depending on cytosolic Ca2+ concentration 20, 21. HMR1556, dofetilide, 
ATX-II, BAPTA-AM and SEA0400 were initially dissolved in dimethyl sulfoxide and 
then diluted so that the concentration of the solvent was <0.1% in the superfusate, 
?? ?????????????? ????? ???? ??? ??????????? ???????? ??? ??? ??? ?????? ?????????? ??R 
stimulation was applied as 100 nM isoproterenol (ISO). This agent was originally 
dissolved in distilled water containing 30 μM ascorbic acid and then stored in the 
dark at 4°C until use. 
 
3.2.4 Data Analysis and Statistics 
 
??????????????????????????????????????????????????????????????????????????????????
? ????????????????????????????????????????????????? ??????????????????????????1. 
In addition, we calculated the coefficient of variability (CV) of APD90 as the 
percentage of standard deviation/mean APD90 8. 
Quantitative data are expressed as mean±SEM. Intergroup comparisons were made 
with Student's t test for unpaired and paired data groups, after testing for the 
normality of distribution. Differences were considered statistically significant if 
P<0.05. 
 
 
3.3 Results 
 
3.3.1 Baseline Characteristics of BVR in Canine LV Myocytes 
 
Figure 1A shows a histogram of 300 consecutive APD90s in a representative 
contracting myocyte during pacing at a CL of 1000 ms. APD90 was normally 
distributed about a mean of 276 ms with a SEM of 0.5 ms. Similar results were 
obtained from 13 cells. A correlation coefficient of 0.90 was calculated between the 
histogram and a normal Gaussian fit. This indicated that APD90 variability within the 
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canine myocyte occurs randomly, which is consistent with previous data from guinea 
pig 8. In 33 cells, pacing rate was varied between CLs of 350 and 4000 ms. APD90 
increased on slowing of the pacing rate, as expected 22. Single representative and 
pooled APD90 data are shown in Figure 1B. 
 
BVR averaged 5.9±0.5 ms at CL 1000 ms (Figure 1B.). Significant increases were 
calculated at both the fastest and slowest pacing rates; at CL 350 ms BVR was 
10.3±2.3 ms and at CL 4000 ms 11.3±1.3 ms (both P<0.05 vs CL 1000 ms). Similar 
patterns were found for CV. At CL 1000 ms CV averaged 2.6±0.2%, increasing to 
4.7±0.8% and 4.4±0.5% at the same extreme rates (both P<0.05 vs. CL 1000 ms; 
Figure 1B). Thus, at (very) fast pacing, rate-dependent adaptation of APD90 
(further decrease) was clearly discordant with that of both BVR and CV (increases). 
Beat-to-beat alternans of both APD90 and contraction amplitude explained this 
discordance, as demonstrated in Figure 1C, left panel. APD90 alternans occurred as 
a very ordered process (interchanging between two values), whereas BVR was 
apparent as a more random APD90 behavior, generally at slower rates (Figure 1C, 
right panel; same cell). This is further exemplified in the Poincaré plots of        
Figure 1D. These data suggest distinct mechanisms for BVR and APD90 alternans. 
Both BVR and CV expressed similar patterns of rate-dependent repolarization 
variability. As BVR incorporates the beat-to-beat consecutiveness of APD90 in its 
formulation whereas CV does not, we used BVR in the remaining analyses. 
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Figure 1: Baseline characteristics of BVR in canine LV myocytes.  
A. Histogram of APD90 from 300 consecutive cycles in a representative cell with Gaussian fit 
(solid line) to the histogram data. Bins of 2 ms width. B. Single-cell (30 APs) and average 
APD90 as a function of pacing CL (Top panel). Bottom panel illustrates the CL dependence of 
both BVR and CV. Average parameters are shown ±SEM. C. Representative AP and 
contraction recordings from the same cell paced at 350 ms and 4000 ms CL. D. Poincaré 
plots of APD90 from the cell shown in C. at the CL of 350 ms (left) and 4000 ms (right). Of 
note is the repetitive behavior seen at 350 ms, whereas at 4000 ms the recordings are more 
chaotic. APD represents APD90. CV, coefficient of variability. CL, cycle length. A.U., arbitrary 
units. 
3.3.2 Influences of Hyper- and Hypokalemia on BVR 
 
Next, we examined the influences of hyper- and hypokalemia. Representative results 
are shown in Figure 2. Myocytes (n=4) were constantly paced at CL 2000 ms. For 
hyperkalemia, [K+?O was raised to 7.0 mM in the superfusate. Along with APD90 
shortening (-15% from 264±35 ms), BVR decreased from 5.3±1.2 ms 
(normokalemia) to 3.0±0.3 ms (P<0.05). For hypokalemia, [K+?O was lowered to 2.5 
mM. Now, APD90 prolonged (+26%) and BVR increased to 9.0±0.8 ms (P<0.05). No 
EADs were observed. Resting membrane potentials varied with the [K+?O changes, as 
expected (see Figure 2A). 
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Figure 2: Response of APD and BVR to changes in [K+?O. 
A. APs recorded from 30 consecutive cycles in a single canine LV myocyte paced at a cycle 
length of 2000 ms under various [K+?O. BVR and APD values and [K+?O are indicated above. 
B. Poincaré plots of APD90 of each of these traces are shown. An increase in BVR is seen 
during a state of hypokalemia, and a decrease in a state of hyperkalemia. 
 
3.3.3 BVR Instability and EAD Generation during IKr Blockade or late-INa 
Augmentation, and R???????????????? ??????? 
 
IKr blockade with dofetilide (1 μM) and late-INa augmentation with ATX-II (20 nM) 
increased APD90 and BVR at pacing CLs of 500, 1000 and 2000 ms, but most 
significantly at the slower rate. This is shown in Figure 3.  In the case of dofetilide 
and for CL 1000 ms, BVR changed from 5.6±0.5 ms at baseline to 16.1±2.9 ms 
(P<0.05; 19 cells; APD90 +37% from 297±15 ms), as calculated from APD90s 
before the first occurrence of EADs (if present; see below). Similarly, in the case of 
ATX-II, BVR increased from 4.4±0.5 ms to 15.5±1.8 ms (P<0.05; 12 cells; APD90 
+47% from 255±17 ms). APD90 histograms remained normally distributed during 
both dofetilide and ATX-II (data not shown). 
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Figure 3: Increases in repolarization instability caused by both IKr blockade and INa 
augmentation ????????????????????? ???????. Representative examples showing the effects of 
dofetilide 1 μM (A.) or ATX-II 20 nM (B.) on BVR ??? ????? ??? ??? ???? ??????? ??? ????
stimulation. AP recordings showing the minimum, maximum and median beats are shown for 
each condition and the ADP90 and BVR are indicated (left). Poincaré plots for each condition 
are also shown.  Group data from all cells is shown on the right. Data is shown as mean + 
SEM. * P<0.05 versus baseline; # P<0.05 versus drug challenge. 
During these drug challenges, th?? ????????? ??? ??R stimulation (ISO; 100 nM) 
drastically reduced APD90 and BVR at all cycle lengths, even to values below 
baseline (Figure 3). EADs were also abolished. For dofetilide at CL 1000 ms, BVR 
decreased from 16.1±2.9 ms to 3.5±0.7 ms (P<0.05; APD90 – 102% to 201±23 
ms). For ATX-II at the same CL, BVR was reduced from 15.5±1.8 ms to 2.8±0.3 ms 
(P<0.05; APD90 –40% to 180±10 ms). In some cells, delayed afterdepolarizations 
(DADs) appeared during ??????? ??????? and drug challenge, however these did not 
reach the threshold for triggering APs. 
 
3.3.4 BVR Instability and EAD G?????????? ??? ??R Stimulation during IKs 
Blockade 
 
IKs blockade with HMR1556 (500 nM) did not affect APD90 at pacing CLs of 500, 
1000 and 2000 ms, in line with previous results 10, 23. For example, at CL 1000 ms 
APD90 was 249±8 ms at baseline compared to 250±8 ms under HMR1556. Likewise, 
BVR remained unaltered at CLs of 500 and 1000 ms. However at CL 2000 ms,          
it increased moderately but significantly (Figure 4, bar graph; n=16). APD90 
histograms remained normally distributed during HMR1556. No EADs or DADs were 
observed during HMR1556 only. 
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Figure 4: ??R stimulation unmasks repolarization instability caused by IKs blockade.   
Representative traces showing the minimum, maximum and median action potential  under 
baseline conditions, IKs blockade and IKs blockade plus ????stimulation during pacing at 1000 
ms. Poincaré plots, APD90 and BVR values for the particular cell are also shown (Left 
Panel). Group data from all cells are shown in the Right Panel showing mean+SEM.  
* P<0.05 versus baseline; # P<0.05 versus drug challenge.  
??????????????????R stimulation during IKs blockade changed this picture drastically: 
BVR increased at all CLs, but most apparently at CL 500 ms and during the window 
of DAD occurrence (Figures 4 and 5). DADs were generated in all cells (n=10), and 
EADs in most of them. At pacing CL 1000 ms, BVR increased to 5.7±0.3 ms during 
HMR1556 plus ISO before the occurrence of DADs from a value of 4.2±0.2 under 
HMR1556 alone. During the subsequent phase with DADs, BVR increased further to 
14.8±1.5 ms (P<0.05). APD90 also showed a significant increase at all CLs. For 
example at CL 1000 ms, APD90 averaged 291±15 ms (+17% versus baseline) during 
HMR1556 plus ISO in the phase with DADs. Obviously, EADs exaggerated BVR and 
APD90 even further (Figure 5).  BVR and APD90 changes, and the generation of 
DADs and EADs, were completely reversible upon washout of ISO. 
 
3.3.5 Differential Magnitudes of BVR in Cells with or without EAD 
Generation, and Rate Dependence of EADs under Different Conditions 
 
During IKr blockade and late-INa augmentation, BVR increases (most pronounced at 
slow rates) were significantly larger in myocytes in which EADs ensued, even though 
BVR was calculated before the first EAD occurred, (n=8/19 for dofetilide and n=5/12 
for ATX-II) versus those cells in which no EADs were seen (n=11/19 and n=7/12, 
respectively). 
 
This is shown in Figure 6A (for CL 2000 ms). In contrast, EADs generated during IKs 
????????????????R stimulation were clearly fast-rate dependent (Figure 6B). Under 
these conditions, BVR was not statistically different for myocytes with ensuing    
????? ????????? ??????? ?????? ???????? ?????????? ??R-stimulated EADs were       
always preceded by DADs and were always accompanied by early aftercontractions 
(Figure 7 and Figure 8, middle panels).  
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Figure 5: Time course of increased repolarization instability during IKs ????????? ????? ??R 
stimulation. Upper panel shows consecutively paced APs at 500 ms CL, together with 
????????? ?????? ??????? ???????? ?????????? ??? ????????? ????????? ??? ??R stimulation increases    
APD and BVR before DADs are seen (2nd panel from above). The occurrence of DADs 
(3rd panel) increases APD and BVR further, and DAD triggered APs and EADs are 
subsequently observed (4th panel). Arrows indicate timings of paced beats, and * indicate 
EADs. Low amplitude EADs are also generated under these conditions. 
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Figure 6: Magnitude of BVR in cells with or without EADs, and rate dependence of EADs 
under various conditions. A. Bar graph showing BVR values in cells that show EADs compared 
to those that did not during various drug treatments. Insets show examples of EADs caused 
by IKr block and INa augmentation together with the preceding beat and the baseline AP. 
Mean data shown ± SEM; BL represents baseline. * P<0.05 versus BVR in cells with no EADs. 
B. Bar graph showing the rate dependence of EADs. Number of EADs per 10 beats are 
plotted at various CLs during all 3 treatment groups. Mean data shown ± SEM. 
Early aftercontractions usually took off before EAD upstrokes (Figure 7, middle 
panel) and, in fact, occurred often without concrete EADs. Collectively, these data 
indicated that EADs and DADs during IKs ????????? ????? ??R stimulation are 
generated as the consequence of cellular Ca2+ overload and spontaneous Ca2+ 
release from the sarcoplasmic reticulum, and they suggested a mechanistic 
contribution of inward Na+-Ca2+ exchange 24, 25.  
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Figure 7: Ca2+ chelator BAPTA-AM rescues from excessive BVR during IKs ????? ??R 
stimulation. Representative traces showing 30 consecutive AP and contraction recordings 
overlapped from the same cell under IKs blockade (left panel), plus ???? ??? ???????  
(middle panel) and together with 5 μM BAPTA-AM (right panel) whilst being paced at 
1000 ms. Inset shows an example EAD caused by IKs blockade plus ??????? ??????? which are 
eliminated during intracellular calcium buffering despite APD lengthening. Dashed line 
indicates the initiation of the early aftercontraction which preceded the EAD upstroke. 
Poincaré plots, APD90 and BVR values for this particular cell are also shown. 
3.3.6 Influences of BAPTA-AM and SEA0400 on BVR Instability and EAD 
Generation during IKs Blockade plus ??????? ??????? 
 
As a final series of experiments, we examined the effects of the intracellular Ca2+ 
chelator BAPTA-AM (5 μM) and the Na+-Ca2+-exchange blocker SEA0400 (300 nM or 
1 μM) on BVR instability and EAD generation by ??????? ??????? during IKs blockade. 
Data were obtained in 6 cells. As shown in Figure 7, BAPTA-AM significantly reduced 
excessive BVR and eliminated all EADs (and DADs). At pacing CL 1000 ms, BVR 
changed from 12.9±1.6 ms during HMR1556 plus ISO (before first EADs) to 4.2±0.1 
ms (P<0.05) during additional BAPTA-AM, even despite extra AP prolongation 
(APD90 +56%). The latter is likely caused by a reduction in ICaL inactivation 26 and an        
IKr-blocking side-effect of BAPTA-AM 27. BVR restabilization was maximal when all 
(after) contractile activity was inhibited by the Ca2+ buffer.                        
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Figure 8: Na+-Ca2+ exchange inhibitor SEA0400 rescues from excessive BVR during IKs plus 
??????? ???????. Representative traces showing 30 consecutive AP and contraction recordings 
from the same cell under IKs blockade (left panel) plus ??????? ??????? (middle panel) plus  
300 nM SEA0400 (right panel) at CL 500 ms. EADs are seen under IKs blockade plus ????
stimulation which are eliminated during application of SEA0400. Poincaré plots, APD90 and 
BVR values for the particular cell are also shown. 
Figure 8 illustrates the effects of SEA0400 (300 nM) at CL 500 ms. BVR decreased 
significantly from 12.2±1.5 ms during HMR1556 plus ??????? ??????? to 2.4±0.2 ms 
(P<0.05) during additional SEA0400. Effects were less pronounced at CLs 1000 and 
2000 ms. All EADs were eliminated upon the addition of SEA0400. BVR effects were 
quantitatively similar for 300 nM and 1 μM SEA0400, as were reductions of APD90 
and contraction amplitude. At CL 500 ms, APD90 decreased from 246±16 ms during 
HMR1556 plus ??????? ??????? to 201±13 ms (P<0.05) during additional SEA0400, 
whilst contraction amplitudes were decreased by 52±5%. 
3.4 Discussion 
The mechanisms underlying BVR at the single-cell level are poorly understood. In the 
present study, we used canine ventricular myocytes to investigate BVR responses at 
baseline and during various proarrhythmic challenges. Our data indicate that IKs 
stabilizes BVR at slow pacing rates under baseline conditions, despite the absence   
of changes in APD90. ???? ??? ??????? of IKs rescues from excessive repolarization 
instability and EAD generation during IKr block and late-INa augmentation. 
Furthermore, our results support the notion that ???? ??? ??????? during drug-
induced IKs block promotes altered Ca2+ handling and enhanced activation of Ca2+-
dependent membrane currents, including inward Na+-Ca2+ exchange, thus 
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exaggerating BVR. Although single myocyte BVR is not the sole contributor to in-vivo 
QT variability, our novel insights are crucial for the understanding of BVR at the 
whole organ level such as seen after IKs blockade and ??????? ??????? 6.   
 
3.4.1 Distinction between BVR and Repolarization Alternans 
 
At baseline, BVR is mainly dependent on APD which in turn is reliant on cycle length. 
At very fast rates, however, APD90 and BVR become discordant as the result of  
beat-to-beat repolarization alternans (Figure 1). The latter is an ordered process, 
characterized by interchanging between two APDs and concomitant contraction 
amplitudes. Although repolarization alternans is considered arrhythmogenic, EADs 
are not normally seen under these conditions, at least not in our experiments. 
Repolarization and contraction alternans arise from beat-to-beat alteration in cellular 
Ca2+ cycling 28. BVR, on the other hand, is characterized by an apparently random 
behavior of APD, generally at intermediate and slow rates. Even during pronounced 
BVR instability, e.g., by hypokalemia, IKr blockade and late-INa augmentation, 
contraction amplitudes remain relatively stable (contraction data not shown). Our 
data thus indicate that in the majority of cases BVR and APD90 show parallel 
changes. However, in specific conditions they can deviate, for example during IKs 
blockade plus ???? ??? ???????, and during IKs blockade plus ???? ??? ??????? and 
BAPTA-AM. This suggests that BVR is not necessarily dependent on APD90 at all 
times, which has major mechanistic implications. 
Cellular BVR likely results from the stochastic activities of transmembrane ion 
transporters, including ion channels, during the AP plateau phase. During this phase, 
around the 0 mV level, the membrane resistance is very high 8, meaning that minute 
changes of the ion fluxes across the membrane can significantly affect the 
membrane potential which in turn will alter the repolarization duration 29. 
Interventions that reduce net outward current will cause a prolongation of this 
vulnerable phase, meaning that there is an extended period at which the voltage is 
around the 0 mV level. Stochastic behavior of the ion channels may then increase 
BVR. It is also possible that this stochastic behavior results indirectly from 
subsarcolemmal Ca2+ fluctuations that lead to modification of Ca2+-dependent ion 
currents. Modeling data has shown that during ISO stochastic ICaL gating in mode 2 
results in APD variability as well as EAD generation 30, and this could contribute to 
the BVR seen in this study. 
 
3.4.2 Cellular BVR during ??????? ???????  
 
In the present study, we have shown that BVR is drastically increased under 
conditions of IKr blockade or late INa augmentation in isolated canine LV 
midmyocytes. The addition of ??????? ???????, however, causes a major reduction in 
BVR and eliminates EAD activity (Figure 3). As IKs ??????????????-sensitive outward 
current in the canine ventricular AP, this current appears responsible for the 
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restabilization of repolarization. If true, ???? ??? ??????? would provoke BVR 
instability during IKs blockade, as IKs could no longer compensate for the increased 
ICaL caused by ???? ??? ???????, which leads to increased cellular Ca2+ load and 
APD90.  This was indeed the case: BVR increased significantly, despite only 
moderate increases in APD90 (Figure 4). In this phase, ??????? ????????also evoked 
DADs and EADs (Figure 5). BVR increased after the first generation of DADs (even 
before EADs occurred; Figure 5), which supports the concept that dynamic 
subsarcolemmal Ca2+ fluxes during cellular Ca2+ overload and diastolic spontaneous 
Ca2+ release from the sarcoplasmic reticulum influence the subsequent (paced) APs 
and BVR via mechanisms yet to be elucidated. Our finding that BVR and EAD 
generation by IKs blockade and ??????? ????????were most pronounced at fast pacing 
rates (as opposed to IKr blockade and late-INa augmentation; Figure 6) fits with this 
concept. Additional support comes from the result that intracellular Ca2+ chelation 
with BAPTA-AM reduces beat-to-beat repolarization instability (Figure 7). Moreover, 
in preliminary experiments in which we used ryanodine (1 μM) during IKs blockade 
???? ???? ??? ??????? (data not shown), blockade of sarcoplasmic-reticulum Ca2+ 
release reduced excessive BVR (while inhibiting the generation of 
afterdepolarizations), again supporting that calcium-dependent membrane currents 
contribute to BVR. 
Our results on afterdepolarization occurrence are partially in agreement with data 
from the canine LV-wedge preparation 31. Burashnikov and Antzelevitch 31 reported 
that under combined IKs blockade and ???? ??? ????????? ????? ????? ???????? ??? ????
epi-, mid- and endocardium. Transmural dispersion of repolarization was 
accentuated. However, no EAD activity was seen. This apparent discrepancy with our 
observations in isolated myocytes could be explained by the difference in cell-to-cell 
electrotonic coupling. The latter, which acts in the LV wedge preparation but not in 
the isolated cell, has been shown to reduce BVR 8. 
 
3.4.3 The Na+-Ca2+ Exchange Inhibitor SEA0400 Attenuates Excessive BVR 
and EADs during IKs Blockade plus ??????? ??????? 
 
Various groups have used the Na+-Ca2+-exchange inhibitor SEA0400 in attempts to 
prevent TdP under conditions of IKr block 32, 33 and INa augmentation 32 with mixed 
results. Milberg et al. 32 showed that the application of SEA0400 (1 μM) in the 
presence of sotalol or veratridine resulted in a significant decrease of monophasic 
APD and an attenuation of EADs in paced Langendorff-perfused rabbit hearts      
with complete atrioventricular block, supporting the hypothesis that the               
Na+-Ca2+ exchanger is an important mediator of EADs 25. However in the study of 
Farkas et al. 33 SEA0400 (1 μM) did not suppress dofetilide-induced TdP nor decrease 
QT variability in unpaced Langendorff-perfused rabbit hearts with complete 
atrioventricular block. The major difference between these two studies was that in 
the study of Milberg 33 hearts were paced at constant cycle lengths, whereas in the 
alternate study 32 hearts were allowed to beat at their intrinsic ventricular rate. Upon 
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administering SEA0400 in addition to dofetilide, the rate instability increased, and 
this additional factor could have increased the susceptibility to TdP, at variance with 
the results of Milberg et al. 33. 
To the best of our knowledge this report is the first to describe the use of Na+-Ca2+-
exchange inhibition in the presence of IKs block combined with ??????? ???????? (as 
such mimicking long-QT syndrome type 1 (LQT1)). In line with Milberg 33, the 
application of SEA0400 resulted in a significant decrease of transmembrane APD and 
an attenuation of EADs (Figure 8). Moreover, SEA0400 rescued from excessive BVR, 
suggesting a repolarization-destabilizing role of inward Na+-Ca2+-exchange under of 
IKs blockade combined with ??????? ??????? 24. 
 
3.4.4 Clinical Perspectives 
 
In LQT1 patients, sympathetic stimulation and epinephrine challenges prolong the 
QT interval 34, increase beat-to-beat QT variability 35 and promote EAD generation 34. 
Our present cellular results may thus have important clinical implications, as they 
support the use of Ca2+ antagonists 36????R blockers 34, 36 and even IK,ATP openers 34 to 
restrain BVR and reduce the risk of TdP in these patients. Indeed, ????blockade, the 
cornerstone of pharmacological treatment in LQT1, decreases epinephrine-prolonged 
monophasic APD and transmural dispersion of repolarization in LQT1 34. Likewise,    
?-adrenergic-receptor blockade with phenylephrine can decrease transmural 
dispersion of repolarization in LQT1 patients, but causes it to increase in LQT2 
patients 37. Whether the Na+-Ca2+ exchanger is a suitable target for antiarrhythmic 
treatment in LQT1 patients is currently under debate. 
 
3.4.5 Conclusions 
 
The repolarizing potassium current IKs stabilizes BVR in single canine LV myocytes. 
During conditions of IKr blockade and late-INa ?????????????? ???? ???mulation of IKs 
rescues from excessive BVR, AP prolongation and EAD generation. However, during 
IKs blockade ???? ??? ???????? provokes excessive BVR, while promoting the 
generation of DADs and EADs. The loss of IKs plus overriding of Ca2+-dependent 
inward currents, including inward Na+-Ca2+-exchange current, likely conspire to 
cellular proarrhythmia under these conditions. 
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Abstract 
 
Spontaneous Ca2+ release from the sarcoplasmic reticulum (SCR) can cause delayed 
afterdepolarizations (DADs) and triggered activity, contributing to arrhythmogenesis 
????????-adrenergic receptor ??????stimulation. Excessive beat-to-beat variability of 
repolarization duration (BVR) is a proarrhythmic marker. Previous research has 
shown that BVR is increased d????????????????? stimulation leading to SCR.  
We aimed to determine ionic mechanisms controlling BVR under these conditions. 
Membrane potentials and cell shortening or Ca2+ transients were recorded from 
isolated canine left-ventricular myocytes in the presence of isoproterenol. Action-
potential (AP) durations following DADs were significantly prolonged. Addition of IKs 
blockade led to further AP prolongation after SCR and this strongly correlated with 
exaggerated BVR. Suppressing SCR via inhibition of ryanodine receptors, CaMKII 
inhibition, or by using Mg2+ or flecainide, eliminated DADs and decreased BVR 
independent of effects on AP duration. Computational analyses and voltage-clamp 
experiments measuring ICaL with and without prior SCR indicated that ICaL was 
increased during Ca2+-induced Ca2+ release after SCR, and this contributes to AP 
prolongation. Prolongation of QT, Tpeak-Tend intervals and left-ventricular monophasic 
AP duration of beats following aftercontractions occurred prior to torsades de pointes 
in an in-vivo dog model of drug-induced long-QT1 syndrome.  
SCR contributes to increased BVR by interspersed prolongation of AP duration, which 
is exacerbated during IKs blockade. Attenuation of Ca2+-induced Ca2+ release by SCR 
underlies AP prolongation via increased ICaL. These data provide novel insights into 
arrhythmogeni?? ??????????? ??????? ???? stimulation besides triggered activity and 
illustrate the importance of IKs function in preventing excessive BVR. 
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4.1 Introduction 
 
Enhanced cellular Ca2+ ?????? ???? ???????? ??????? ?-??????????? ????????? ??????
stimulation, results in augmentation of Ca2+ release from the sarcoplasmic reticulum 
(SR), larger Ca2+ transients (CaT), and enhanced contractile force 1. Under certain 
conditions Ca2+ load is increased beyond a certain threshold, leading to spontaneous 
Ca2+ release (SCR) from the SR during diastole 2.  In turn, this diastolic leak causes  
a transient inward current (ITI), causing delayed afterdepolarizations (DADs), mainly 
due to activation of the electrogenic Na+-Ca2+ exchanger (NCX), with the           
Ca2+-activated Cl- current (ICl(Ca)) contributing in some species 3, 4. Previous work has 
shown that both DADs and early afterdepolarizations (EADs) may share a common 
mechanism, ??????????????????????? ??????????????2+ overload, namely SCR-induced 
currents 5. Both types of afterdepolarizations have been incriminated in the formation 
of ventricular tachycardia (VT), via triggered activity (TA) and/or by increasing 
dispersion of repolarization 6. 
 
Beat-to-beat variability of repolarization duration (BVR) occurs as an apparently 
random alteration in repolarization duration, and can be observed at all levels, from 
the action potential (AP) of the single cardiac myocyte to the QT interval on the body 
surface 7 - 9. Exaggerated BVR has been reported to be a more reliable indicator of 
arrhythmogenic risk than repolarization prolongation per se, at least in several 
experimental VT models 10 - 12 and in selected human subjects 8, 13.  
 
Although BVR has been investigated in multiple studies, the mechanisms underlying 
this phenomenon at the single-cell level remain to be fully elucidated. 
Pharmacological interventions influencing ion channels that operate during the AP 
plateau can markedly alter BVR 7, 14. Despite the fact that inhibition of the slowly-
activating delayed-rectifier K+ current (IKs) alone has minimal effects on both cellular 
AP duration (APD) and BVR 14, we have recently shown that during increased Ca2+ 
loading in myocytes subjected to blockade of IKs ??????????????????????????? ?????????
BVR is significantly enhanced, even before the occurrence of EADs and TA 14. 
 
In the present study, we investigated the relationship between SCR and BVR using a 
combined experimental and computational approach in both canine ventricular 
myocytes and in-???????????? ?????????? ?????????? ????????????????? ??????????????
only lead to ITI and DAD formation, but also to a prolonged duration of the following 
AP via increased L-type Ca2+ current (ICaL), which in turn leads to increased BVR 
when analyzing multiple consecutive APs. Pharmacological interventions that inhibit 
SCR (either with reduced or preserved systolic contraction) prevent this SCR-
associated AP prolongation and reduce BVR.   
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4.2 Methods 
 
This investigation conformed to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). Animal handling was in accordance with the European Directive for 
the Protection of Vertebrate Animals Used for Experimental and Other Scientific 
Purposes (86/609/EU). 
 
4.2.1 Myocyte Isolation and Electrophysiology 
 
Canine left ventricular myocytes were isolated as previously described 15. 
Transmembrane APs were recorded at ~37°C using high-resistance (30-?????????????
microelectrodes filled with 3 mol/L KCl. Myocyte contractions were recorded with a 
video edge motion detector. 
 
4.2.2 Calcium Measurement 
 
We used the perforated patch-clamp technique under current- or voltage-clamp 
control as previously described 16. Myocytes were stimulated to elicit APs (current 
clamp) or ICaL (voltage clamp). Changes in intracellular Ca2+ concentration ([Ca2+?i) 
were measured using Fluo-3 or Fura-2 AM 16. 
 
4.2.3 Computational Analysis 
 
A recent model of the canine ventricular ???????? ?????????????????? ?????????? ????
stimulation 17 was extended with a method to induce diastolic SR Ca2+ release in one 
of two identical Ca2+ domains in a controlled fashion (Figures 1 and 2). Simulations 
were performed in single cells as well as a one-dimensional homogeneous strand or 
two-dimensional tissue of electrically-coupled cells to determine the effects of 
diastolic Ca2+ release in the presence of electrotonic coupling.   
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Figure 1: Schematic overview of the computational model of the canine ventricular myocyte. 
Adapted from Heijman et al. 17. The model was divided into two identical domains to simulate 
the local origin of SCR. Only components on the left side of the model are labeled for clarity, 
identical components are located on the right side. The domains are coupled via diffusion of 
Ca2+ (Idiff,cyt and Idiff,nsr). All other abbreviations are as previously described 17.  
Similar simulations were performed in a one-dimensional homogeneous strand of 
electrically-coupled cells to determine the effects of diastolic Ca2+ release in the 
presence of electrotonic coupling. 
 
4.2.4 In-Vivo Dog Model of Drug-Induced Long-QT1 Syndrome 
Torsades de Pointes (TdP) arrhythmias were induced in an in-vivo dog model of 
long-QT1 (LQT1) syndrome, as previously described.11 ECG, left ventricular pressure 
(LVP) and left ventricular monophasic action potentials (LV MAPs) were recorded 
throughout the experiments and analyzed offline. 
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Figure 2: Validation of model properties. A. Steady-state APD-rate dependence under 
baseline conditions (left panel), in the presence of ISO (middle panel) or in the presence of 
ISO + HMR1556 (right panel) for APs without prior DAD. Average APD for each cell is shown 
in grey. Average APD over all myocytes is indicated with symbols. Model APD is shown in 
black. Model APD-rate dependence falls within experimental range and is close to the 
experimental average for all conditions and CLs. B. Average APD difference between APs 
preceded by a DAD and those without prior DAD in the presence of ISO or ISO + HMR1556. 
Average APD difference for each cell is shown in grey. Average group data is indicated with 
symbols. Model APD prolongation after SCR is indicated with grey bars. Model APD 
prolongation is consistent with experimental observations. 
4.2.5 Data Analysis and Statistical Comparisons 
APD was quantified at 90% repolarization. BVR was quantified as variability of APD 
?????? ???? ???????? ??????? ?? - ??????????????????? ???? ??? ???????????? ???? ??? ????
absence of TA 10. DADs were detected with a semi-automated method using a 
custom software script. Where applicable, data were reported as mean±SEM of n 
experiments, and significance tested with either a t-test or one-way ANOVA. 
Differences were considered statistically significant if P<0.05.  
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4.3 Results 
 
4.3.1 DADs Prolong Subsequent APs and Increase BVR 
 
Under baseline conditions, a small beat-to-beat APD variability was observed (Figure 
3A; left panel??? ???? ??? ???????? ????? ?????????????? ?????? ?????????? ???? ????
enhanced contraction (Figure 3A; middle panel). In the majority of cells, 100 
nmol/L ISO caused DADs during pacing at 1000 ms CL. APs following a DAD were 
prolonged, leading to increased BVR due to interspersed occurrence of normal and 
prolonged APs (Figure 3A; middle panel). Pharmacological inhibition of IKs by 
HMR1556 (500 nmol/L) in the presence of ISO further prolonged APD and increased 
BVR (Figure 3A; right panel). In separate experiments, Ca2+ transients were 
recorded together with APs after HMR1556 and ISO. HMR1556 alone did not increase 
the Ca2+-transient amplitude nor lead to any SCR events. The combination of 
HMR1556 and ISO, however, led to large increases in Ca2+ amplitude and SCR, as 
expected.18 APs following SCR were prolonged and had a reduced systolic Ca2+-
transient amplitude compared to those where no diastolic release preceded the AP, 
indicating reduced SR Ca2+ load at the start of the AP (Figure 3B), consistent with 
the reduced cell shortening following an aftercontraction (Figure 3A).  
 
APD prolongation following a DAD was significantly more pronounced in the presence 
of ISO + HMR1556 compared to ISO alone at all CLs (e.g., 41±6 ms vs. 15±4 ms at 
CL = 1000 ms, P<0.05, Figure 4A) and this coincided with a significant increase in 
BVR (17±2 ms vs. 7±1 ms; P<0.05, Figure 4B). As such, HMR1556 was added in all 
subsequent experiments in the presence of ISO to maximize effects on APD, 
essentially creating a cellular model of drug-induced LQT1 syndrome 14. DADs 
showed typical rate-dependent properties, including increased amplitude and 
decreased AP-DAD coupling interval at shorter pacing CL, consistent with previous 
results 19. IKs blockade did not alter rate-dependent DAD properties (Figure 5). 
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Figure 3: Occurrence of DADs in canine ventricular myocytes is associated with prolongation 
of subsequent APs and increased BVR. A. APD90 for 75 consecutive beats at 2000-ms CL at 
baseline (left panel: I), during wash-in of ISO (middle panel: II) and in the presence of 
HMR1556 and ISO (right panel: III). APDs preceded by a DAD are indicated with filled 
symbols, APDs without DADs depicted by open symbols. Dashed rectangle indicates a set of 5 
beats for which cell shortening and membrane potential are depicted below. Insets show 
diastolic potentials at an expanded scale. Beats without prior SCR are indicated in black, 
beats with prior SCR in grey. B. Membrane potential (top) and [Ca2+?i for four consecutive 
beats. APD90s are indicated below each AP. SCR is indicated with arrows. 
To determine whether DAD-like membrane-potential changes alone (i.e., without 
underlying alterations in intracellular Ca2+) influenced the subsequent AP, current 
was injected to induce small alterations in the resting membrane potential (25-mV 
amplitude, 150-ms duration; Figure 4C; top panel). There was no significant 
difference between APDs in the absence or presence of these diastolic pulses 
(Figure 4D), independent of the timing of the pulse (not shown). In contrast, when 
these cells were stimulated with HMR1556 + ISO, DADs occurred and subsequent 
APD was significantly prolonged (Figure 4C; bottom panel), indicating that 
alterations in the subsequent APD were influenced by DAD-related events other than 
membrane-potential alterations per se. 
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Figure 4: A. Group data for APD90 under baseline conditions, in the presence of ISO, or in 
the presence of ISO + HMR1556 at CLs of 500, 1000 and 2000 ms. DADs cause a significant 
prolongation during ISO and ISO + HMR1556 treatment. APD90 differences are indicated 
above each pair of bars. *; P<0.05 based on paired T-test.  B. BVR values for the conditions 
in panel A. The number of cells and number of dogs for each condition are indicated below 
each bar. Comparisons between conditions were made using ANOVA. C. Cell shortening (top 
trace) and membrane potential (bottom trace) under baseline conditions with DAD-like 
electrical pulses (in the absence of SCR) applied every 4th beat (top panel) or with DADs after 
ISO + HMR1556 in the same cell (bottom panel). APD90 is indicated below each beat.         
D. Subthreshold diastolic pulses do not alter APD90 within the same cell (left panel) nor BVR 
compared to cells without diastolic pulses (right panel).  
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Figure 5: Rate-dependent characteristics of DADs in the presence of ISO (left panels) or  
ISO + HMR1556 (right panels). A. Percentage of cells which ??????? ????? ??????? ??? 
stimulation. Number of cells and number of dogs are indicated in each bar. B. Average 
percentage of APs which had a DAD. C. Coupling interval between end of repolarization 
(APD90) and subsequent DAD for those beats which showed a DAD. D. Average DAD 
amplitude. * indicates P<0.05 based on one-way ANOVA with Tukey-Kramer post-hoc test. 
DADs occur earlier and are larger at faster rates. Data are consistent with those of Priori and 
Corr 20 in canine ventricular myocytes measured using a pace-pause protocol. 
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4.3.2 Coupling Between the Occurrence of DADs and EADs During             
?-Adrenergic Stimulation and IKs Blockade 
 
In addition to DADs, EADs were observed. EADs occurred predominantly at 500-ms 
CL and exclusively in the presence of HMR1556 + ISO.  
 
Figure 6: Relationship between diastolic SCR and EADs. A.Top panel: Cell shortening (top 
trace) and membrane potential (bottom trace) for 5 consecutive APs followed by an AP with 
EAD (indicated with *) in a representative cell at 500-ms CL in the presence of HMR1556 + 
ISO. APD90 is given below each beat and DADs are indicated with arrows. Vertical line 
indicates timing of start of aftercontraction. Bottom panel indicates the percentages of APs 
that showed a DAD in the 5 beats preceding every EAD. Horizontal dashed line indicates 
overall DAD occurrence at 500-ms CL in the presence of HMR1556 + ISO, independent of 
EADs. The beat before an EAD has a DAD 95% of the time. *: P<0.05 compared to overall 
DAD occurrence. B. Similar to panel A (top) for 2 beats in the presence of ISO only. A similar 
contraction pattern can be observed but APD prolongation is insufficient to promote EAD 
formation. C. Time differences between rise of aftercontraction and EAD, indicating that 
aftercontractions occur earlier than EADs. 
 
We observed early aftercontractions preceding EAD upstrokes by 21±5 ms (Figure 6 
A, C and 5), consistent with the observations by Zhao et al. in rabbit ventricular 
myocytes challenged with ISO and the ICaL agonist Bay K 8644,20 suggesting a role of 
SCR for EAD formation under these specific conditions 5.  
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We quantified the occurrence of DADs in the beats preceding an EAD and found that 
DADs were significantly more likely to occur in the 2 beats directly preceding an EAD 
(53% and 95% of APs) compared to average DAD occurrence for all beats (34%; 
Figure 6A bottom panel). Figure 6B shows the responses during ISO alone. 
 
4.3.3 Blockade of (Spontaneous) SR Ca2+ Release Reduces BVR 
 
We sought to further investigate how eliminating SCR would affect APD and BVR. 
Blockade of the ryanodine receptor (RyR) with ryanodine eliminated DADs and led to 
a drastic reduction in BVR, despite leading to an increased APD (Figure 7A, B). APD 
prolongation under these conditions was not associated with any arrhythmogenic 
events. A drastic reduction in systolic contraction was also seen, as expected, 
indicating that blockade of RyRs was achieved effectively.  
 
Tetracaine reduces the open probability (Po) of RyR leading to a decrease in the 
frequency of SCR in unstimulated rat ventricular myocytes 21 and the abolishment of 
ISO-induced SCR in voltage-clamped rat ventricular myocytes 22. Similar                 
to ryanodine, tetracaine led to an elimination of DADs in our experiments,            
and a reduction in BVR at all CLs. However, unlike ryanodine, cell shortening 
remained largely unaltered, indicating that systolic Ca2+ release was largely intact 
(Figure   7C, D).   
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Figure 7: Inhibition of (diastolic) SCR abolishes DADs and reduces BVR. Cell shortening (top 
panels; arbitrary units) and membrane potential (bottom panels) for 5 representative beats 
during treatment with ISO + HMR1556 (A.????????????????????????????????????????????B.). 
APD90 is indicated below each beat and mean APD90 and BVR are shown for 30 beats in the 
Poincaré plot on the right. DADs are indicated with arrows. Panels C. and D. show similar 
????? ???? ??????????????? ??????????? ??? ????????? ?????????????? ?????????????? ?????????????
and DAD occurrence. Ryanodine and tetracaine abolish DADs and reduce BVR. 
To determine the effects of increasing the Po of RyRs, as opposed to decreasing it, 
we used low concentrations of caffeine (maximally 500 μmol/L) 23. Under these 
conditions the percentage of APs showing DADs was increased at all CLs. 
Interestingly, this led to a significant decrease in BVR compared to HMR1556 and 
ISO alone, since DADs occurred before every AP (Figure 8, right-most grey bars).  
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Figure 8: Interventions that abolish or homogenize SCR lower BVR. A. APD90. ncells / ndogs are 
indicated below each bar. B. DAD occurrence. C. BVR at CL = 1000 ms at baseline, in the 
presence of ISO, HMR1556 + ISO, or HMR1556 + ISO combined with interventions to 
modulate SCR. Interventions are grouped by type (RyR modulation, grey; Calmodulin/CaMKII 
modulation, black; or agents also used clinically; striped). All interventions except caffeine 
result in a significant lowering of DAD incidence and a concomitant reduction of BVR, with 
?????????? ????????????? ?????????? ????????????? ??????????? ??? ?????????? ??? ?????????? ???? ???
????????? ????? ??? ????????? ?Mg+?? ??? ????????? ???90?? ????????? ????? ????? ???? ????????
regularizes SCR occurrence, increasing DAD occurrence but lowering BVR without changing 
APD90. *; P<0.05 versus HMR1556 + ISO. 
Several studies have shown that Ca2+/CaMKII is an important signaling molecule 
affecting Ca2+-induced Ca2+ release (CICR) and that its inhibition can be 
antiarrhythmic 24. Curran et al. 25 demonstrated that SR Ca2+ leak durin?? ????
stimulation is mediated by CaMKII. In our experiments, inhibition of calmodulin using 
W7 reduced DAD incidence in all cells (from 44% to 8% at 1000 ms CL, P<0.05) and 
completely abolished them in 3/7 cells. The decrease in DAD occurrence was 
paralleled by a decrease in BVR. Average APD was unaltered by W7, and systolic 
contractions remained intact. Application of the CaMKII inhibitor KN93 led to similar 
results (Figure 8, black bars). 
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Mg2+ has been shown to suppress both EADs and DADs in different models 26, 27 and 
is used clinically as a first-line agent against TdP. Increasing extracellular [Mg2+??
from 1 mmol/L to 5 mmol/L abolished DADs induced after HMR1556 and ISO in 4/7 
cells. In the remaining 3 cells, DAD incidence was significantly reduced. A 
concomitant reduction in BVR was seen. APDs were not significantly altered, and 
although systolic contractions were slightly reduced compared to beats that did not 
show SCR events before Mg2+, they remained stable, suggesting that the SR content 
remained constant (not shown). Similar results (albeit with reduced APD) were 
obtained with the class-IC antiarrhythmic agent flecainide (Figure 8, striped bars), 
which has been shown to be effective in preventing catecholaminergic polymorphic 
VT due to its effects on RyR and Na+ channels 28.  
 
4.3.4 Increases in [Ca2+]O Can Reinstate SCR Only When (Residual) RyR 
Function is Available 
 
We hypothesized that increases in [Ca2+?O after interventions that reduced DAD 
occurrence would lead to recurrence of SCR, DADs and increase BVR. Therefore,    
we raised the [Ca2+?O from 1.8 mmol/L to 3.6 mmol/L after application of ryanodine, 
tetracaine, or W7. This led to a reinduction of DADs after tetracaine or W7,           
and a significant decrease of APD (Figure 9A - C). However, raising [Ca2+?O       
after ryanodine did not lead to DADs, nor did it alter BVR, indicating that RyR 
function is required for SCR and without this BVR cannot be altered. Interestingly, 
BVR was not significantly reincreased after W7 and high [Ca2+?O, whereas           
after tetracaine and high [Ca2+?O it was, despite DADs being reinstated under       
both conditions (Figure 9B, C). In the presence of W7, APs following SCR were      
no longer prolonged (Figure 9C, inset). These data suggest that calmodulin 
inhibition has a direct effect on the coupling between SCR and APD, possibly via ICaL. 
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Figure 9: Effect of increased [Ca2+?o on APD90 (top panels), DAD occurence (middle panels), 
and BVR (bottom panels) under baseline conditions, HMR1556 + ISO, HMR1556 + ISO + 
Intervention or HMR1556 + ISO + Intervention + 3.6 mmol/L [Ca2+?o. A. Ryanodine. B. 
Tetracaine. C. W7. * indicates P<0.05. Only significance of intervention versus intervention in 
the presence of high [Ca2+?o is indicated for clarity reasons. Inset in lower-right panel shows 
APD90 in the presence of HMR1556 + ISO + W7 + increased [Ca2+?o for beats in the absence 
or presence of a preceding DAD. 
4.3.5 Reduced Ca2+-Dependent Inactivation of ICaL Underlies APD 
Prolongation After SCR 
 
We employed a computational model of the canine ventricular myocyte to further 
investigate the ionic basis of the coupling between SCR and APD prolongation. After 
pacing to steady state, a partial release of SR Ca2+ was induced during diastole.  
After this release, APD was prolonged, consistent with experimental observations 
(Figure 10A; 1000-ms CL in the presence of ISO). The prolonged APD was 
associated with a decreased CaT, an increase in the sustained component of ICaL and 
increased IKs. The increase in IKs was due to the increased plateau potential resulting 
from the larger ICaL and counteracted the repolarization delay. As such, APD 
prolongation was significantly larger when IKs was inhibited (Figure 10B).             
An increase in plateau Vm was also observed in experimental recordings (maximum 
amplitude of plateau was 114±1 mV without prior DAD and 118±1 mV following 
DADs at 1000 ms CL in the presence of HMR1556 + ISO, P<0.05). 
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Several currents underlying the ventricular AP are modified by intracellular Ca2+. To 
determine the relative contribution of each component, we used the model             
to selectively inhibit each current for one final beat at steady state following either  a 
normal diastole or SCR. Inhibition of the main currents (INaCa and ICl(Ca) 3, 29) only     
had  a minor impact on the APD differences in the presence and absence of SCR 
(Figure 10C). In contrast, inhibition of ICaL or RyR was able to significantly reduce 
the DAD-provoked APD prolongation. More specifically, when only Ca2+-dependent 
inactivation (CDI) of ICaL was inhibited, APD after SCR was no longer prolonged 
compared to APD without prior SCR (Figure 10C). Further investigation showed any 
differences in APD in these conditions were due to ‘priming’ of CDI due to a 
transition of L-type Ca2+ channels to the Ca2+-dependent tier of the Markov model 
induced by the Ca2+ that was released during the SCR, prior to activation of 
inhibition. 
 
Combined, our data implicate reduced SR Ca2+-release-dependent inactivation of ICaL 
as the mechanism underlying APD prolongation after SCR. This prediction was 
confirmed under voltage-clamp conditions in native canine ventricular myocytes 
when the extracellular solution was modified to isolate ICaL (Figure 11).  
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Figure 10: Computational model of the canine ventricular myocyte implicates reduced SR 
Ca2+-dependent inactivation of ICaL to cause APD prolongation. A. AP, intracellular Ca2+, ICaL 
and IKs (top to bottom) with (dashed lined) or without (solid lines) prior SR Ca2+ release for a 
single beat after pacing to steady state in the presence of ISO at CL of 1000 ms. The DAD 
resulting from the SCR is indicated by an arrow. Inset in 3rd panel shows ICaL during AP 
plateau on an expanded scale.  B. Similar to panel A in the presence of ISO and complete 
inhibition of IKs. C. After pacing to steady state in the presence of ISO, SCR was triggered 
(shaded bars) or not (white bars) and individual currents/fluxes were blocked for one final 
beat. APD90 differences are indicated above each bar. Only inhibition of SR Ca2+ release (RyR) 
or ICaL CDI was sufficient to completely abolish the APD prolongation after SCR.  
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Figure 11: ICaL inactivation is slowed after SCR. A. Voltage-clamp protocol (top panel), 
intracellular Ca2+ (middle panel) and membrane current (bottom panel) in a representative 
canine ventricular myocyte in the presence of HMR1556 + ISO + increased [Ca2+?o (3.6 or 5.0 
mmol/L) in the absence (black) or presence of prior SCR (grey). Right inset shows membrane 
current at an expanded scale. 4-AP (5.0 mmol/L) and BaCl2 (0.1 mmol/L) were used to isolate 
ICaL. Left inset shows model results under similar conditions. B. Quantification of average 
membrane current integral (shaded area in right inset of panel A) in 6 canine ventricular 
myocytes in the absence or presence of SCR. Prior SCR significantly increases total inward 
current (*: P<0.05). 
During a voltage step to +10 mV from a holding potential of -80 mV a significant 
increase in the integral of ICaL ???? ????????? ?????? ????? ??CaL = 27.9±3.5 nC vs 
33.0±3.5 nC in the absence or presence of SCR, respectively (P<0.05).  
4.3.6 Relation Between Aftercontractions, Repolarization Prolongation and 
Dispersion, and Arrhythmogenesis in the Intact Canine Heart 
To evaluate whether the single-cell mechanisms described could affect 
arrhythmogenesis in-vivo, we employed a canine model of drug-induced LQT1 11. 
Application of a bolus of ISO during continuous HMR1556 infusion resulted in 
aftercontractions exclusively in the LVP signal prior to the development of ventricular 
premature beats and TdP (Figure 12A). In parallel with the occurrence of 
aftercontractions, we observed paradoxical QT prolongation during ??? heart-rate 
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acceleration, resulting in a significant increase of the QT interval in the last sinus 
beats prior to the extrasystoles triggering TdP (Figure 12B). Similarly, LV MAP 
duration was significantly prolonged in these beats and a significant increase in  
Tpeak-Tend interval was noted (Figure 12B), which could reflect an increased 
dispersion of repolarization.  
 
      
 
 
Figure 12: Aftercontractions and repolarization prolongation precede the occurrence of TdP 
in an in-vivo canine model of LQT1.  
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A. ECG, LV MAPs and LVP in the 6 beats prior to the first extrasystolic beat and initiation of 
TdP in a representative experiment after a bolus of ISO in the presence of HMR1556. Inset 
shows TdP inducibility by ISO during HMR1556 in the absence or presence of verapamil. B. 
Group data showing electrophysiological properties (RR interval, QT interval, LV MAP duration 
and Tpeak-Tend interval) and average amplitude of the preceding aftercontraction in the 
absence (filled squares; n=14) or presence (open circles; n=5) of verapamil. * indicates 
P<0.05 compared to beat -6 (ANOVA for repeated measures with Bonferroni post-hoc test); $ 
indicates P<0.05 versus the absence of verapamil for the same beat. Data are shown relative 
to the start of TdP or during the maximal chronotropic response to ISO. C. Comparison of the 
electrophysiological properties of the beats preceding (light grey) and following (dark grey) 
the first aftercontraction during HMR+ISO: RR interval, QT interval, LV MAP duration,     
Tpeak-Tend interval. *; P<0.05 compared to pre 1st AC. D. Effect of diastolic Ca2+ release in 
25% of the cells on average repolarization time (top) and spatial dispersion of repolarization 
(bottom) in 1-dimensional strand simulations and 2-dimensional tissue simulations with intact 
or disabled ICaL CDI. 
 
 
We focused on repolarization duration by comparing the beats preceding and 
following the first notable aftercontraction. QT, LV MAP and Tpeak-Tend durations were 
significantly increased in the beat after the first aftercontraction, whereas the RR 
intervals were unchanged (Figure 12C). Furthermore, the ICaL inhibitor verapamil 
(0.4 mg/kg) prevented TdP induction by ISO during continuous HMR1556 infusion in 
5/5 animals (Figure 12A), although some ventricular extrasystolic activity could still 
be observed (Figure 13). Similar chronotropic responses were seen after ISO in the 
presence of verapamil but, in the absence of aftercontractions, QT, LV MAP and 
Tpeak-Tend prolongation were significantly smaller when compared to HMR1556      
and ISO alone (Figure 12B). These data illustrate the role of Ca2+-dependent 
regional repolarization prolongation for TdP induction in this model. 
 
To further test the hypothesis that SCR at the single-myocyte level can contribute to 
the QT and Tpeak-Tend interval prolongation seen in-vivo, we performed computer 
simulations of both a homogeneous one-dimensional strand and a two-dimensional 
tissue of electrically-coupled myocytes. Consistent with our hypothesis, diastolic SR 
Ca2+ release increased repolarization duration and spatial dispersion of repolarization 
in both simulations (Figures 12D, 14 and 15), and this effect was completely 
abolished by inhibition of ICaL CDI (Figure 12D and 16). 
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Figure 13: A. ECG, left-ventricular (LV) monophasic action potential (MAP) and LV pressure 
(LVP) recordings following a bolus of ISO during continuous HMR1556 infusion in the absence  
or B. presence (of verapamil (0.4 mg/kg) in the same dog. RR intervals are indicated above 
the ECG traces and QT and LV MAP durations are indicated below the ECG and LV MAP 
signals, respectively. TdP was induced in the absence of verapamil and was preceded by 
aftercontractions in the LVP signal (indicated by arrows). Verapamil reduced the systolic LVP 
by approximately 17% and prevented the aftercontraction formation and TdP induction. 
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Figure 14: Multicellular simulations in a one-dimensional strand of 128 cells in the presence 
of ISO and IKs blockade. A. APs during steady state pacing at CL = 1000 ms (top panel). Prior 
to beat (0), diastolic SR Ca2+ release was initiated in cells 32-96 (arrow). The bottom panel 
shows an overlay of Vm for cell 10 (orange, no DAD), cell 64 (grey, with DAD indicated by 
arrow) and cell 118 (green, no DAD) for these three beats. B. APD90 for all cells in the strand 
for these 3 beats. Cells 10, 64 and 118 have been indicated by vertical dashed lines. The 
presence of a preceding diastolic SR Ca2+ release causes a pronounced prolongation of APD90 
of beat (0) throughout the strand (black line). In addition, an increase in the spatial 
dispersion of repolarization could be observed. C. Average repolarization time (activation time 
+ APD90; left panel) and spatial dispersion of repolarization (maximum repolarization time – 
minimum repolarization time; right panel) as a function of the number of cells with diastolic 
SR Ca2+ release (SCR). SCR caused a progressive increase in the average repolarization time. 
Dispersion of repolarization was influenced by the number of cells with SCR (with a maximum 
around 50%). A low spatial dispersion of repolarization was expected at 100%, when all cells 
exhibit SCR. However, spatial dispersion of repolarization also depends on the timing of the 
SCR. Since SCR was initiated at the same time in all cells, but the time of Ca2+-induced Ca2+-
release differs due to action potential propagation along the strand, there is a longer time for 
SR refilling after the SCR in cell 128 than in cell 1. As such, the amount of APD prolongation 
differs throughout the strand resulting in an increased spatial dispersion even at 100%. 
Spatial dispersion of repolarization is a complex, non-monotonic function that depends on the 
number of cells with SCR, their location in the strand, the timing of the SCR and the 
conduction velocity. 
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Figure 15: Multicellular simulations in homogeneous two-dimensional tissue of         
200x200 nodes in the presence of ISO and IKs blockade. A. APs (top panel) and [Ca2+???
(bottom panel) for 5 beats during steady-state pacing at 1000-ms CL for a cell on  the edge 
of the tissue (at coordinates (4,4), black lines) and a cell in the center of the tissue (blue 
lines).  The location of these cells is indicated with stars in panels B and C (left). APD90 of 
each AP is given below each beat in the corresponding color. Diastolic SR Ca2+ release was 
induced from 1925 to 1950 ms (indicated by arrows) for a region of 100x100 cells           
(25% of the cells) around the center of the tissue (i.e., cells with x and y coordinates 
between 50 and 150, dashed box in panels B and C). B. Spatial electrophysiological 
properties of beat 2. The left panel shows repolarization time (activation time + APD90) at 
every point in the tissue. Average repolarization time was 291 ms and spatial dispersion of 
repolarization (maximum-minimum repolarization time) was 29 ms. The eight smaller panels 
on the right show voltage maps at different time instants. The voltage maps show a 
homogeneous diastolic interval followed by a planar wave propagating from left to right 
following pacing (conduction velocity of 49 cm/s). Repolarization occurs uniformly around 
1290 ms. C. Similar to panel B for beat 3 which is preceded by diastolic Ca2+ release in a 
subset of the cells. Average repolarization time is longer (305 ms) and shows increased 
spatial dispersion (45 ms), in line with one-dimensional simulations and in-vivo experimental 
data. Voltage maps identify the DAD in the center of the tissue and the prolonged 
repolarization of this same area during the following beat. 
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Figure 16: Multicellular simulations in homogeneous two-dimensional tissue of 200x200 
nodes in the presence of ISO and IKs blockade after inhibition of Ca2+-dependent inactivation 
(CDI) of ICaL. Simulation protocol and figure layout are identical to Figure 15, except for the 
inhibition of CDI for these 5 beats (after pacing to steady-state in the presence of ISO and IKs 
blockade). Inhibiting CDI prolongs APD90, consistent with experimental data 30 and single-cell 
simulations (Figure 10). Inhibition of CDI prevents APD prolongation following diastolic     
SR Ca2+ release despite similar DAD and systolic Ca2+ transient properties and prevents 
increased spatial dispersion of repolarization. Note that due to this APD prolongation different 
time-points were used for the voltage maps in panels B and C (indicated in purple). 
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4.4 Discussion 
 
In this study, we elucidated the relationship between SCR, AP prolongation and BVR 
in canine LV myocytes and provide arguments for its arrhythmogenic significance in 
the in-vivo beating heart. Our data indicate that under conditions of ISO-induced 
Ca2+ loading, SCR can occur over a wide range of pacing CLs and that APD following 
SCR is significantly prolonged. Reduced CICR-dependent inactivation of ICaL after SCR 
is involved in this AP prolongation. The increase in BVR was strongly dependent on 
the degree of APD prolongation after SCR. In anesthetized dogs subjected to similar 
conditions, we observed the occurrence of mounting aftercontractions in parallel with 
QT, Tpeak-Tend and LV MAP prolongation just prior to TdP which could be prevented by 
inhibition of ICaL and Ca2+ load with verapamil. SCR-related repolarization 
prolongation was reproduced in multicellular computer simulations. Our data align 
??????????????????????????????????????????? ???????????????????????????????????????
rabbit heart, leading to Ca2+-mediated focal arrhythmia 31. In the setting of 
exaggerated spatio-temporal dispersion of repolarization such focal activity may 
trigger TdP, as actually observed in the canine model of drug-induced LQT1 
???????????????????? ??????????????????11).    
 
Previous cellular studies 32 - 34 have shown that large CaTs result in abbreviation of 
APD, whereas a small CaT after SR Ca2+ depletion corresponds to prolonged APD. In 
agreement, we find substantial APD prolongation after application of ryanodine due 
to reduced CDI of ICaL. Furthermore ICaL CDI is sensitive to (partial) SR Ca2+ 
unloading by SCR. These changes in CDI are sufficient to modulate APD on a beat-
to-beat basis over a wide range of CLs. Interestingly, Spencer and Sham reported 
the opposite effect in guinea-pig ventricular myocytes perhaps due to species 
differences in the balance of NCX and ICaL 35. In the present study, we used Ca2+-
sensitive fluorescent probes and cell shortening as Ca2+ indicators. Both measures 
reflect cytosolic Ca2+ levels, which are substantially different from the 
subsarcolemmal [Ca2+????????????????2+-activated membrane currents. 
 
4.4.1 The Importance of IKs Blockade 
 
Burashnikov and Antzelevitch 36 demonstrated that IKs block alone was insufficient to 
induce DADs or modulate repolarization heterogeneity in canine transmural 
ventricular tissues 36. However, it amplified the effects of adrenergic stimuli. At the 
myocyte level, we have previously shown that IKs blockade (via KCNQ1 inhibition 37) 
has minimal effects on APD and BVR under baseline conditions. D?????? ????
stimulation and IKs blockade, BVR is significantly increased and this is at least partly 
dependent on [Ca2+?i 14. Here we extend this by determining an important role for 
CDI of ICaL, at least in the presence of SCR. Under baseline conditions, IKr is the main 
repolarizing current in canine ventricular myocytes and inhibition of IKr can cause 
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EADs due to APD prolongation and subsequent ICaL reactivation 14. During additional 
??????? ??????????????????????????????????????????????????????????????????????????????
IKs becomes more prominent; enhanced IKs prevents repolarization instability and EAD 
generation by other proarrhythmic mechanisms (e.g., IKr inhibition or augmentation 
of late INa). In contrast, inhibition of IKs ??????? ???? ??? ???????? ?????? ??? ????
prolongation, increased BVR and EADs indicating ???????????????????????????????????
stimulation, IKs is a major contributor to repolarization. Barandi et al. 38 have 
previously shown that the degree of APD prolongation induced by pharmacological 
block of repolarizing currents or augmentation of depolarizing currents, depends on 
baseline APD. Consistent with these results, we find a more pronounced APD 
prolongation after SCR at slow CL and in the presence of IKs blockade. In our 
experiments, APD prolongation after SCR is particularly pronounced because the 
increase in ICaL also elevates the plateau potential which increases IKs activation and 
offsets the prolongation induced by ICaL (Figure 10A, bottom panel). This 
compensating mechanism is absent when IKs is inhibited. Thus, IKs inhibition 
exacerbates the effect of SCR on APD prolongation. 
 
 4.4.2 The Role of SCR in Arrhythmogenesis 
 
It has long been established that SCR-induced triggered activity is a major 
arrhythmogenic mechanism during Ca2+ overload and its occurrence is increased in 
various pathological conditions 6, 39. Here we observed that diastolic SCR prolongs the 
subsequent APD, suggesting that even SCR below the threshold for triggered activity 
has important electrophysiological effects that may be proarrhythmic. Regional 
prolongation of APD after SCR in the intact heart may cause increased spatial 
dispersion of repolarization between regions with the highest Ca2+ load (generating 
SCR) and regions with lower Ca2+ loading. In agreement with this hypothesis, we 
observed increased QT duration and Tpeak-Tend intervals following the first 
aftercontraction upon a challenge with a bolus of ISO during IKs blockade in-vivo. 
Regional heterogeneities in ion-channel expression or intercellular conduction may 
further amplify this dispersion. Combined, these mechanisms can promote functional 
reentry. Stabilization of Ca2+ handling may therefore not only reduce the incidence of 
arrhythmogenic triggers but also prevent their reentrant perpetuation.  
 
Although current pharmacological interventions do not allow specific targeting of SCR 
or measurement of cellular Ca2+ handling in the in-vivo dog heart, we found that ICaL 
inhibition with verapamil could prevent aftercontractions and TdP in our model of 
LQT1, and this was associated with a reduction in the paradoxical increase in QT and 
Tpeak-Tend intervals following ISO. 
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We have also shown that the combination of ISO and fast pacing can give rise to 
diastolic SCR which prolongs APD sufficiently such that the next SCR occurs before 
the end of repolarization, generating an EAD. The common dependence of DADs and 
EADs on SCR in the presence of ISO has previously been described 5, 19 and is in 
agreement with recent findings in rabbit ventricular myocytes 20. Our results provide 
novel mechanistic insights on the coupling between SCR, APD prolongation and EAD 
occurrence and illustrate that diastolic SCR is a central element in both triggered 
activity and repolarization instability. However, the ionic mechanisms of EAD 
generation, particularly the relative roles of INCX and ICaL, are complex and cannot be 
fully determined based on our data. Moreover, the measurement of the lag between 
the start of the aftercontraction and the EAD upstroke does not take into account the 
delay between SCR and activation of contraction or the SCR-induced slowing          
of repolarization in the priming phase before the EAD upstroke. This lag is likely due 
to differential Ca2+ thresholds for the activation of contraction versus the activation 
of membrane currents. 
 
APD prolongation after SCR results from increased ICaL, which enhances Ca2+ loading 
via increased sarcolemmal Ca2+ influx. Enhanced loading along with reduced Ca2+ 
efflux serves to restore and fine-tune SR Ca2+ content to maintain CICR efficacy, as 
has previously been described in rat ventricular myocytes 32, 34. However, during 
increased Ca2+ load these mechanisms will readjust, promoting SCR, facilitating the 
occurrence of afterdepolarizations. Consistent with this reasoning, we found that the 
probability of observing a DAD was not significantly altered by the presence of a DAD 
on the previous beat. This strongly implies that, under our experimental conditions, 
the reduction in myocyte Ca2+ load during a DAD is overcome by the increased 
sarcolemmal Ca2+ influx during the following prolonged AP. Thus, APD prolongation 
after SCR contributes to the vicious cycle of Ca2+ loading and ultimately overload. 
These results are in agreement with the recent modeling study by Morotti et al. who 
established that ICaL predominantly inactivates due to CDI and that (strongly) 
reduced CDI can cause Ca2+ overload and DADs 40. 
 
Inhibition of SCR by ryanodine and tetracaine has previously been described 19, 22, 
and the results presented here agree with those data. We extend these observations 
by showing a concomitant decrease in BVR. Both ryanodine and tetracaine are useful 
for mechanistic studies but due to their deleterious effects in vivo cannot be used as 
therapeutic agents. In contrast, both magnesium and flecainide are commonly used 
antiarrhythmic agents. Here we show that both these agents can lead to a reduction 
in BVR and arrhythmogenic events, most likely due to stabilization of Ca2+ handling 
in the single myocyte. Similarly, we confirm the usefulness of modulating 
Calmodulin/CaMKII during increased Ca2+ loading as an antiarrhythmic strategy 24.  
CaMKII phosphorylation has been shown to induce a different gating mode      
(mode 2) of the ICaL channel, thereby reducing inactivation, favoring Ca2+ entry and  
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the occurrence of EADs and DADs 41. Interestingly, when CAMKII inhibition is applied 
a disconnect appears between SCR events and APD. Whether this is due to 
alterations in Ca2+-dependent inactivation, or due to effects on other CAMKII 
substrates, such as INaL, is not clear and further investigation is warranted.  In this 
regard, the development of selective CaMKII modulators suitable for antiarrhythmic 
interventions in humans is awaited. 
4.4.3 Conclusions 
 
We have shown that after SCR, inactivating ICaL is increased and APD and QT 
intervals are prolonged, most likely due to reduced CICR-dependent inactivation of 
this current. The degree of APD prolongation is exacerbated by inhibition of IKs. This 
contributes to increased BVR and spatial dispersion of repolarization during         
ISO-induced diastolic Ca2+ release and, aside from DAD-mediated triggered activity, 
may be an additional mechanism contributing to arrhythmogenesis. Pharmacological 
interventions that regularize SCR or inhibit SCR with or without preserved systolic 
contractions reduce BVR. Our data provide novel insights into arrhythmogenic 
mechanisms during increased Ca2+ loading. 
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Supplementary Methods 
 
Cell-Isolation Procedure 
 
Adult female beagle dogs were used for the myocyte isolations. Anesthesia was 
induced with 45 mg/kg pentobarbital. Once full anesthesia was reached, the chest 
was opened via a left thoracotomy and the heart was excised and placed in an      
O2-gassed Ca2+-free standard buffer solution at approximately 4°C. The cell-isolation 
procedure was the same as previously described 1. Briefly the left anterior 
descending coronary artery was cannulated and perfused. After ~20 min                
of collagenase perfusion and subsequent washout of the enzyme, the epicardial 
????????????????????????????????????????????????????????????????????????????????
Softened tissue samples were collected from the midmyocardial layer underneath 
while contamination with the endocardium was avoided. Samples were             
gently agitated, filtered and washed. LV midmyocytes were stored at room 
temperature in standard buffer solution (vide infra) and only quiescent rod-shaped 
cells with clear cross-striations were used for the experiments. Cells were used within 
48 h of isolation. 
 
Sharp-Electrode Action Potential Recordings 
 
Transmembrane action potentials (APs) were recorded at 37°C using high-resistance 
(30–??? ???? ?????? ???????????????? ??????? ????? ?? ?????? ???? ????? ?? ???????????????
amplifier (Axoclamp-2B, Axon Instruments, Inc). Intracellular pacing was done at 
various cycle lengths (CLs; 500 ms – 2000 ms). Only cells showing a stable spike-
and-dome AP morphology and resting membrane potential were accepted for the 
experiments. Myocyte contractions were recorded with a video edge motion detector 
(Crescent Electronics, Sandy, UT, USA).  
 
Ca2+ Measurements 
 
Isolated myocytes were loaded with the acetoxymethyl ester of indicator Fluo-3 or 
Fura-?? ??????????? ???????? ?? ???????? ?? ???? ???????? ???? ??? ???? ??-esterification). 
Electrophysiological control for current clamp and voltage clamp experiments with 
simultaneous [Ca2+?i measurements was achieved using the perforated patch clamp 
technique with amphotericin-?????????????????????????-clamp facility (frequency 1–3 
kHz and gain 1–3) of the Axoclamp-2B voltage clamp amplifier (Axon Instruments, 
CA, USA) was used to overcome the access resistance of the perforated patch. All 
experiments were performed at 37°C. 
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Drugs and Experimental Solutions 
 
The standard buffer solution used for the experiments was composed of (in mmol/L): 
NaCl 145, KCl 4.0, CaCl2 1.8, MgCl2 1.0, glucose 11 and HEPES 10, pH 7.4 with NaOH 
at 37°C. In a subset of experiments, extracellular [Mg2+????????????????????????????
by the addition of 4 mmol/L MgSO4. In other experiments, extracellular [Ca2+??????
increased to 3.6 mmol/L to further increase cellular Ca2+ loading. 
 
500 nmol/L HMR1556 ((3R,4S)-(+)-N-[3-hydroxy-2,2-dimethyl-6-(4,4,4-
trifluorobutoxy)chroman-4-???-N-methylmethanesulfonamide; a gift from Dr. H. 
Gögelein, Sanofi-Aventis Germany GmbH, Frankfurt, Germany) was used to 
selectively and completely block IKs 2, 4. Sarcoplasmic reticulum (SR) Ca2+ release 
???????? ???? ?????????? ????????? ?????????? ???????????????????????? ?????????? ??????
????????????????? ??? ??????????? ?????? ?? ??????? ??????????? ??????, Zwijndrecht, The 
Netherlands). Caffeine (Sigma, Z????????????????????????????????? ?????????????????
was used to increase RyR open probability. Ca2+/Calmodulin-dependent kinase 
(CaMKII) activity was modulated using the CaMKII inhibitor KN93 (Sigma, 
Z???????????? ???? ????????????? ?? ???????? ???? ???? ??? ??????? ?????????? ??? ????????
???????????? ????????? ???? ?? ??ol/L). The class-1C antiarrhythmic agent flecainide 
(MedaPharma, Amstelveen, The Netherlands) was employed in a subset of 
?????? ??????????????????? ??????????????????? ?????????????????? ??????????????? 5 as 
well as affecting multiple other targets (40% inhibition of ITO 6, significant inhibition 
of (late) INa 7 and ~50% inhibition of HERG K+ channels 8). 
 
For perforated patch experiments the patch pipette solution contained (in mmol/L): 
KCH3O3S 125, KCl 20, NaCl 10, HEPES 10, MgCl2 5, K2EGTA 0.1, titrated to 7.2 with 
KOH with patch pipette resistance being 2-?? ???? ??? ???????? ?????? ?????? ??????    
K+ currents were blocked by addition of 500 nmol/L HMR1556, 5 mmol/L                
4-aminopyridine and 100 nmol/L BaCl2 to the standard buffer solution. Extracellular 
Ca2+ was raised (to 3.6 or 5.0 mmol/L) to further enhance cellular Ca2+ loading.  
 
HMR1556, ryanodine, tetracaine, caffeine, W7 and KN93 were initially dissolved in 
dimethyl sulfoxide (DMSO) and then diluted so that the concentration of the solvent 
was maximally 0.1% in the superfusate, a concentration that has no measurable 
effects on AP or ionic currents.  
 
??R stimulation was applied by 100 nmol/L isoproterenol (ISO) in all experiments. 
???????????????????????????????????? ??????????????????? ??????????????????????????????
acid and then stored in the dark at 4°C until use. 
 
When assessing the effect of pharmacological interventions, all conditions were kept 
constant for several minutes until APD and cell shortening reached steady state. 
Analyses were performed using these steady-state data. 
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Data Analysis 
 
Detection of EADs, DADs and determination of APD, BVR and DAD parameters was 
done in a semi-automated fashion using a custom Matlab (The Mathworks, Natick, 
MA, USA) script. Briefly, Axon (Axon Instruments, CA, USA) data files were loaded 
into Matlab. AP upstroke was detected based on peaks in the numerically calculated 
dV/dt, and APD90 was determined. Subsequently, the diastolic interval between APD90 
of one beat and the point of maximum dV/dt of the next beat was processed for all 
beats. The signal was low-pass filtered at 30 Hz to reduce noise. All peaks in the 
filtered signal were determined and resting membrane potential was defined as the 
average value between the smallest (most negative) local maximum and local 
minimum. The amplitude of all other peaks was determined relative to this resting 
membrane potential. DADs were identified as a local maximum in the filtered signal 
of more than 2 mV in amplitude and manually confirmed by the investigators. EADs 
were detected as positive local maxima in the low-pass filtered dV/dt signal preceded 
and followed by negative local minima. Detection of EADs was manually validated. 
BVR was determined using a sliding window of consecutive 30 bea????????????????i+1 
- APDi|)/[nbeats????????????????????????????????????????????????????????????????????
intervention) was determined for each cell. 
 
In-Vivo Dog Model of LQT1 
 
TdP arrhythmias were induced in an in-vivo dog model of long QT 1 syndrome as 
previously described 9. Briefly, general anesthesia was induced in 10 beagle dogs by 
lofentanil (0.075 mg/kg body weight i.v.), scopolamine (0.015 mg/kg), 
succinylcholine (1.0 mg/kg), hourly slow injections of fentanyl (0.025 mg/kg i.v.), 
and continuous infusion of etomidate (1.5 mg/kg/hour). Dogs were ventilated with 
30% oxygen in pressurized air to normocapnia. The body temperature was kept at 
37°C with a heated water mattress. ECG standard lead II was continuously recorded 
and the QT interval (QT; ms) measured from the onset of the QRS to the final end of 
the T wave. Left ventricular (LV) intracavitary pressures were recorded with       
high-fidelity catheter-tip micromanometers (Gaeltec Ltd, Dunvegan, UK and Millar 
Instruments Inc, Houston, TX). Under fluoroscopic guidance a MAP catheter (Boston 
Scientific-EP Technologies, San Jose, CA, USA) was placed at the endocardium of the     
LV and RV, near the apical septum. HMR1556 (dissolved in 20% HP-?-cyclodextrin) 
was infused i.v. in the dogs, initially at a rate of 0.025 mg/kg/min for 30 min and 
followed (if necessary) by infusions at 0.05 mg/kg/min and 0.1 mg/kg/min. At 
regular time intervals, boluses of ISO (1.25, 2???????????????????????????????????????
TdP and in prevention experiments verapamil (0.4 mg/kg) was infused pre-ISO 
challenge after confirming TdP inducibility with HMR1556 + ISO in the same animal. 
External electrical cardioversion was applied to terminate sustained TdP or its 
deterioration into ventricular fibrillation, if induced by ISO. 
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Computational Modelling 
 
?? ????????????? ??? ???? ??????? ???????????????????? ?????????????????? ?????????? ????
stimulation 10 was extended to induce diastolic SR Ca2+ release in a controlled 
fashion, similar to a recent approach by Xie et al. 11. Both timing (start, duration) and 
amplitude of diastolic SR Ca2+ release could be controlled.  
 
In particular, the model was divided into two identical domains (Figure 1) coupled 
by Ca2+ diffusion between cytosol and network SR to simulate the local origin of SCR. 
Diffusion time constants were based on the local control model by Restrepo et al. 12. 
and diffusion was significantly slower in SR compared to cytosol, consistent with 
experimental observations 13. The late component of INa (INaL) was increased in the 
model to simulate the midmyocardial origin of the myocytes used in our experiments, 
consistent with experimental data from Zygmunt et al. 14. Model APD rate 
dependence at baseline, in the presence of ISO and in the presence of 
ISO+HMR1556 (simulated as 100% inhibition of IKs) was consistent with 
experimental data (Figure 2A). Parameters of the L-type Ca2+ current were adjusted 
based on the experiments in the presence of ryanodine to obtain quantitative 
agreement on the amount of APD prolongation in the absence of SR Ca2+ release.  
 
To initiate SCR, steady-state RyR activation was set to a constant value in one of the 
two domains for the interval of diastolic SR Ca2+ release such that the desired 
reduction in local JSR Ca2+ was achieved. When steady-state RyR activation was set 
to 0.375 (SCRlevel= 0.375) from t = 925 ms until t = 950 ms (at CL = 1000 ms), the 
SCR-induced prolongation of APD was consistent with experimental observations 
(Figure 2B). 
 
The model was paced to steady state (2000 seconds of pacing) in the presence of 
??????? ?????????????????????????Ks inhibition, to mimic experimental conditions. The 
effect of diastolic SR Ca2+ release was examined by determining APD of a single beat 
at steady-state as a function of the timing and amplitude of the preceding diastolic 
Ca2+ release. In some simulations other currents / fluxes (ICaL, INaCa, ICl(Ca), Jrel) were 
blocked for the duration of this final beat. 
 
One-dimensional strand simulations were performed as previously described 15. 
Steady-state conditions of single-cell simulation in the presence of ISO and IKs 
blockade were used as initial conditions for the homogeneous strand of 128 cells. 
The strand was subsequently paced by direct stimulation of the first 3 cells (-80 
pA/pF for 2.0 ms) for 100 seconds to achieve steady-state conditions for the strand. 
The effect of diastolic SR Ca2+ release was determined by applying the methodology 
described above to k cells in the middle of the strand. SR Ca2+ release was initiated 
simultaneously in all k cells. The exact mechanisms by which SCR synchronizes 
across a sufficient number of myocytes to generate ventricular ectopic beats remain 
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incompletely understood. Recent research by Wasserstrom et al. has suggested that 
an intrinsic synchronization occurs due to a decrease in variability of SCR events with 
increasing Ca2+ load 16, 17. ?????????????????????????????????????????? ????????????? 
can produce spatiotemporal synchronization of SR Ca2+ overload and release, which 
can produce focal activity and arrhythmia in normal rabbit hearts 18.  Although direct 
diffusion of Ca2+ between cells through gap junctions could further contribute to the 
synchronization of SCR 19, this was not implemented in the current model because 
the main goal of the present research was to determine the electrophysiological 
consequences of SCR, independent of the synchronization method. 
 
A similar approach was used to study the effect of diastolic SR Ca2+ release on 
homogeneous two-dimensional sheets of virtual ‘tissue’. The tissue size was 2 x 2 cm 
and was simulated using 200 x 200 grid points, in line with previous studies 20, 21. 
Steady-state conditions of single-cell simulations in the presence of ISO and IKs 
blockade were used as initial conditions and 5 beats were simulated following 
stimulation of the left-most column of 200 cells (-80 pA/pF for 2.0 ms), resulting in a 
planar wave activating the entire sheet. Conduction velocity was 49 cm/s. Diastolic 
SR Ca2+ release was initiated simultaneously in 25% of the 40.000 cells surrounding 
the center of the tissues (i.e., cells with x and y coordinates between 50 and 150). 
 
Alterations in Model Equations Compared to Heijman et al. 10. 
 
The superscript symbol x, is used to designate one of the two identical Ca2+ domains. 
Whole-cell concentrations / currents are defined as the average of both domains and 
are indicated without superscript x. 
 
Altered INaL: 
 
I????? = 1.6 ? 6.500 ? 10?? ? (m?)? ? h? ? (V? ? E??)  
 
I????,???? = 1.6 ? 1.600 ? 10?? ? (m?)? ? h? ? (V? ? E??)  
 
Altered ICaL: 
 
I?,?? = ??
??.?????????(?????.??)/??.?????
? ??????????(?(????.???)/??.???)?
  
 
I?,?? = ??.?? ? ?0.02 +
?
??????(?????.???)/?.??????  
 
Is?,?? = ??.???? ? ?0.0004 +
?
??????(?????.???)/?.??????  
 
 
125 
CHAPTER 4  
Altered RyR: 
 
h? = 10  
 
I???,??? = ????
??? ????,??????????
? ?
?? ?
??????
????????????
? ??.??
?.???? ?
? SCR?????  
 
I???,?? = 1.9925 ? ????
??? ????,??????????
? ?
?? ?
??????
????????????
? ??.??
?.???? ?
? SCR?????  
 
 
Altered Ca2+ diffusion: 
 
I??? =
?????????
? ??????????
?
??? , ??? = 100 ms  
 
I????,???? =
???????
?????????
?
?????,??? , ?????,??? = 1.00 ms, y: other Ca
?? domain  
 
I????,???? =
?????????
? ??????????
?
?????,??? , ?????,??? = 25.0 ms, y: other Ca
?? domain  
 
????????,?
?
?? = ??
????,?? ?????? ????????,?? ??????????
?????????? + I??
? ? ???????? ? I????
? ? ???,?????? ? I????,???
? ?  
 
??????????
?
?? = I??? ? I??? ?
????
???? + I????,???
?   
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Abstract 
 
Right (RV) and left ventricles (LV) have different embryologic, structural, metabolic 
and electrophysiologic characteristics, but whether interventricular differences exist 
????-??????????????????????????responsiveness is unknown. This study was designed 
to e??????? ???????? ???? ??? differs in RV versus LV and study the associated 
signaling mechanisms. LV and RV intracavitary pressures were recorded in 
anesthetized beagle dogs. Sarcomere shortening, Ca2+ transients, ICaL and IKs 
???????????????????????????????????????????????????????????????????????????????????
and PKA activity were measured by live cell imaging using FRET-based sensors.  
A bolus injection of isoproterenol increased RV dP/dtmax ~5-fold versus 3-fold in LV. 
Isoproterenol increased sarcomere shortening ~10-fold and Ca2+-transient amplitude 
~2-fold in LV midmyocytes (LVMs) versus ~25-fold and ~3-fold in RVMs. FRET 
imaging using targeted Epac2camps sensors revealed no change in subsarcolemmal 
???????????????-?????????????-?????? ?????????????????????????????????????????????
LVMs. Acc?????????? ?AR regulation of ICaL and IKs were similar between LVMs and 
RVMs, whereas cytoplasmic PKA activity was increased in RVMs. Both PDE3 and 
????? ???????????? ??? ???? ???? ??????????? ??? ???????????? ???????? ???? ???? ???????????
between LVMs and RVMs was abolished by PDE3 inhibition and attenuated by PDE4 
inhibition. In conclusion can???????????????????????????????AR response due to intrinsic 
????????????????????????-AR d???????????????????????????????AR responsiveness of 
the RV results from higher cAMP elevation in the cytoplasm, due to a decreased 
degradation by PDE3 and PDE4 in the RV compared to the LV. 
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5.1 Introduction 
 
The sympathetic nervous system is responsible for adaptation of cardiac output to 
stress and physical exercise. This “fight-or-flight” response is mediated primarily by 
noradrenaline and adrenaline acti???????-???????????????????????ARs) at the surface 
??????????????????????ARs are coupled through G?s to adenylyl cyclases (AC) and the 
generation of cAMP, which in turn activates the cAMP-dependent protein kinase 
(PKA). PKA then phosphorylates key proteins involved in excitation-contraction 
coupling (ECC) including sarcolemmal L-type Ca2+ channels (ICaL), ryanodine 
receptors (RyR2), phospholamban and troponin I 1. In addition, PKA phosphorylates 
slowly-activating delayed rectifier K+ (IKs) channels to control cardiac repolarization 2.  
 
The levels of cAMP and thus the degree of PKA activation are finely regulated by 
cyclic nucleotide phosphodiesterases (PDEs) that degrade the second messenger  
into 5’-AMP. Cardiac PDEs degrading cAMP belong to 5 families (PDE1-4 and PDE8) 
which can be distinguished by distinct enzymatic properties and pharmacology 3.     
In rodents, PDE3 and PDE4 are the major contributors to the total cAMP-hydrolytic 
activity 4, 5 and ????? ???????????? ?????????????AR regulation of cAMP levels 6 - 9. 
Multiple ??????????????????????????????ARs 10 - 12, RyR2 13, SERCA2 14, 15, ICaL 16 and IKs 
17 to exert local control of ECC. In larger mammals, PDE3 activity is dominant     in 
microsomal fractions 18 - 20 and PDE3 inhibitors exert a potent positive inotropic  
effect 21. Selective inhibition of PDE3 with milrinone has been shown to improve 
cardiac contractility in patients with congestive heart failure 22. The role of PDE4      
is less well defined but evidence is emerging that PDE4 may also play an important  
role in these species. In the canine heart, a large PDE4 activity is found in            
the cytoplasm 18 but PDE4 is also present in microsomal fractions, where it accounts 
for ~20% of the activity 19. Recent studies have indicated that PDE4 is expressed    
in human ventricle where, similar t?? ????????? ??? ??????????? ????? ?????? ????? and 
phospholamban 5, 13. Moreover, PDE4 controls ECC and arrhythmias in human    
atrium 23. 
 
The right (RV) and left (LV) ventricles originate from different progenitor cells 24, 25  
and differ in several important ways. Both ventricles have different mass (under 
normal conditions LV mass is ~6-fold RV mass), volume, morphologies and  
pressures 26, 27. Electrical heterogeneity has been well characterized between 
ventricular epicardial, endocardial and midmyocardial layers 28 - 31. Although less 
studied, different electrophysiological properties were also reported between the two 
ventricles. In rats and dog, the action potential (AP) is shorter in the RV than in the 
LV 32, 33. In dog, the notch in phase 1 of the AP is deeper in the RV than the LV 33, 34. 
These differences are related to larger repolarizing K+ currents, ITO and IKs in dog RV 
33, 34. In this species, a larger RV IKs correlates with a higher expression of KCNQ1 
and KCNE1, the principal and auxiliary subunit of the IKs channel, respectively 35. 
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Regional heterogeneity between the LV and the RV may also exist for ATP-activated 
K+ current, IKATP 36, 37. 
 
In contrast to these electrophysiological studies, a recent proteomic study reported 
no difference in the expression level of more than 600 proteins between the RV and 
the LV from pig and rabbit. Most of these were contractile/structural proteins, 
oxidative phosphorylation components, and enzymes from intermediary metabolism. 
No plasma membrane voltage-gated ion channels were analyzed, but a few major 
Ca2+ handling proteins (SERCA2, RyR2) and signal transduction components 
(Ca2+???? ??????? ??????? ????????? ????? ?? ???? ???? ???????????????????? ??????????????
level 38.  
 
These studies raise the question of whether functional differences between the LV 
and the RV are limited to electrophysiological features or extend to other aspects of 
ventricular function. Surprisingly, only limited information is available concerning ECC 
and its neurohumoral regulation in RV versus LV comparisons. However, previous 
reports in rat have shown that, despite similar interventricular expression levels,      
a higher proportion of the total SERCA2a pool is associated with phospholamban, 
resulting in lower Ca2+ reuptake rate and prolonged Ca2+ transients in RV myocytes 
compared with LV myocytes 39. In mouse, opposite inotropic responses to ?1-AR 
stimulation were reported, and attributed to different effects on myofilament Ca2+ 
sensitivity 40. In human, recent clinical studies indicate that ventricular load increases 
more for the RV than the LV during exercise 41 and this may reflect, at least partly, 
the relative differences in maximal pulmonary-arterial versus aortic pressure rise. It 
is currently unclear whether interventricular differences exist in the sympathetic 
responsiveness of the human heart.  
 
In canine, stimulation of the cardiac sympathetic nerves induces greater changes in 
contractile force in the RV than in the LV 42. These changes are insensitive to ?1-AR 
blockade by phentolamin??? ? ?????????? ???????????? ??? ?AR response 43. However, 
several stud???????????????????????????????AR density, AC activity and its activation by 
catecholamines between RV and LV under normal conditions 44 - 46. 
 
Intrigued by these apparent ??????????????????????????????AR regulation of cardiac 
contractility in dog RV and LV in vivo and in isolated myocytes. Our data reveal 
enha???????????????????????????????AR stimulation, and provide evidence that PDE3 
and PDE4 shape distinct compartmentalized cAMP signals that underlie 
interve?????????????????????????AR stimulation. 
  
134  
INTERVENTRICULAR DIFFERENCES IN BETA-ADRENERGIC RECEPTOR SIGNALING 
5.2 Materials and Methods 
 
This investigation conformed with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). Animal handling was in accordance with the European Directive for 
the Protection of Vertebrate Animals Used for Experimental and Other Scientific 
Purposes (86/609/EU). The study was conducted in accordance with the Declaration 
of Helsinki principles, and approved by the Ethical Committees of our institutions. 
 
5.2.1 In Vivo Experiments  
 
General anesthesia was induced in 4 beagle dogs (3 F/1 M; average weight 11±1 kg) 
by lofentanil (0.075 mg/kg body weight i.v.), scopolamine (0.015 mg/kg), 
succinylcholine (1.0 mg/kg), and subsequent hourly slow injections of fentanyl 
(0.025 mg/kg i.v.) and continuous infusion of etomidate (1.5 mg/kg/h). Dogs were 
ventilated with 30% oxygen in pressurized air to normocapnia. The body 
temperature was kept at 37°C with a heated water mattress. ECG standard lead II 
was continuously recorded. Under closed-chest conditions, LV and RV intracavitary 
pressures were recorded simultaneously with high-fidelity catheter-tip 
micromanometers introduced via the femoral artery and vein (Gaeltec Ltd, 
Dunvegan, UK and Millar Instruments Inc, Houston, TX, USA). In each animal a bolus 
injection of isoproterenol (ISO, ???? ??????? ???? ????????????? ???? ????????? ???????
with each next infusion given after baseline values had been stably reestablished. 
 
5.2.2 Cell-Isolation Procedure 
 
Adult female beagle dogs were used for myocyte isolations. A total of 12 dogs were 
included in the study. Anesthesia was induced with 45 mg/kg pentobarbital. Once full 
anesthesia was reached, the chest was opened via a left thoracotomy and the heart 
was excised and placed in an O2-gassed, Ca2+-free standard buffer solution at 
approximately 4°C. The cell-isolation procedure was the same as previously 
described 33. Briefly, both the left-anterior-descending and right coronary arteries 
were cannulated and perfused simultaneously. After ~20 min of collagenase 
perfusion and subsequent washout of the enzyme, the epicardial surface layer was 
??????????????????????????????????????????????????????????????????????????????
Softened tissue samples were collected from the midmyocardial layer underneath, 
while contamination with the endocardium was avoided. Samples were gently 
agitated, filtered and washed. Midmyocytes were stored at room temperature in 
standard buffer solution (vide infra) and only quiescent rod-shaped cells with clear 
cross-striations and without granulation were used for the experiments. Cells were 
used within 48 h of isolation.  
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5.2.3 Adenoviral Infection of Dog Ventricular Myocytes 
 
Isolated cells were suspended in minimal essential medium (MEM: M 4780; Sigma,  
St Louis, Missouri, USA) containing 1.2 mM Ca2+, 2.5% fetal bovine serum (FBS, 
Invitrogen, Cergy-Pontoise, France), 1% penicillin-streptomycin, 2% HEPES (pH 7.6) 
and plated on 35 mm, laminin-??????? ??????????????? ?????????? ????????????????? ??
density of 104 cells per dish. Dishes were kept in an incubator (95% O2, 5% CO2, 
37ºC) for 2 h. ?????????????????????????????????????????????-free MEM containing 
adenoviruses encoding for the cytoplasmic cAMP sensor Epac2-camps 47 at a 
multiplicity of infection (MOI) of 1000 pfu/cell, the plasma-membrane targeted 
pmEpac2-camps 48  at a MOI of 700 pfu/cell and the cytoplasmic PKA sensor AKAR3-
NES 49 at a MOI of 1000 pfu/cell.  
 
5.2.4 ICaL Recordings 
 
The whole-cell configuration of the patch-clamp technique was used to record       
ICaL. Patch-electrode resistance was between 1–?? ??? ????? ??????? ????? ?nternal 
solution containing (in mM): CsCl 118, EGTA 5, MgCl2 4, Na2phosphocreatine 5, 
Na2ATP 3.1, Na2GTP 0.42, CaCl2 0.062 (pCa 8.5), HEPES 10, adjusted to pH 7.3 with 
CsOH. Extracellular Cs+-Ringer solution contained (in mM): CaCl2 1.8, MgCl2 1.8, NaCl 
107.1, CsCl 20, NaHCO3 4, NaH2PO4 0.8, D-glucose 5, sodium pyruvate 5, HEPES 10, 
adjusted to pH 7.4 with NaOH. The cells were depolarized every 8 s   from –50 to 0 
mV during 400 ms. The use of –50 mV as holding potential allowed the inactivation 
of voltage-dependent Na+ currents. K+ currents were blocked by replacing all K+ ions 
with external and internal Cs+. Amplifiers RK-400 (Bio-Logic, Claix, France) or 
Axopatch 200B (Axon Instruments, Inc., Union City, CA, USA) were used for voltage 
clamping and acquisition. Currents were analogue filtered at 3 kHz and digitally 
sampled at 10 kHz using a 12-bit analogue-to-digital converter (DT2827; Data 
translation, Marlboro, Massachusetts, USA) connected to a compatible PC or a 
Digidata 1440A interface connected to a computer equipped with pClamp 10 
software (Axon Instruments, Inc., Union City, CA, USA). The maximal amplitude of 
whole-cell ICaL was measured as previously described 50. Currents were not 
compensated for capacitance and leak currents.  
 
5.2.5 IKs Recordings 
 
The whole-cell configuration of the patch-clamp technique was also used to record 
IKs. Patch electrodes had a resistance between 0.5–?????????? ???????????? ?????????
solution containing (in mM): K-aspartate 125, KCl 20, MgCl2 1.0, MgATP 5, HEPES 5 
and EGTA 10, pH 7.2 with KOH. The external solution had the following composition 
(mM): NaCl 145, KCl 4.0, CaCl2 1.8, MgCl2 1.0, glucose 11 and HEPES 10, pH 7.4 
with NaOH at 37°C. During the recordings, KCl was omitted from the external 
solution to increase IKs amplitude, which occurs through changes in the concentration 
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gradient, while leaving the kinetics of IKs activation and deactivation uninfluenced 51. 
ICaL ????????????????????????????????????????Kr ?????????????????????????????????????
were depolarized from a holding potential of -50 mV to +50 mV for 3 s, with the tail 
currents on repolarization to 0 mV quantified as IKs. Ten baseline pulses were 
recorded followed by 3 pulses during brief (15 s) stimulation with ISO (plus or minus 
PDE inhibitor) and this was followed by a further 50 pulses during perfusion with 0 
mM K+ (± PDE inhibitor). Fast solution changes were achieved with the complete VC-
6 fast-step perfusion system (Harvard Apparatus, Holliston, MA, USA) together with a 
???????????? ?????? ???????? ????? ???? ??????????? ???? ??? ????? ???? ????? ??????? ?????
application. 
 
5.2.6 Recordings of Ca2+ Transients and Sarcomere Shortening 
 
????????? ????? ??????? ????? ?? ??? ????-2 AM (Invitrogen) during 15 min at room 
temperature and then washed with Ringer solution containing (in mM): NaCl 121.6, 
KCl 5.4, MgCl2 1.8, CaCl2 1.8, NaHCO3 4, NaH2PO4 0.8, D-glucose 5, Na-pyruvate 5, 
HEPES 10, adjusted to pH 7.4 with NaOH. The loaded cells were field-stimulated     
(5 V, 4 ms) at a frequency of 0.3 Hz. Then, sarcomere length and Fura-2 ratio 
(measured at 512 nm upon excitation at 340 nm and 380 nm) were simultaneously 
recorded using an IonOptix System (IonOptix, Milton, MA, USA). Cell contraction was 
assessed as the percentage of sarcomere shortening, which is the ratio of twitch 
amplitude (difference of end-diastolic and peak systolic sarcomere lengths) to     
end-diastolic sarcomere length. Ca2+-transient amplitude was assessed by the 
percentage of variation of the Fura-2 ratio, by dividing the twitch amplitude 
(difference of end-diastolic and peak systolic ratios) to end-diastolic ratio. All 
parameters were calculated offline with dedicated software (IonWizard 6x, IonOptix). 
 
5.2.7 FRET Measurements 
 
The same Ringer solution as described above for Ca2+ transients and cell shortening 
measurements was used in these experiments. Images were captured every 5 s 
using the 40x oil immersion objective of a Nikon TE 300 inverted microscope 
connected to a software-controlled (Metafluor, Molecular Devices, Sunnyvale, 
California, USA) cooled charge coupled (CCD) camera (Sensicam PE; PCO, Kelheim, 
Germany). CFP was excited during 150-300 ms by a Xenon lamp (100 W, Nikon, 
Champigny-sur-Marne, France) using a 440/20BP filter and a 455LP dichroic mirror. 
Dual-emission imaging of CFP and YFP was performed using an Optosplit II emission 
splitter (Cairn Research, Faversham, UK) equipped with a 495LP dichroic mirror and 
BP filters 470/30 and 535/30, respectively. A region of interest including the entire 
cell was used for measurement of average CFP and YFP intensity. CFP and YFP 
intensities were background corrected and the YFP emission was corrected for     
CFP bleed through. The ratio of CFP over corrected YFP was used as an index of 
cAMP concentration. 
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5.2.8 Reagents 
 
Cilostamide was from Tocris Bioscience (Bristol, UK) and Ro 20-1724 was from 
Calbiochem (Darmstadt, Germany). Unless specified, all other drugs were           
from Sigma (Saint Quentin, France). Isoproterenol (ISO) was first dissolved in 
????????????????????????????????????????? acid and then kept in the dark at 4°C until 
use. 
 
5.2.9 Data Analysis and Statistics 
 
All results are expressed as mean±SEM. For statistical evaluation the paired and 
unpaired Student’s t-test were used, and a difference was considered statistically 
significant when P was <0.05. 
 
 
5.3 Results 
 
5.3.1 In Vivo Inotropic Response to Isoproterenol in RV and LV  
 
Pressure recordings were obtained simultaneously from the RV and LV at baseline 
and during infusion of ISO in anesthetized beagle dogs. Representative examples 
relative to the ECG are shown in Figure 1A. At baseline, systolic pressures and 
dP/dtmax were significantly higher in the LV than in the RV (Figure 1B). For example, 
dP/dtmax was 2582±194 mm Hg/s in the LV versus 534±45 mm Hg/s in the RV 
(P<0.001). Upon ISO, dP/dtmax increased ~3.4-fold in the LV compared to almost 5-
fold in the RV (P<0.05; Figure 1B, left panel). Accordingly, the relative increase in 
????????? ????????? ??? ?AR stimulation was significantly higher in the RV than LV, 
reaching on average 66±19 mm Hg (+61±6%) and 172±31 mm Hg (+20±4%), 
respectively (P<0.01) during ISO (Figure 1B, right panel). Complete recovery from 
the positive inotropic response (Figure 1C) occurred faster in the LV than the RV 
after the ISO bolus infusions (Figure 1C, right panel). Diastolic pressures did not 
show discernable interventricular differences from baseline to ISO.  
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Figure 1: Differential r?????????????? stimulation in the LV versus RV in anesthetized dogs 
A. Representative pressure recordings, together with ECG lead II, before and 60 s after bolus 
????????? ??? ???? ??? agonist ISO at 2.5 μg/kg. B. Bar graphs showing average values       
(n=4 dogs) for dP/dtmax and peak systolic pressures in the LV and RV before and after 
infusion of ISO. C. Bar graphs illustrating the average time courses of alterations in dP/dtmax 
and peak systolic pressures after infusion of ISO, including recovery phase. Data are shown 
as change from baseline *, P<0.05. 
5.3.2 Sarcomere Shortening and Ca2+-Transient Measurements in 
?????????????AR Stimulation in RV and LV Midmyocytes  
 
Sarcomere shortening and Ca2+ transients were simultaneously measured in Fura-2-
loaded RVMs and LVMs obtained from the same hearts and paced at 0.3 Hz. There 
was no significant difference in basal sarcomere length, basal sarcomere shortening, 
basal Fura-2 ratio and basal Ca2+-transient amplitude (Table 1). As shown            
by the individual traces of Figure 2A and 2B, a pulse application of ISO             
(100 nM, 15 s) increased the amplitude of sarcomere shortening and Ca2+ transient 
in both LVMs and RVMs, but these effects were exacerbated in RVMs. Indeed,        
on average ISO increased sarcomere shortening by ~25-fold in RVMs versus ~10-
fold in LVMs and increased Ca2+ transients ~3-fold in RVMs versus 2-fold in LVMs 
(Figure 2C and 2D).  
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Table 1 
 RVMs N LVMs n 
Contraction     
SL (μm) 1.74±0.01 20 1.72±0.01 18 
?????? 1.30±0.27 20 1.23±0.20 18 
Calcium     
Fura-2 ratio 4.93±0.28 20 4.66±0.27 18 
?????? 8.31±0.84 20 9.00±1.01 18 
Electrophysiology     
Cell capacitance (pF) 132.9±3.7 89 123.0±3.5 92 
ICaL density (pA/pF) 2.9±0.2 89 3.3±0.2 92 
IKs density (pA/pF) 1.1±0.2 18 0.8±0.1 (P<0.05) 13 
 
Table 1: Basal parameters measured in RVMs and LVMs. The effect of ISO lasted also longer 
in RVMs than in LVMs, as indicated by the time to half-maximal recovery (t1/2off) of sarcomere 
shortening (79±11 s in RVMs versus 54±3 s in LVMs) and Ca2+ transient (82±7 s in RVMs 
versus 49±6 s in LVMs). These results indicate that the differential in vivo positive inotropic 
effects by ISO have a cellular origin. 
 
5.3.3 ?AR Regulation of Cytoplasmic cAMP Signals and PKA Activity in RV 
and LV Midmyocytes  
 
???????AR stimulation of ECC involves cAMP mobilization, this second messenger was 
measured in intact LVMs and RVMs by fluorescence resonance energy transfer 
(FRET) using the cytoplasmic sensor Epac2-camps 47. Figure 3A shows pseudocolor 
images of a LVM and a RVM expressing Epac2-camps. At 1 min after application of 
ISO (100 nM, 15 s), the CFP/YFP ratio increased to a greater extent in RVMs than in 
LVMs. As shown in Figure 3B, ISO led to a transient increase in the CFP/YFP ratio 
that was on average ~2-fold higher in RVMs versus LVMs (P<0.001) reflecting 
enhanced cytoplasmic cAMP accumulation in RVMs. Because PKA is the primary 
target of cAMP for short-term regulation of ECC, cytoplasmic PKA activity was 
monitored using the PKA FRET sensor AKAR3-NES 49. As shown in the illustrative 
pseudocolor image of Figure 3C and on the average time course of Figure 3D, 
although the maximal increase in YFP/CFP ratio was identical at 1 min, the signal 
decayed faster in LVMs than RVMs and became significantly higher in RVMs than 
LVMs after 2 min. This indicates that cytoplasmic PKA activity was higher in RVMs   
than in ?????????????????????AR stimulation.  
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Figure 2: ?AR Regulation of ECC in LV and RV Midmyocytes (A, B) Raw traces of sarcomere 
shortening A. and Ca2+ transients B. recorded in Fura-2 loaded LVMs and RVMs paced at 0.3 
Hz. The solid bar indicates application of isoproterenol (ISO, 100 nM, 15 s). (C, D) Average 
maximal effect of ISO on sarcomere shortening C. and Ca2+ transients amplitude D. in LVMs 
(n=10) and RVMs (n=12). E, F. ???????????????????????AR response estimated by the time to 
50% decrease (t1/2off) of sarcomere-shortening amplitude E. and Ca2+-transient amplitude F. 
The bar graphs indicate the mean+SEM. Statistically significant differences between LVMs 
and RVMs are indicated by *, P<0.05. 
The lack of difference in the YFP/CFP ratio at the beginning of the stimulation was 
most likely due to saturation of the AKAR3-NES sensor at this concentration of ISO, 
as indicated by the lack of a sharp peak in RVMs and by previous experiments in rat 
ventricular myocytes showing that a ~40% change in YFP/CFP represents the 
maximal FRET change that can be obtained with this sensor (data not shown). 
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Figure 3: RV Midmyocytes Display Enhanced cAMP Accumulation and PKA Activity in 
?????????????AR Stimulation. A. Pseudocolor images of a dog LVM (upper images) and a dog 
RVM (lower images) expressing the cytoplasmic cAMP FRET sensor Epac2-camps. Illustrated 
are the percent increases of the CFP/YFP ratio over baseline at 1 min and at 3 min after ISO 
(100 nM, 15 s) stimulation. B. Average cytoplasmic cAMP accumulation elicited by ISO pulse 
stimulation in RVMs (n=36) and LVMs (n=37). C. Pseudocolor images of a dog LVM (upper 
images) and a dog RVM (lower images) expressing the cytoplasmic PKA sensor AKAR3-NES. 
Illustrated is the percent increase of the YFP/CFP ratio over basal at 1 min and at 3 min after 
the ISO pulse stimulation. D. Average PKA activation elicited by ISO pulse stimulation in 
RVMs (n=5) and LVMs (n=4). Statistically significant differences between LVMs and RVMs are 
indicated by *, P<0.05. 
 
5.3.4 ?AR Regulation of Subsarcolemmal cAMP, ICaL and IKs in RV and LV 
Midmyocytes  
 
Because subsarcolemmal cAMP plays an important role in ECC, we next used a 
plasma-membrane targeted version of Epac2-camps (pmEpac2-camps  48) to monitor 
cAMP specifically in this compartment. To our surprise, comparison of LVMs and 
????? ????????? ??? ??????????? ??? ??????????????? ????? ??????????? ?????????? ???    
?AR stimulation with an ISO pulse. Indeed, neither the maximal cAMP elevation nor 
its decay kinetics was different between LVMs and RVMs (Figure 4A).                 
We  next wondered whether the same was true for the major sarcolemmal targets of 
the ?AR/cAMP/PKA pathway, ICaL and IKs. As shown in Table 1, there was no 
difference in basal ICaL density between RVMs and LVMs. A pulse stimulation with ISO 
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(100 nM, 15 s) resulted in a similar transient increase of ICaL between LVMs and 
RVMs, both in terms of amplitude and duration (Figure 4B). In contrast to ICaL, 
basal IKs density was higher in RVMs than LVMs (Table 1), which is consistent with 
earlier ???????????????????????????????AR stimulation increased IKs to similar degrees 
in LVMs and RVMs (Figure 4C).  
 
Figure 4: ?AR Regulation of Subsarcolemmal cAMP, ICaL and IKs in LV and RV Midmyocytes A. 
Left, average time-courses of ISO (100 nM, 15 s)-induced subsarcolemmal cAMP signals 
measured with pmEpac2-camps in RVMs (n=13) and LVMs (n=7). Right, bar graphs 
comparing average maximal amplitude and time to 50% decrease (t1/2off) of the cAMP 
response. B. Left, average time-courses of ICaL following ISO (100 nM, 15 s) stimulation in 
RVMs (n=22) and LVMs (n=25). Right, bar graphs comparing average maximal amplitude and 
time to 50% decrease (t1/2off) of the ICaL response. C. Left, average time-course of IKs 
response to ISO (100 nM, 15 s) in RVMs (n=8) and LVMs (n=8) Right, bar graphs comparing 
average maximal amplitude and time to 50% decrease (t1/2off) of the IKs response. 
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These results in??????? ????? ??? ???????????? ??? ?AR cAMP signals between LVMs and 
RVMs are compartment-specific and ii) the increased stimulation of ECC by ISO in 
RVMs does not involve differential regulation of ICaL, and IKs. 
 
????? ???? ????? ?????? ????????? ?AR cAMP signals in RVMs and LVMs. We next 
investigated whether phosphodiesterases (PDEs) are involved in the differences in 
cytoplasmic cAMP accumulation observed between RVMs and LVMs upon               
?AR stimulation. We first tested the implication of PDE3, because of its critical 
importance for the control of cardiac contractility in dog 21. Thus, myocytes 
expressing Epac2-camps were challenged with ISO (100 nM, 15 s) in the presence of 
the specific PDE3 inhibitor cilostamide (Cil, 1 μM), and the inhibitor was maintained 
during ISO washout. Figure 5A shows that Cil doubled the maximal amplitude of 
the ISO-induced cAMP transient in LVMs, while having little effect in RVMs. Cil also 
profoundly impaired cAMP recovery in both LVMs and RVMs, as indicated by the   
~3-fold increase in time to half maximal decay (t1/2off) values (Figure 5A). We next 
tested the implication of PDE4, which represents the major soluble cAMP-PDE activity 
in dog ventricle 18 by using the specific PDE4 inhibitor Ro-201724 (Ro, 10 μM). 
Figure 5B shows that Ro induced a 3-fold increase in the amplitude of the cAMP 
transient elicited by ISO in LVMs and a 2-fold increase in RVMs. PDE4 inhibition also 
significantly delayed cAMP recovery, as demonstrated by a ~2.5-fold increase in 
time-to-half-maximal decay (t1/2off) values. Thus, PDE3 and PDE4 regulate 
cytop??????? ????? ????????????? ????? ?AR stimulation in canine ventricular 
midmyocytes. However, this control is less stringent in RVMs compared to LVMs, 
resulting in higher cyto???????????????????????????????AR stimulation. 
 
Regulation of membrane cAMP, ICaL and IKs by PDE3 and PDE4 in RVMs and LVMs. 
Given the large contribution of PDE4 to cytoplasmic cAMP hydrolysis upon              
?AR stimulation, we compared the respective ?????? ??? ????? ???? ????? ??? ???? ?AR 
regulation of subsarcolemmal cAMP in canine ventricular myocytes. As shown in 
Figure 6A, inhibition of PDE3 with 1 μM Cil had no effect on the maximal cAMP 
elevation at the plasma membrane but delayed cAMP recovery in LVMs and RVMs.  
 
Interestingly, the difference in average t1/2off values between ISO and ISO+Cil 
reached statistical significance only in LVMs (t1/2off was 107±17 s for ISO, and  
232±50 s for ISO+Cil, P<0.05 whereas in RVMs, t1/2off was 112±17 s for ISO alone 
and 171±39 s for ISO+Cil, p=0.36) suggesting a stronger contribution of          
membrane-bound PDE3 in LVMs versus ????? ??? ????? ??????????? ????? ?AR 
stimulation. In sharp contrast to what was observed in the cytoplasm, PDE4 
inhibition with Ro at 10 μM had no effect, neither on the amplitude nor on the 
recovery kinetics of the cAMP transient generated by ISO pulse stimulation at the 
plasma membrane (Figure 6B). We next investigated the respective contribution of 
PDE3 and PDE4 to the regulation ICaL and IKs. 
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Figure 5: ???????????????AR Cytoplasmic cAMP Signals by PDE3 and PDE4 in LVMs and RVMs 
A. Left, average time course of cAMP levels measured in the cytoplasm with Epac2-camps 
fol??????? ?AR stimulation with ISO (100 nM, 15 s) alone (gray and black lines, data from 
Figure 3B) or during administration of the PDE3 inhibitor cilostamide (Cil, 1 μM, white circles: 
LVMs, n=13; black circles: RVMs, n=17). Right, Bar graphs representing the average maximal 
amplitude and time to 50% recovery (t1/2off) of the cytoplasmic cAMP transients induced by 
ISO alone or ISO with Cil in LVMs (n=13) and RVMs (n=17). B. Left, average time course of 
cy???????? ????? ??????? ?????????? ?AR stimulation with Iso (100 nM, 15 s) alone or during 
administration of the PDE4 inhibitor Ro 20-1724 (Ro, 10 μM; white circles: LVMs, n=21; black 
circles: RVMs, n=24). Right, bar graphs representing the average maximal amplitude and 
time to 50% recovery (t1/2off) of the cAMP transients induced by Iso alone or ISO with Ro in 
LVMs (n=21) and LVMs (n=24). PDE inhibitors were added to the Iso solution and in the 
washout solution. Symbols and bar graphs indicate the mean±SEM. Statistical difference 
between ISO alone and ISO+PDE inhibitor in LVMs and RVMs is indicated as *, P<0.05; ***, 
P<0.001. 
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Figure 6: Regulation of Subsarcolemmal cAMP by PDE3 and PDE4 after b??????????timulation 
A. Left, average time course of cAMP levels measured at the plasma membrane with 
pmEpac2-camps fol??????? ?AR stimulation with ISO (100 nM, 15 s) alone (gray and black 
lines, data from Figure 4A) and representative examples of the effect of the PDE3 inhibitor 
cilostamide (Cil, 1 μM) in a LVM (white circles) and a RVM (black circles). Right, bar graphs 
representing the average maximal amplitude and time to 50% recovery (t1/2off) of the 
sarcolemmal cAMP transients induced by ISO alone or ISO with Cil in LVMs (n=5) and RVMs 
(n=5). B. Left, average time course of the plasma membrane cAMP levels fol??????? ?AR 
stimulation with ISO (100 nM, 15 s) alone (gray and black lines, data from Figure 4A) and 
representative examples of the effect of the PDE4 inhibitor Ro 20-1724 (Ro, 10 μM) in a LVM 
(white circles) and a RVM (black circles). Right, bar graphs representing the average maximal 
amplitude and time to 50% recovery (t1/2off) of the cAMP transients induced by ISO alone or 
ISO with Ro in LVMs (n=9) and LVMs (n=5). PDE inhibitors were added to the ISO solution 
and in the washout solution. Symbols and bar graphs indicate the mean±SEM. Statistical 
difference between ISO alone and ISO+PDE inhibitor in LVMs and RVMs is indicated as *, 
P<0.05. 
As shown in Figure 7A, PDE3 inhibition had no effect on the maximal ICaL 
stimulation induced by ISO (100 nM, 15 s), but significantly delayed ICaL recovery in 
LVMs and RVMs (in LVMs, t1/2off was 91±7 s for ISO, and 203±22 s for Iso+Cil, 
P<0.001; in RVMs, t1/2off was 113±11 s for ISO alone and 176±19 s for           
ISO+Cil, P<0.05). Interestingly, PDE3 inhibition also slowed IKs recovery in RVMs and 
LVMs (data not shown). In contrast, inhibition of PDE4 with Ro at 10 μM did not 
modify ICaL (Figure 6B) nor IKs recovery. 
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Figure 7: Regulation of ICaL by PDE3 and PDE4 ?????? ?????? ?AR stimulation. Average time 
course of ICaL (left) and mean values of time for 50% recovery (t1/2off) (right) in response to 
?AR stimulation with ISO (100 nM, 15 s) alone or with A. cilostamide (Cil, 1 μM; white circles: 
LVMs n=18; black circles: RVMs, n=11); B. Ro 20-1724 (Ro, 10 μM; white circles: RVMs, 
n=15; black circles: LVMs, n=11) and C. the combination of Cil and Ro (Cil+ Ro, white 
circles: LVMs, n=11; black circles: LVMs, n=11). PDE inhibitors were added to the ISO 
solution and in the washout solution. The symbols and bar graphs indicate the mean±SEM. 
Statistical difference between ISO alone and ISO+PDE inhibitor in LVMs and RVMs is 
indicated as **, P<0.01; ***, P<0.001. 
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However, when PDE3 was inhibited by Cil, concomitant inhibition of PDE4 drastically 
???????????????AR stimulation of the current (Figure 6C), with t1/2off values reaching 
381±66 s in RVMs (P<0.05 versus ISO+Cil) and 381±51 s in LVMs (P<0.01 versus 
ISO+Cil). These results indicate that although PDE3 is domi??????????AR regulation 
of ICaL in canine myocytes, PDE4 becomes important when PDE3 is inhibited. 
 
5.4 Discussion 
 
This study provides direct evidence that canine RV and LV differ in their sensitivity to 
?AR stimulation due to intrinsic postsynaptic differences in myoc?????AR signaling. 
The increased positive inotropic effect of ISO observed in the RV in vivo is correlated 
with enhanced efficiency of ISO to stimulate Ca2+ transients and sarcomere 
shortening in RVMs compared to LVMs isolated from the same hearts. Enhanced     
?AR responsiveness in RVMs is not ass???????????????????????????????AR signaling at 
???? ??????? ?????????? ?????? ?AR stimulation of subsarcolemmal [cAMP??? ???? ???
membrane currents ICaL and IKs are similar in RVMs and LVMs. However, RVMs 
display a higher cAMP accumulation and PKA activity in the cytoplasm compared to 
LVMs, and the difference in cAMP is abolished by inhibition of PDE3 and PDE4. Thus, 
PDE3 and PDE4 shape distinct compartmentalized cAMP signals that underlie 
regionally-specific differences i???????????????????????????????AR stimulation. 
 
Recent clinical studies indicate that during intense physical exercise, the afterload of 
the RV increases more than that of the LV 41, 52. Because the sympathetic system is 
strongly activated during exercise, these observations suggest that the RV could be 
more sensitive to sympathetic stimulation than the LV in humans. Earlier studies that 
compared the responsiveness of the LV versus RV to sympathetic nerve stimulation 
in dog are consistent with this notion: Norris and Randall showed that stimulation of 
the left and right ansae subclavia has a stronger inotropic effect in the RV than in the 
LV 42. Similarly, Abe et al. 43 reported stronger effects of sympathetic nerve 
stimulation on RV systolic pressure, which were not modified by ?1-AR blockade. 
Thus, previous data suggested ???? ?????????? ??? ????????????? ?AR stimulation in RV 
versus LV, but until now its clear demonstration has been lacking and the potential 
mechanisms involved remain elusive. Our experiments show that ISO infusion in vivo 
exerts a stronger relative increase in RV contractility compared to that of the LV 
(Figure 1). Importantly, myocytes isolated from the midmyocardial layer of the     
RV showed enhanced and prolonged stimulation of Ca2+ transients and contraction 
by ISO compared to their LV counterparts (Figure 2). These results demonstrate 
that the ????? ???????????? ??? ???? ??? ??? ?AR stimulation relies at least partly on an 
intrinsic property of RV myocytes, and raise the question of which mechanisms are 
involved.  
 
?AR control of cardiac ECC operates mainly through activation of cAMP and PKA. 
Consistent with in???????? ??????????? ???????? ??? ?ARs, cytoplasmic cAMP and PKA 
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activity were found increased in RVMs upon ISO pulse stimulation (Figure 3). 
However, this difference was compartment-????????? ?????? ????????? ?AR responses 
were not observed at the plas??? ?????????? ??????? ???????? ?AR regulation of 
subsarcolemmal cAMP signals nor that of ICaL and IKs were modified in RV compared 
to LV (Figure 4). Since ICaL was not involved in the enhanced inotropic effect of ISO 
in RV, other ECC proteins must be differentially regulated. Likely candidates are RyR2 
and PLB, which control SR Ca2+ release and reuptake by SERCA2a, respectively. 
 
Although differential SERCA2a-PLB association was observed in RV versus LV          
in rat 39, we did not observe differences in the decay kinetics of Ca2+ transients in  
RV versus LV dog myocytes (data not shown). To our knowledge, whether RyR2 and 
PLB are differentially phosphorylated in response to ISO stimulation in RV versus LV 
has not been investigated. 
 
????????? ?AR functional effects in RVMs could result from increased cAMP 
generation in RVMs. However, the lack of difference at the plasma membrane 
(Figure 4) does not support this idea. Moreover, previous studies in dog indicate 
?? ????? ?????????? ??? ?ARs, AC activity and AC stimulation ??? ?-ARs in RV versus       
LV 44 - 46. Because in rodents PDEs can generate cAMP gradients within cardiac 
myocytes 8, 9, 53, 54, we tested the hypothesis that they could be involved in the 
interventricular differences in cytoplasmic cAMP accumulation in dog. Our results 
????????? ????? ????? ??????????? ????????? ?????????????? ??? ?????????? ??? ????? ?????   
???? ??? ????????? ?????? ??????? ??????? ??????? ??????? ??? ?????????? ??? ?????? ?????
abolishing the differences between RVMs and LVMs. PDE3 inhibition also significantly 
prolonged the effect of ISO ??? ????????? ??? ????? ???? ???? ??? ????? ?Figure 7A). 
????? ??????????? ???????????? ???? ???? ??? ?????????? ??? ????? ????? ???? ????? ?????   
?AR stimulation, with a more pronounced effect in RVMs. As a consequence, the 
????????????????? ??????????? ??? ?????????? ????????????? ???? ??????????? ????? ?????
inhibition. We conclude that regionally-specific differences in subcellular cAMP 
compartmentation arise from a more stringent co??????????ARs cAMP signals by PDE3 
and PDE4 in LVMs than in RVMs. 
 
????? ?AR stimulation, the relatively balanced contribution of PDE3 and PDE4 to 
cAMP hydrolysis in the cytoplasm (Figure 5) and the dominance of PDE3 at the 
sarcolemma (Figure 6) is at variance with previous results in rodents, where PDE4 is 
dominant in both compartments 6 - 9. Because in dog PDE3 inhibitors have strong 
inotropic effects in contrast to PDE4 inhibitors 18, our results raise the question of the 
functional role of PDE4 in dog. When the respective role of these two PDEs was 
evaluated on the stimulation of ICaL (Figure 7) by ISO, inhibition of PDE3 but not 
PDE4 significantly prolonged ICaL upregulation. This is consistent with a 
predominance of PDE3 in T-tubular membranes, whereas only a fraction of PDE4 is 
sarcolemmal and most of the activity is soluble 18, 19. However, when PDE3 was 
inhibited, PDE4 inhibition drastically prolonged ICaL ????????? ????? ?AR stimulation 
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(Figure 7). Thus, PDE4 can regulate ICaL, but under normal conditions it is masked 
by the predominant PDE3. Therefore, the hierarchy between PDE3 and PDE4 
appears to be opposite in dog compared to rat 9. 
 
In conclusion, the current study demonstrates that RV and LV differ in their 
sensitivity to βAR stimulation both in vivo and in vitro, and reveals regionally-specific 
differences in βAR coupling to PDE3 and PDE4 and subcellular cAMP 
compartmentation in the heart. The fact that these results were obtained in a large 
mammal increases the likelihood that they represent the human situation. If this is 
the case, such enhanced sensitivity to βAR stimulation may be an important factor 
for RV dysfunction not only in the context of sports medicine, but also in RV failure 
consequent to left-sided heart failure or pulmonary hypertension. 
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Abstract 
 
AZD1305 is an investigational antiarrhythmic agent for management of atrial 
fibrillation. It blocks various cardiac ion currents at different potencies and has atrial-
predominant electrophysiological effects. We investigated the electrophysiological 
and proarrhythmic effects of AZD1305 versus dofetilide in dogs with chronic 
complete atrioventricular block (AVB) and myocardial hypertrophic remodeling. In 
the present study AZD1305 was administered to anesthetized mongrel dogs before 
and >2 weeks after the induction of AVB and ventricular and atrial 
electrophysiological parameters were assessed. In all dogs, the selective IKr blocker 
dofetilide was used to examine susceptibility to acquired torsades de pointes (TdP) in 
chronic AVB and for comparison. At normal sinus rhythm, AZD1305 increased QT and 
RR intervals from 290±7 to 397±15 ms (+37%, P<0.0001) and from 603±22 to 
778±32 ms (+29%, P=0.002), respectively. In the same animals at chronic AVB, 
AZD1305 increased the QT interval from 535±28 to 747±36 ms (+40%, P<0.05), 
similar to the QT prolongation by dofetilide (511±22 to 703±45 ms (+38%, 
P<0.0001)). AZD1305 slightly slowed the idioventricular rhythm. Whereas all (n=14) 
chronic-AVB animals exhibited TdP upon dofetilide, the arrhythmia was induced in 
only 4/11 dogs after AZD1305. Beat-to-beat variability of left-ventricular (LV) 
monophasic-action-potential duration (MAPD90) increased after dofetilide (2.3±0.2 
to 6.3±0.7 ms; P<0.00010), but not after AZD1305 (2.8±0.3 to 3.7±0.3 ms; 
P=0.20), despite similar LV MAPD90 prolongations. Despite causing similar degrees 
of repolarization delay as the selective IKr blocker dofetilide, the combined ion-
channel blocker AZD1305 induces less repolarization instability and has a lower 
ventricular proarrhythmic potential in the remodeled dog heart. 
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6.1 Introduction 
 
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the Western world, 
with age-related prevalence reaching >10% in octogenarians 1. It has been predicted 
that over 5.6 million patients in North-America will be diagnosed with AF by 2050 2. 
This arrhythmia is a frequent complication of uncorrected hypertension, myocardial 
ischemia or valvular disease. Moreover, familial AF or lone AF without apparent 
familial segregation is increasingly recognized. 
 
Currently, the pharmacological treatments aimed at maintaining sinus rhythm include 
class I, II and III antiarrhythmic agents. Termination of persistent AF may require 
any of these options (with variable effectiveness) or electrical cardioversion. 
However, none of the aforementioned therapies are considered atrial-specific and 
cause effects on ventricular electrical activation and repolarization, and some carry 
an inherent risk of ventricular proarrhythmia.  
 
The proarrhythmic liability of anti-AF drugs could potentially be circumvented by 
designing compounds with composite actions on multiple ion channels. Vernakalant, 
a predominantly atrial-selective compound targeting IKur, IKr, ITO and INa 3 was 
recently approved in Europe for the rapid conversion of recent (seven days or less) 
onset AF to sinus rhythm. Clinically, vernakalant has been shown to be effective in 
restoring sinus rhythm in patients with AF episodes lasting between 3 hours and 7 
days4 with a low proarrhythmic risk. This compound has been shown to be less 
efficacious in patients with congestive heart failure5. However to date, no results 
have been reported on patients with severe heart failure in whom cardiac remodeling 
could predispose to altered drug efficacy or adverse side effects. Dronedarone is 
another new agent for the management of AF with composite actions at multiple ion 
channels. Although this compound may have an improved safety profile compared to 
amiodarone, it is less efficacious in reducing AF recurrence rates 6. 
 
AZD1305 (Figure 1A) is an investigational compound that has been under 
development for the management of persistent AF. Although AZD1305 
predominantly blocks IKr, it also has major inhibitory effects on ICaL and INa 
(predominantly INaLate) and minor effects on other K+ currents 7, 8. In the normal 
canine heart, this compound exerts atrial-predominant electrophysiological effects, 
both in vivo and in vitro 9. In the anesthetized methoxamine-sensitized rabbit model 
of torsades de pointes ventricular tachyarrhythmia (TdP), intravenous AZD1305 
increased the QT interval without inducing ventricular extrasystoles or TdP 7. Beat-to-
beat variability of repolarization duration (BVR of the QT interval) also remained 
unaltered. In contrast, the selective IKr blocker dofetilide prolonged the QT interval, 
increased BVR and induced TdP in the majority of animals tested 7. AZD1305 has 
been shown to depress excitability and suppress delayed-afterdepolarization-induced 
triggered activity in canine pulmonary-vein sleeve preparations 10. Recent clinical 
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data suggest that this compound has electrophysiological effects that may translate 
into antiarrhythmic efficacy in AF patients and may have a reduced proarrhythmic 
potential as compared to selective IKr blockers 11, 12. 
 
In the present study, we investigated the electrophysiological effects of AZD1305 in 
anesthetized dogs with remodeled hearts, with our hypothesis being that due to the 
composite ion-channel blockade by AZD1305, less ventricular proarrhythmia will be 
seen when compared to IKr blockade alone, despite leading to equivalent 
repolarization prolongation. To this aim, we used the dog with chronic complete 
atrioventricular block (AVB), a sensitive model to examine the proarrhythmic 
potential of new chemical entities. After the induction of AVB, the heart undergoes 
electrical and structural remodeling, creating a substrate for TdP 13, 14. We analyzed 
ventricular and atrial repolarization parameters and compared the effects of 
AZD1305 with those of the selective IKr blocker dofetilide (Figure 1A), which exerts 
torsadogenic actions in this animal model. 
 
 
6.2 Materials and Methods 
 
6.2.1 General 
 
Animal handling was in accordance with the Dutch Law on Animal Experimentation 
and the European Directive for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes, European Community Directive 
86/609/CEE, and under the regulations of the Committee for Experiments on Animals 
of Maastricht University, The Netherlands. 
 
Fourteen adult mongrel dogs (10 female and 4 male; body weight 20.1±0.8 kg; 
Marshall BioResources, NY, USA) were included in these experiments. After overnight 
fasting, animals were sedated with 0.5 mg/kg methadone, 0.5 mg/kg acepromazine, 
and 0.5 mg atropine intramuscularly. Anesthesia was induced with sodium 
pentobarbital 25 mg/kg intravenously and maintained by isoflurane (0.5% to 1%). 
After intubation, the dogs were artificially ventilated with a mixture of oxygen and 
compressed air (2 : 1). Proper animal care was taken before, during, and after the 
experiments, including a thermal mattress to maintain body temperature, fluid 
administration to prevent volume depletion (0.9% NaCl), and administration of 
antibiotics (ampicillin 1000 mg intramuscularly) and analgesics (buprenorphine 0.015 
mg/kg intramuscularly). 
 
In all experiments, standard lead and precordial ECG registrations were combined 
with endocardial monophasic action potential (MAP) recordings and continuously 
stored. MAPs (Hugo Sachs Elektronik, Germany) were recorded from left ventricular 
(LV), right ventricular (RV) and right atrial (RA) endocardial sites. MAP signals were 
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accepted on the basis of amplitude, morphology and stability. MAP catheters were 
kept in the same position during drug infusions. 
 
6.2.2 Experimental Design 
 
The experimental protocol is shown in Figure 1B. AZD1305 was dissolved in an 
equimolar amount of 0.1 mol/L tartaric acid and then diluted in 0.9% saline. 
AZD1305 was infused at a rate of 36 μg/kg/min for a total of 30 min >1 week before 
creating AVB to investigate the effects of this compound in the normal unremodeled 
heart with sinus rhythm, and in acute and chronic AVB. AVB was induced by 
radiofrequency catheter ablation of the His bundle as previously described 15. 
 
Dofetilide was dissolved in 0.9% saline and intravenously administered at a dose of 
12.5 μg/kg/5 min to test for TdP inducibility 2-3 weeks after inducing AVB (chronic 
AVB) in all dogs. Three animals developed intractable ventricular fibrillation during 
TdP. To investigate whether AZD1305 suppresses dofetilide-induced TdP, a bolus 
(870 μg/kg) of the compound was administered after the first episode of TdP in 4 
dogs (Figure 1B). In 4 animals 12.5 μg/kg/5 min dofetilide was also infused >1 
week before AVB was created so a comparison of atrial effects of this compound 
could be made pre and post remodeling, and compared with AZD1305. 
 
In a total of 11 chronic-AVB dogs, AZD1305 (36 μg/kg/min for 30 min) was 
administered at 3±1 weeks after the induction of AVB (chronic AVB) to examine its 
electropharmacological effects in the remodeled heart. In 4 of these experiments, 
after the AZD1305 infusion, a dofetilide challenge was reapplied to investigate 
preventive effects of AZD1305 against dofetilide-induced TdP (Figure 1B). 
 
When TdP did not stop spontaneously within 10 to 20 seconds or when the 
arrhythmia deteriorated into ventricular fibrillation, the dog was electrically 
cardioverted. If TdP recurred in a period longer than 10 minutes magnesium 
sulphate (100 mg/kg for 2 min) was used to restore a regular rhythm. 
 
After sacrifice, hearts were excised and weighed (n=11 dogs with chronic AVB). 
Average heart weights were 217±11 g. Heart-weight to body-weight ratios averaged 
10.5±0.2 g/kg, similar to previous studies on chronic AVB and significantly higher 
than unremodeled dog hearts 13, 14, 15. 
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Figure 1:  A. Chemical structures of the combined ion-channel blocker AZD1305 and the 
pure IKr blocker dofetilide. B. Experimental protocol. 
6.2.3 Plasma Analysis of AZD1305 
Venous blood samples were obtained at baseline and then at 5, 10, 15, 30, 35, 45, 
60, 90, 120 and 150 min after start of AZD1305 infusion. Samples were collected in 
K2-EDTA tubes, centrifuged for 10 min at 4000 rpm at 4°C and the plasma stored at 
???°C. The plasma concentration of AZD1305 was determined by on-line solid-phase 
extraction followed by tandem mass spectrometric detection. The lower limit of 
????????????????????????????????? 
 
6.2.4 Data Analysis 
RR, QRS, QT, PP and PR intervals in ECG lead II, LV and RV MAP duration (LV and 
RV MAPD) at 90% repolarization (MAPD90), and RA MAPD at 50% (MAPD50) and 
90% repolarization were measured offline using a custom-made computer program 
(IDEEQ, IDEE, Maastricht University). QT intervals were corrected for heart rate 
changes according to Van de Water et al. (QTcV=QT-0.087(RR-1000)) 16. Most data 
were averaged from 30 consecutive beats measured at -5 and 0 min (baseline) and 
at 5, 10, 15, 30, 35, 45 and 60 min after start of AZD1305 or dofetilide infusion. If 
extrasystolic activity was seen, parameters were measured before the first 
extrasystole. Beat-to-beat variability of repolarization duration (BVR) was quantified 
??????????????????????????????????????????????????????????????????n -LV MAPDn-1) 
?????????? 
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Electrophysiological parameters were compared using (repeated-measures) ANOVA 
followed by Bonferroni's test. Data are reported as mean±SEM. Countables, such as 
TdP episode numbers, were tested with a Mann-Whitney rank sum test and are 
reported as median (interquartile range). Differences were considered statistically 
significant if P<0.05. 
 
 
6.3 Results 
 
6.3.1 Concentration-Dependent Prolongation of Ventricular Repolarization 
by AZD1305 in the Normal Dog Heart 
 
In 14 normal anesthetized dogs, intravenous administration of AZD1305 resulted in a 
maximal plasma concentration of 1.57±0.05 μmol/L at 30 min (Figure 2). The QT 
and QTcV interval increased from 290±7 ms and 324±6 ms at baseline to 397±15 
ms and 417±14 ms at 30 min AZD1305, respectively (+37% and +29%, P<0.0001), 
along with an increase in the RR interval (Figure 2 and Table 1). Repolarization 
prolonged in a concentration-dependent manner, with MAPD90 increasing more in 
the LV than in the RV (+48% versus +39%; Figure 2). LV and RV BVR did not 
change significantly. P-wave duration and the QRS interval were slightly but 
significantly increased by AZD1305 (Table 1). The compound did not induce 
ventricular or atrial arrhythmias in these normal hearts. After stopping infusion, 
AZD1305 plasma levels rapidly declined, reaching 0.57±0.05 μmol/L 30 min later. 
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Figure 2: Rate-Dependent Repolarization Effects of AZD1305 in the Normal, Acutely-
Overloaded and Chronically-Remodeled Dog Heart. Changes in QT interval, LV and RV 
MAPD90, and RR interval in relation to plasma concentration of AZD1305 (36 μg/kg/min 
intravenously for 30 min) in the normal canine heart with sinus rhythm. 
 
In 6 dogs, steady-state pacing was applied at a cycle length (CL) of 500 ms in the 
normal heart (right-atrial pacing), and at 500 ms and 1000 ms just after AVB 
induction and at chronic AVB (RV-apex pacing). Figure 3 illustrates the rate-
dependent effects of AZD1305 (versus baseline) on LV MAPD90. Effects during 
pacing are plotted next to those during sinus or idioventricular rhythm. At a pacing 
CL of 500 ms, AZD1305 led to a 20% increase of LV MAPD90 in the normal heart, 
30% increase at acute AVB and 37% prolongation at chronic AVB at 3 weeks. 
Reverse use-dependent prolongation of LV and RV MAPD90 was most accentuated in 
the remodeled heart at chronic AVB. 
 
164 
AZD1305 IN THE REMODELED DOG HEART 
 
 
Figure 3: Rate-dependent repolarization effects of AZD1305 at normal sinus rhythm, acute 
and chronic AVB. Depicted are the changes in LV MAPD90 before (open triangles) and after 
(closed triangles) treatment at different intrinsic (sinus/idioventricular) and paced rates (“P”; 
right-atrial pacing in normal heart; RV pacing in acute and chronic AVB). *, P<0.05 versus 
before treatment at the same CL (or sinus/idioventricular rate). 
 
6.3.2 Repolarization Prolongation and Proarrhythmic Potential by 
AZD1305 and Dofetilide in the Chronic-AVB Dog Heart 
 
In chronic AVB, intravenous administration of AZD1305 resulted in a maximal plasma 
concentration of 1.77±0.29 μmol/L at 30 min (Figure 4) decreasing to 0.66±0.10 
μmol/L 30 min after stop of infusion. Plasma concentrations at all time points were 
not significantly different compared to those seen in sinus rhythm. The QT and QTcV 
interval increased from 535±28 ms and 444±30 ms at baseline to 747±36 ms and 
634±35 ms at 30 min AZD1305, respectively (+40% and +43%, P<0.0001;       
Table 1). A slowing of the idioventricular rate was noted (Table 1). The LV MAPD90 
was prolonged from 431±22 ms to 692±34ms (+61%, P<0.0001) whereas the LV 
BVR remained unaltered (2.8±0.3 versus 3.7±0.3 ms, P=0.20). Similar results were 
obtained for the RV repolarization variables. Figure 5 illustrates changes in 
repolarization induced by AZD1305 infusion in the same dog both at normal sinus 
rhythm and chronic AVB. 
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Figure 4: Changes in QT interval, LV and RV MAPD90, and RR interval in relation to plasma 
concentration of AZD1305 (36 μg/kg/min intravenously for 30 min) in the remodeled canine 
heart with chronic AVB. 
In separate experiments, dofetilide was administered to test for TdP inducibility. 
Similar to AZD1305, dofetilide prolonged the QT and QTcV interval, by 38% and 
41%, respectively (Table 1). The LV MAPD90 was prolonged by 51% (411±17 ms to 
625±26 ms; P<0.0001) and was accompanied by an increase in BVR from 2.3±0.2 
ms to 6.3±0.7ms (P<0.0001). 
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Figure 5: Effects of AZD1305 on ventricular repolarization in the same dog before and after 
cardiac remodeling by chronic AVB. Representative recordings of ECG lead II and LV MAPs 
before (Baseline) and at the end of the 30-min infusion of AZD1305. MAPD90 (ms) is 
indicated below the LV MAP signals. RR and QT intervals (ms) are shown below and above 
the ECGs, respectively. Vertical calibration bars depict 1 and 10 mV for ECG and MAP 
recordings, respectively. 
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Table 1: Ventricular electrophysiological and proarrhythmic effects of AZD1305 and the 
reference compound dofetilide in the normal and remodeled canine heart. *, P<0.05 versus 
baseline. SR indicates sinus rhythm; CAVB, chronic complete atrioventricular block; LV, left 
ventricular; MAPD, monophasic-action-potential duration; RV, right ventricular; BVR, beat-to-
beat variability of repolarization; TdP, torsades de pointes. 
 
Next, we examined the appearance of ventricular extrasystolic beats in the presence 
of AZD1305 and dofetilide. In the case of AZD1305, these were observed at 6.2±0.3 
min after the start of infusion in 6/11 dogs. Except for two dogs, no ventricular 
extrasystolic beats occurred beyond 8±1 min during the remainder of the experiment 
in any of the animals. By contrast, during exposure to dofetilide, ventricular 
extrasystoles were induced in all dogs (P=0.009 versus AZD1305), on average at 
4.1±0.1 min. There were no repolarization differences in beats prior, during and 
after extrasystolic activity (Figure 6). 
  
SR CAVB
Control AZD1305 P Control Dofetilide P Control AZD1305 P
PP 611?24 780?34* <0.0001 591?18 733?19* <0.0001 602?17 760?33* =0.0006
RR 603?22 778?32* <0.0001 1775?124 1863?95 =0.79 2044?217 2326?221* =0.002
QT 290?7 397?15* <0.0001 511?22 703?45* =0.0009 535?28 747?36* <0.0001
QTcV 324?6 417?14* <0.0001 441?17 624?41* <0.0001 444?30 634?35* <0.0001
P wave duration 72?3 77?3* <0.0001
PR duration 122?3 125?3 P=0.20
QRS duration 75?5 79?5* =0.0007
LVMAPD90 253?6 374?15* <0.0001 411?17 625?26* <0.0001 431?22 692?34* <0.0001
RVMAPD90 229?5 319?9* <0.0001 332?34 472?22* =0.004 339?31 536?26* =0.02
LV BVR 0.6?0.1 0.9?0.2 =0.07 2.3?0.2 6.3?0.7* <0.0001 2.8?0.3 3.7?0.3 =0.20
RV BVR 1.0?0.3 1.1?0.3 =0.69 2.9?0.8 5.6?1.7 =0.18 5.4?2.4 5.6?1.9 =0.98
TdP Inducible 0 of 14 14 of 14 4 of 11
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Figure 6: Repolarization duration of ventricular extrasystolic and post-extrasystolic beats 
after AZD1305 and dofetilide in the chronic-AVB dog. A. Representative examples of ECGs 
and LV MAPs. QT intervals and MAPD90 values (ms) are indicated below the traces. Vertical 
calibration bars depict 1 and 10 mV for ECG and MAP recordings, respectively. B. Average 
values for LV MAPD90 as a function of RR CL for the last beat of the idioventricular rhythm, 
the ventricular extrasystole and the post-extrasystolic beat, respectively. Data are from all 4 
dogs that exhibited ventricular extrasystoles during AZD1305. *, P<0.05 versus baseline 
beat; †, P<0.05 versus extrasystole. 
BVR was significantly different during infusion of AZD1305 versus dofetilide.    
Figure 7 illustrates how both LVMAPD90 and BVR were altered in two chronic AVB 
animals after either AZD1305 or dofetilide infusion. Dofetilide caused a progressive 
and parallel increase in LVMAPD90 and BVR promoting extrasystolic activity and TdP. 
In contrast, AZD1305 infusion did not increase BVR despite significantly prolonging 
MAPD90 (see also Table 1). Whereas dofetilide caused TdP in all dogs, this occurred  
in only 4 out of 11 dogs after AZD1305 (P=0.0007 versus dofetilide). Furthermore, 
dofetilide-induced TdP episodes occurred more frequently, lasted longer and required 
electrical cardioversion more often. The cycle lengths of AZD1305- versus dofetilide-
induced TdP were similar (311±18 ms versus 286±7 ms, respectively, P=0.10).  
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Figure 7: Panel (1), baseline. Panel (2), AZD1305. BVR is not increased in this animal after 
AZD1305. No arrhythmias were seen in this animal. Panel (3), baseline. Panel (4), dofetilide. 
BVR increased by dofetilide and TdP ensued after this. Right panels, LV MAPD90s (ms) are 
shown below signals. Vertical calibration bars, 10 mV. Horizontal calibration bars, 1 s. 
 
Figure 8 illustrates an example of TdP during infusion of AZD1305, occurring at 6.5 
min. Spontaneous conversion from TdP to idioventricular rhythm occurred twice in 
this animal. 
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6.3.3 Suppressive Effects of AZD1305 on Dofetilide-Induced TdP 
 
In 4 chronic-AVB dogs with confirmed TdP induction by dofetilide in separate 
experiments, dofetilide was infused again after the administration of AZD1305 
(Figure 1B). Under these conditions, first extrasystolic activity was postponed, 
occurring at 13±2.2 min after the start of dofetilide infusion (versus 3.8±0.2 min 
after dofetilide without AZD1305 pretreatment; P<0.002). LV MAPD90 prolonged 
from 412±24 ms at baseline to 644±40 ms during AZD1305 (P=0.002 versus 
baseline) to 684±49 ms after AZD1305 plus dofetilide (P=0.02 versus AZD1305). In 
2/4 animals, no TdP was seen at all, despite previous TdP susceptibility to dofetilide 
alone. In the other two animals, dofetilide after AZD1305 caused significantly fewer 
TdPs than during its solo administration: 1 (0-2) versus 7 (3-11) episodes, 
respectively (P=0.02). 
 
As an alternative regimen (Figure 1B), AZD1305 was administered as a fast bolus 
infusion (870 μg/kg) after the first dofetilide-induced TdP (n=4). Under these 
conditions, the number of TdP episodes was decreased (2 (1-3) versus 7 (3-11); 
P=0.05) compared to dofetilide alone. 
 
6.3.4 Atrial Effects of AZD1305 in the Normal and Remodeled Dog Heart  
 
The atrial effects of AZD1305 are illustrated in Figure 9. In the normal unremodeled 
heart, right-atrial MAPD50 (+31% from 137±6 ms at baseline, P=0.001) and 
MAPD90 (+33% from 228±5 ms, P<0.001) were significantly increased by AZD1305, 
as was the PP CL. These effects were very similar to those seen with dofetilide 
(Figure 10). 
 
After chronic AVB, baseline right-atrial MAPD50, MAPD90 and PP intervals were 
similar as during sinus rhythm and atrial repolarization and PP CL was still 
significantly prolonged by AZD1305 (Figure 9). For example, right-atrial MAPD90 
was 223±9 ms at baseline versus 270±17 ms (P=0.03, +21%) at the end of 
AZD1305 infusion. Interestingly, even after remodeling dofetilide still led to 
significantly prolonged atrial repolarization (Figure 10). 
 
172 
AZD1305 IN THE REMODELED DOG HEART 
 
 
Figure 9: Atrial effects of AZD1305 in the normal and remodeled canine heart. Upper panels, 
Representative right-atrial MAPs at baseline and at the end of a 30-min infusion of AZD1305 
in the same dog before (Sinus rhythm) and 3 weeks after AVB induction (Chronic AVB). 
Above the signals, cycle length (ms). Below, MAPD90s (ms). Lower panels, Average values 
for right-atrial MAPD50 and MAPD90, and PP intervals from 11 dogs. Vertical calibration bars, 
10 mV.  *, P<0.05 versus baseline. 
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Figure 10: Atrial effects of dofetilide in the normal and remodeled canine heart. Upper 
panels, Representative right-atrial MAPs at baseline and at the end of a 5-min infusion         
of dofetilide in the same dog before (Sinus rhythm) and 3 weeks after AVB induction  
(Chronic AVB). Above the signals, cycle length (ms). Below, MAPD90s (ms). Lower panels, 
Average values for right-atrial MAPD50 and MAPD90, and PP intervals from 4 dogs. Vertical 
calibration bars, 10 mV.  *, P<0.05 versus baseline. 
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6.4 Discussion 
 
In this study we used the dog model with chronic AVB to compare in vivo cardiac 
electrophysiological effects, and any pro- and antiarrhythmic actions, of the novel 
investigational agent AZD1305 with dofetilide in the remodeled heart. Chemically, 
dofetilide is a methanesulphonamide derivative and thus a member of the same 
family of specific IKr-blocking antiarrhythmic agents such as ibutilide and d-sotalol 
(Figure 1A). AZD1305, on the other hand, is a disubstituted 9 oxabispidine 
compound structurally related to its congener AZD7009 (Figure 1A). Interestingly, 
the minor structural differences in AZD1305 vs AZD7009 introduce potent ICaL-activity 
to the IKr and INa-blocking characteristics described for both agents 7, 8, 17. Hence, 
with its combined ion channel-blocking profile, AZD1305 has been proposed           
as an antiarrhythmic agent against AF with a lower proarrhythmic potential than 
other antiarrhythmic drugs. AZD1305 has been demonstrated to cause             
atrial-predominant effects in the healthy dog heart and attenuates ventricular 
repolarization-related instability caused by sudden rate changes during selective      
IKr blockade 8. In fact, AZD1305 was devoid of proarrhythmia in anesthetized 
methoxamine-sensitized rabbits, whereas other selective IKr blockers proved very 
torsadogenic in this animal model 7, 18.  
 
In our experiments on anesthetized dogs with normal hearts, AZD1305 caused 
ventricular and atrial repolarization prolongation, but no repolarization instability or 
proarrhythmias. In chronic-AVB dogs with remodeled hearts and a high susceptibility 
to acquired TdP, AZD1305 was much less proarrhythmic than dofetilide, despite 
causing similar ventricular repolarization prolongation. If TdP occurred during 
AZD1305, the arrhythmia(s) arose early during the 30-min infusion phase, when the 
plasma concentrations were still rising. At 10 min, the AZD1305 plasma 
concentration averaged 1.3±0.3 μmol/L (n=6 dogs with chronic AVB; Figure 4). In 
vitro findings indicate that AZD1305 has a higher potency against hERG (IC50 0.4 
μmol/L) in this concentration range than against ICaL and hNav1.5 (IC50s of 1.2 and 
1.5 μmol/L, respectively) 7. Although these in vitro findings can only be used with 
caution to predict potential effects in vivo, we speculate that the surge of ventricular 
extrasystoles and TdP during early AZD1305 infusion was due to initial proarrhythmic 
IKr inhibition, followed by antiarrhythmic ICaL and INa suppression upon mounting 
levels of the compound. Inhibition of either INa or ICaL has previously been shown to 
be effective in suppressing IKr-block-induced TdP in various experimental models. For 
example, INa block by lidocaine attenuated the incidence of TdP by almokalant in 
rabbits without influencing the almokalant-induced QT prolongation 19. Similar effects 
have been shown in the chronic-AVB dog after dofetilide-induced TdP, both with 
lidocaine and the novel INaLate blocker ranolazine 20, although in the latter study 
multiple ventricular ectopic beats were not completely abolished. In the same animal 
model, Oros et al. 21 showed a robust antiarrhythmic effect of both flunarizine and 
verapamil against dofetilide-induced TdP. To our knowledge, AZD1305 is the first 
compound, with the exception of amiodarone and dronedarone, with effects on IKr 
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together with ancillary dual INa and ICaL-blocking effects that has been investigated in 
this proarrhythmic model, and our results suggest that compounds with this profile 
could be devoid of proarrhythmic side effects if the ion-channel-blocking potencies 
are balanced (more so than for AZD1305), leaving no IKr block unattended. 
 
6.4.1 Repolarization Lability and Proarrhythmia Liability 
 
Various research groups have investigated the value of BVR parameters to predict 
imminent arrhythmia under conditions of repolarization lability. In the chronic-AVB 
dog, increases of beat-to-beat variability of MAPD have been shown to predict drug-
induced TdP 22, 23. Compounds increasing MAPD per se, but not BVR, are generally 
not torsadogenic in this experimental model. Beat-to-beat variability of the QT 
interval has also proven useful in heralding arrhythmia in other TdP models 7, 24, 25.  
In the clinical setting, increased BVR of the QT interval characterized patients with 
drug-induced proarrhythmia, even in the absence of QTc prolongation 26. Likewise, 
this parameter identified latent repolarization disorders in patients with congenital 
long QT syndrome 27. BVR of the QT interval was also found to be increased in 
patients with dilated cardiomyopathy and heart failure, probably reflecting acquired 
repolarization disturbances and an increased susceptibility to sudden arrhythmic 
death 28. In the present study, we have demonstrated that the combined inhibition of 
ICaL and INa together with IKr blockade does not significantly increase BVR in dogs with 
chronic AVB despite causing marked repolarization prolongation. These data 
reinforce the notion that BVR is a robust predictor of TdP, more so than 
repolarization duration per se, at least under these experimental conditions. 
 
6.4.2 Atrial Effects of AZD1305 in the Remodeled Heart 
 
AZD1305 has been shown to be an effective antiarrhythmic agent in various animal 
models of AF 9, 10. It causes an atrial-predominant blockade of INa (particularly tonic 
inhibition) which is suggested to translate into high antiarrhythmic efficacy 9. 
Previously, the predecessor to AZD1305, AZD7009, was shown to restore sinus 
rhythm in up to 82% of patients with AF episodes lasting up to 30 days and with 
minimal proarrhythmic side effects 29, 30. AZD7009 was less effective in patients with 
AF durations exceeding 1 month. A recent clinical study showed that AZD1305 was 
effective in converting AF to SR, with a conversion rate of 50% within 90 min in the 
highest dose group, despite AF episode durations of up to 3 months 12. 
 
In the present study, AZD1305 led to significant increases in right-atrial MAPD50 and 
MAPD90 in both the normal and the AVB-remodeled dog heart (Figure 9). The 
mechanisms and consequences of atrial remodeling during chronic AVB are still 
incompletely understood. In an early study in dogs, right-atrial pressures were 
increased during acute and chronic overload 31, thus promoting dilatation and 
hypertrophy. In goats, progressive atrial dilatation has been demonstrated in chronic 
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AVB, along with atrial hypertrophy, prolongation of induced AF paroxysms and local 
conduction delays 32. Importantly, atria undergoing remodeling due to electrically-
induced AF were less responsive to IKr blockers given as solo administration 33. The 
additional blockade of IKur, ITO and IKAch, which prolonged the early atrial 
repolarization, led to restoration of the antiarrhythmic class-III action of the IKr 
blocker in this goat model 33. In other dog models, the myocardial substrate of AF in 
congestive heart failure appeared very different from that of rapid-atrial-pacing 
related AF, 34 with contrasting efficacy of dofetilide 35. Collectively, these data 
illustrate the impact of the type of remodeling on atrial drug responsiveness. 
 
6.4.3 Conclusions 
 
Despite causing a similar degree of repolarization delay, the combined ion-channel 
blocker AZD1305 induces less ventricular repolarization instability, reflected in LV 
BVR, and has a lower proarrhythmic potential than the selective IKr blocker dofetilide 
in the chronic AVB-remodeled dog heart. AZD1305 can still lead to TdP in the 
remodeled heart, although in a minority of animals, during an infusion phase when 
plasma levels of the compound are still increasing. This is likely due to differential 
affinities of the drug for various ion channels, resulting in a window of preferential 
proarrhythmic IKr block. Further development of safer combined ion-channel blockers 
as antiarrhythmics could take this information into account. 
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Abstract 
QT prolongation is commonly used as a surrogate marker for Torsades de Pointes 
(TdP) risk of non-cardiovascular drugs. However, the use of this indirect marker 
often leads to misinterpretation of the realistic TdP risk, as tested compounds may 
cause QT prolongation without effectively evoking TdP in man. A negative electro-
mechanical (E-M) window has recently been proposed as an alternative risk marker 
for TdP in a canine LQT1 model. The current work studied the E-M window in 
anaesthetized guinea-pigs as a screening marker for TdP in man. The effects of 
various reference drugs and changes in body temperature on the E-M window were 
assessed in instrumented guinea-pigs. The E-M window was defined as the delay 
between the duration of the electrical (QT interval) and mechanical (QLVPend) 
systole.  Drugs with documented TdP liability (quinidine, haloperidol, domperidone, 
terfenadine, thioridazine and dofetilide) consistently decreased the E-M window, 
whereas compounds with no TdP risk in man (salbutamol and diltiazem) failed to 
affect the E-M window. Interestingly, drugs with documented clinical QT 
prolongation, but with low risk for TdP (amiodarone, moxifloxacin and ciprofloxacin) 
did not decrease the E-M window. Furthermore, the E-M window was minimally 
affected by changes in heart rate or body temperature. In conclusion a decreased      
E-M window was consistently observed with drugs documented to have high TdP 
risk, but not with drugs with low or no TdP risk. These results suggest that the E-M 
window in anaesthetized guinea-pigs is a risk marker for TdP in man.  
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7.1 Introduction 
Delayed ventricular repolarization – whether by congenital defects such as the long 
QT syndrome (LQTS) 1 or by the effects of potassium channels blocking drugs such 
as terfenadine or dofetilide – is associated with a high incidence of Torsades de 
Pointes (TdP) and sudden cardiac death. The incidence of TdP with cardiac pro-
arrhythmic drugs is 1-8 % while the incidence with non-cardiac drugs is considerably 
lower (approximately 1 in 100 000) 2. Because of its infrequent occurrence TdP is 
typically not seen in clinical trials. As such, QT interval prolongation has become a 
surrogate marker of TdP risk and is commonly used as a preclinical and clinical 
biomarker for pro-arrhythmic activity of non-cardiovascular drugs 3. 
 
Currently QT prolongation is a major safety issue in drug development and              
a dedicated regulatory guideline (ICH S7B) describes strategies for identification     
of drug candidates affecting cardiac repolarization. Since no single assay is sufficient 
to predict the risk of TdP in humans, the ICH S7B document recommends              
an integrated approach including at least an in vitro assessment of inhibition of     
the rapidly activating delayed rectifier potassium current (IKr) and an in vivo         
QT-assay. In line with the ICH S7B guideline, frontloading of cardiovascular safety 
data, i.e. screening for TdP liability early on in drug development has become 
common practice. In this view, guinea-pigs have received a great deal of attention 
with regards to evaluation of effects of newly discovered drugs on the QT interval at     
the early stage. Indeed, the anesthetized guinea-pig model is a useful tool for     
“first in line” in vivo cardiovascular safety assessment due to the limited amounts    
of test compound required; the similarity of cardiac ionic currents between guinea-
pigs and man 4, and the ease of manipulation of guinea-pigs. Over the last years 
many reference drugs have been evaluated in the anaesthetized guinea-pig model 
and the predictive value of this model for QT prolongation in humans is well 
documented 5, 6, 7.  
 
Although the current strategies based on identification of drug-induced QT 
prolongation in animal models (ICH S7B) and its clinical counterpart - the thorough 
QT study (ICH E14) - have been relatively successful in the attrition of unsafe drug 
candidates, this approach inherently generates a number of false positive results due 
to the lack of direct association between the surrogate marker (QT interval) and the 
final endpoint (TdP risk). Indeed, the magnitude of QTc prolongation does not 
correlate with the TdP risk in man; and several drugs prolong the QT interval without 
causing TdP in man 2, 8, 9. 
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Over the last years a number of new risk markers and models for TdP risk evaluation 
have been proposed, illustrating the absolute need of the pharmaceutical industry to 
develop more accurate markers for TdP risk in man. The current state-of-the-art of 
risk markers and pro-arrhythmia models are comprehensively described       
elsewhere 8, 10, 11. The electro-mechanical (E-M) window has recently been proposed 
as one of these alternative risk markers for TdP in man. 
 
The current work aimed to evaluate the E-M window in anaesthetized guinea-pigs as 
a new risk marker for TdP. The E-M window is defined as the delay between the 
electrical (QT-interval) and mechanical (QLVPend) systole (E-M window = QLVPend 
interval – QT interval, Figure 1). Despite intensive studies on E-M coupling in man 
since the 1980’s, the concept of disturbed E-M coupling as a risk marker for TdP was 
only recently introduced in safety pharmacology 12. In healthy individuals, the 
duration of the electrical systole (QT interval) is shorter than, but closely parallels the 
duration of mechanical systole (measured indirectly by the time between the Q wave 
and the second heart sound; QS2) throughout the normal range of resting heart 
rates 13. Interestingly, changes in autonomic tone 14 or high circulating catecholamine 
levels 15 were reported to invert the normal QT/QS2 ratio. Furthermore, the QT/QS2 
ratio was found to be a useful indicator for several cardiovascular diseases 16, 17, 18. 
Moreover, patients with the Romano-Ward inherited long QT syndrome were found 
to have an altered QT/QS2 ratio 19. Recently, van der Linde et al. (2010) 12 showed 
that in a canine LQT1 dog model an inverted (negative) E-M window is a prerequisite 
for the initiation of TdP. A negative E-M window is a highly pro-arrhythmic condition, 
due to the fact that under these conditions there is a mismatch of electrical and 
mechanical activity. This provides a situation where arrhythmias can ensue, most 
likely because Ca2+ can continue to enter the cardiac myocytes favoring the 
occurrence of Ca2+ overload, leading to both early and delayed afterdepolarizations 
as well as aftercontractions which may eventually lead to TdP. Restoration of the E-M 
??????? ??? ?????????? ?? ?-adrenergic ????????? ?????? antagonist, or verapamil, an      
L-Type Ca2+ channel blocker, prevented the induction of TdP by IKs blockade in 
???????????????????? stimulation 12. 
 
Based on these observations we hypothesized that a negative E-M window in the 
anaesthetized guinea-pig model might be a (LQT1) risk marker of TdP in man. 
Implementation of such a new risk marker for TdP in an early screening platform, 
like the anaesthetized guinea-pig model, would mean a significant breakthrough in 
cardiovascular safety pharmacology. In an attempt to document the predictive value 
of the E-M window in anaesthetized guinea-pigs the effects of various 
pharmacological agents with different torsadogenic profiles (high, low and no TdP 
risk) were assessed. 
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Figure 1: The Wiggers diagram illustrates the synchronization of the electrical 
(electrocardiogram, ECG) and mechanical (left ventricular pressure, LVP) activity of the 
cardiac muscle in anaesthetized guinea-pigs. The electro-mechanical window (E-M window) is 
defined as the delay between the duration of the electrical (QT interval) and mechanical 
(QLVPend interval) systole. E-M window = QLVPend interval – QT interval. 
7.2 Methods 
7.2.1 Animal Use and Care 
The studies were approved by the Ethical Committee of Vito (Mol, Belgium) and 
conformed to the Guide for the Care and Use of Laboratory Animals published by the 
US National Institute of Health (NIH Publication No. 85-23, revised 1996).  
Female Dunkin Hartley guinea-pigs (weight 380-540 g) were purchased from Charles 
Rivers (L’Arbresle, France). Animals arrived at the animal facilities at least 1 week 
before the study and were housed in groups (up to 5 animals per cage; >3500 cm² 
per cage) with access to food and water ad libitum. 
 
7.2.2 Surgical Procedure 
Animals were anaesthetized by intraperitoneal administration of sodium pentobarbital 
(60 mg/kg). A tracheotomy was performed and the guinea-pigs were mechanically 
ventilated with room air (model ‘683’ respirator, Harvard Apparatus, Les Ulis, France) 
using a stroke volume of 10 ml/kg at a rate of 60 strokes/min. The tracheal tube was 
connected to a pressure transducer to monitor the pulmonary inflation pressure 
throughout the experiment. Animals were placed on an electrical heat pad at 37°C 
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(small operating table, Harvard Apparatus). Both jugular veins were cannulated for 
respectively intravenous drug administration (right jugular vein) and continuous 
infusion of pentobarbital (6 mg/h) to maintain anaesthesia (left jugular vein). An 
open-lumen catheter was inserted in the left carotid artery for blood pressure 
measurement and collection of arterial blood samples. A tip catheter (SPR-249, Millar 
Instruments, Houston, Texas, USA) was positioned in the left ventricle for 
measurement of left ventricular pressure (accessed via the right carotid artery). Four 
needle electrodes were put subcutaneously to record the electrocardiogram (ECG). 
Pressure and ECG signals were relayed to a bio-amplifier (EMKA Technologies, Paris, 
France) with output to a data acquisition system (IOX, EMKA Technologies). Raw 
data were captured at sampling rates of 1000 Hz (ECG signals) or 500 Hz (blood 
pressure and left ventricular pressure). After being instrumented animals were 
allowed to stabilize for a period of at least 20 min. 
 
7.2.3 Experimental Protocol 
 
The effect of various reference drugs on cardio-electrophysiological and cardio-
hemodynamic parameters was assessed in anaesthetized guinea-pigs. Guinea-pigs 
received consecutively five increasing doses of the test compounds. All compounds 
were infused intravenously at a rate of 1 ml/kg over a 10-min infusion period with 5-
min intervals between consecutive doses. Animals in the separate vehicle group were 
infused equal volumes of saline. At the end of the vehicle experiments dofetilide was 
infused over a 1-min period as positive control.  
 
In addition, a separate set of experiments (n=3) were performed to assess the effect 
of temperature (range 38°C-34°C) on the cardiovascular parameters. After 
stabilization the heating pad was switched-off and temperature (measured via a 
rectal probe) and associated cardiovascular parameters were monitored during the 
cooling phase. 
 
7.2.4 Data Analysis 
 
Analysis of raw data was performed using ECG-Auto software (version 2.5.1, EMKA 
Technologies). ECG signals (lead II) were automatically analyzed based on      
shape-recognition linked to a user-defined library of ECG waveforms. The QTcB 
interval was calculated for every single beat by using the previous RR interval. The 
end of the ventricular relaxation (LVPend point) was defined by applying a threshold  
(-100 mmHg/s) on the first derivative of the relaxation part of the LVP signal. The RR 
interval, PQ interval, QRS interval, QT interval, QTcB interval, QLVPend interval and 
the E-M window were calculated beat by beat. The accuracy of the analysis was 
reviewed by manual over-reading. For each minute-interval, median values were 
calculated and used for reporting. 
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The QT interval, the QLVPend interval and the E-M window were reported in actual 
units (ms), whereas for QTcB the changes from baseline in percentage were 
calculated. The parameters 60 seconds prior to the first drug administration       
were defined as baseline values. (t = 0 min). The results from individual animals 
were pooled by treatment group and visualized in graphs as mean±. 
 
7.2.5 Chemicals 
 
Clinical reference substances were purchase as dry powder. Quinidine, haloperidol, 
domperidone, terfenadine and diltiazem were purchased from Tocris Bioscience 
(Bristol, United Kingdom); moxifloxacin, ciprofloxacin, thioridazine, isoprenaline     
and salbutamol were purchased from Sigma (Bornem, Belgium). The dry powder 
(taking into account a correction factor for the different molecular weights  of various 
salt forms) was dissolved in a vehicle consisting of physiological saline solution. 
Vehicles of terfenadine and domperidone contained 10 % hydroxypropyl-?-
cyclodextrin to increase solubility. Amiodarone was purchased in a clinically available 
formulation (Cordarone® 150 mg per 3 ml, Sanofi Aventis) and was diluted          
with saline. 
 
7.2.6 Statistics 
 
Results were expressed as mean±SEM. Changes from baseline (in actual units) were 
analyzed by a one-way ANOVA test with Bonferroni post-hoc test.  
  
 
7.3 Results 
 
Various pharmacological agents were administered intravenously to instrumented 
and anaesthetized guinea-pigs. Following drug administration the duration of the QT 
interval and the QLVPend interval was continuously monitored. In addition, the E-M 
window, defined as the delay between the electrical and mechanical systole (E-M 
window = QLVPend interval – QT interval) was calculated beat by beat (Figure 1).  
 
7.3.1 Drugs with Well-Documented TdP Risk 
 
Drugs associated with prolongation of the QT interval and with well-documented TdP 
risk in man (quinidine (n=4), haloperidol (n=3), domperidone (n=4), terfenadine 
(n=4), thioridazine (n=5) and dofetilide (positive control, n=4) all showed dose-
dependent prolongation of the QT and QTcB interval (Figure 2 and Figure 3). The 
QLVPend interval was not prolonged to the same extent as the QT interval resulting in 
a dose-dependent decrease of the E-M window. Administration of quinidine, 
haloperidol and domperidone eventually lead to a negative E-M window (Figure 3), 
whereas terfenadine and thioridazine decreased the E-M window, but failed to make 
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this parameter negative (Table 1). Interestingly, quinidine decreased the E-M 
window, but a slight restoration of the E-M window between consecutive doses was 
observed, which was not observed for the QTcB interval. Terfenadine caused marked 
bradycardia and hypotension at the highest dose (10 mg/kg) thereby generating less 
reliable results at this dose. 
 
7.3.2 Negative Controls (No TdP Risk) 
 
Intravenous administration of vehicle (saline, n=4) did not affect the E-M window or 
the QTcB interval (Figure 2 and Figure 4). Administration of the positive control 
(dofetilide) caused a negative E-M window and prolongation of the QTcB interval, 
illustrating the validity of the assay. In addition, two clinical drugs with no TdP risk 
were tested: salbutamol (n=5) and diltiazem (n=4). Both drugs failed to affect the  
E-M window. Salbutamol caused a drastic increase in heart rate (data not shown) 
thereby significantly decreasing the QT and QLVPend interval. The QTcB interval was 
shortened by salbutamol illustrating the limitations of Bazett’s formula for heart rate 
correction, whereas the E-M window was hardly influenced by the strong changes in  
heart rate. Diltiazem caused a decrease of heart rate (data not shown) and 
eventually cardiovascular collapse at 3 mg/kg and animals died at the highest dose 
10 mg kg-1. However, the E-M window was not altered by diltiazem administration. 
 
7.3.3 Amiodarone, Moxifloxacin and Ciprofloxacin 
 
Amiodarone (n=4) and moxifloxacin (n=4) showed remarkable results (Figure 2 and 
Figure 5). Both drugs caused a significant prolongation of the QTcB interval of 
respectively 12 % and 14 %. However, since the QLVPend interval prolonged to the 
same (moxifloxacin) or higher (amiodarone) extent no negative E-M window was 
observed after administration of these compounds. Furthermore, dofetilide failed to 
evoke a negative E-M window following amiodarone administration. Ciprofloxacin 
(n=4) showed a tendency for QT prolongation (5 % increase) at the highest dose, 
but the E-M window was not affected by ciprofloxacin administration. 
 
7.3.4 Isoprenaline 
 
Isoprenaline (n=4) showed a shortening in the QT interval, as would be expected 
due to the chronotopic effects of this compound. At the same time a decrease of the 
QLVPend interval was observed, which was not completely synchronized with the 
effects on QT. This led to a transient decrease in the E-M window at the highest 
concentrations (Figure 2 and Figure 4). 
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Figure 2: Graphs show the effect of various pharmacological agents on the electro-
mechanical coupling in anaesthetized guinea-pigs. Drugs with high TdP risk (quinidine, 
haloperidol, domperidone, terfenadine, dofetilide and thioridazine) induced unequal changes 
of the QT interval versus the QLVPend interval, whereas drugs with low TdP risk (amiodarone, 
moxifloxacin and ciprofloxacin), with no TdP risk (vehicle, salbutamol and diltiazem) induced 
parallel changes of the QT interval and LVPend interval. Finally, isoprenaline showed different 
kinetics of its effect on the QT and QLVPend interval leading to a transient decrease of the E-M 
window. Plots show mean±SEM. 
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Figure 3: Graphs show the effects of drugs with documented TdP risk on the commonly 
used surrogate marker for TdP risk (QTcB, % change from baseline; left panels) and on the 
E-M window (ms; right panels). Quinidine, haloperidol, domperidone, terfenadine and 
ioridazine prolonged the QTcB interval and consistently decreased the E-M window. Graphs 
show mean±SEM. 
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Figure 4: Plots show the effects of vehicle, of drugs with no TdP risk (diltiazem, salbutamol), 
of isoprenaline and of changes in body temperature (lowest graphs) on the commonly used 
surrogate marker for TdP risk (QTcB, % change from baseline; left panels) and on the E-M 
window (ms; right panels). The vehicle did not cause QTcB prolongation or shortening of    
the E-M window. Salbutamol and diltiazem, respectively, increased and decreased heart    
rate (data not shown), but did not affect the E-M window. Isoprenaline transiently reduced 
the   E-M window due to the different kinetics of its effect on the QT and QLVPend interval. 
Finally, cooling of anaesthetized animals from 38°C to 34°C prolonged the QTcB interval 
??????????????), but had no major effect on the duration of the E-M window. Graphs show 
mean±SEM. 
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Figure 5: Graphs show the effects of amiodarone and two antibiotics (moxifloxacin and 
ciprofloxacin) on the commonly used surrogate marker for TdP risk (QTcB, % change from 
baseline; left panels) and on the E-M window (ms; right panels). Amiodarone increased the 
QTcB interval, but did not decrease the E-M window; in fact, it significantly increased the E-M 
window and prevented induction of a negative E-M window by dofetilide. Moxifloxacin and 
ciprofloxacin hardly affected the E-M window despite prolongation of the QTcB interval. 
Graphs show mean±SEM. 
7.3.5 Effect of Temperature 
The effect of temperature on the electro-mechanical coupling was investigated in a 
different set of experiments (n=3, Figure 4). Cooling of the animals from 38°C to 
34°C caused increases of the QT interval, the QTcB interval (slope: -14.6 ???°C-1) 
and the QLVPend interval. The E-M window remained stable during cooling; and even 
slightly increased when cooling below 35.5°C. 
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Table 1 
Change from baseline (ms) baseline dose 1 dose 2 dose 3 dose 4 dose 5 
(actual 
units) 10  min 25 min 40 min 55 min 70 min 
quinidine E-M 
window 28.4?5.9 -1.2?1.7 -7.7?5.7 -24.2?8.8 -43.6?9.9** -50.4?8.9** 
n=4  QTcB 403.0?6.2 7.9?0.6 21.6?4.3 46.5?10.1* 76.5?11.4*** 105.9?14.2*** 
haloperidol E-M 
window 43.2?4.0 -3.6?0.7 -7.4?2.2 -21.3?7.8 -39.8?7.7** -66.0?7.5*** 
n=3 QTcB 407.4?6.8 13.7?2.7 31.4?7.2 47.2?11.8* 82.5?6.6*** 117.2?15.8*** 
domperidone E-M 
window 37.3?3.4 -4.5?1.7 -10.5?2.9 -17.0?3.8 -34.0?4.6*** -48.0?5.6*** 
n=4 QTcB 369.3?10.0 11.8?2.8 26.2?3.9* 37.5?4.3*** 68.9?4.8*** 88.3?7.1*** 
terfenadine E-M 
window 32.8?4.0 -2.3?2.1 -7.9?3.8 -20.4?5.3 -28.0?2.2 -12.6?17.9 
n=4 QTcB 385.9?5.2 10.6?2.4 25.5?2.1* 54.5?3.7*** 79.8?6.1*** 92.5?9.7*** 
thioridazine E-M 
window 28.2?3.0 -3.0?1.3 -7.4?2.0 -15.2?3.9 -20.9?6.8* -28.6?6.8** 
n=5 QTcB 364.9?11.6 11.5?4.2 18.0?2.9 27.6?6.0* 36.9?7.8** 53.1?9.3*** 
vehicle E-M 
window 27.7?9.2 -1.7?0.7 -2.3?0.9 -3.2?0.4 -1.0?2.6 -2.3?1.8 
n=4 QTcB 365.3?9.1 4.6?2.2 7.5?3.5 -0.9?7.2 0.7?7.9 3.0?7.9 
salbutamol E-M 
window 25.0?5.3 4.4?3.2 2.6?2.7 2.2?2.9 1.6?3.4 0.1?2.6 
n=5 QTcB 372.1?6.2 -8.6?4.4 -15.7?3.9 -21.6?6.9 -27.3?5.5** -36.5?5.8*** 
diltiazem E-M 
window 40.2?6.0 0.8?4.9 3.4?11.0 0.5?16.4 -28.0?2.2 -12.6?17.9 
n=4 QTcB 382.9?17.2 7.1?2.9 0.7?8.9 5.6?14.4*** 79.8?6.1*** 92.5?9.7 
amiodarone E-M 
window 26.3?2.3 -6.3?1.9 -10.5?1.8 -9.5?2.2 -6.0?4.4 12.0?2.4 
n=4 QTcB 373.1?2.3 13.6?3.6 19.9?3.2 26.1?5.9* 37.5?7.7** 38.2?6.0** 
moxifloxacin E-M 
window 39.0?5.0 -2.0?0.9 -1.0?2.8 -3.0?2.4 -6.8?2.8 -13.5?3.3* 
n=4 QTcB 364.6?12.9 10.6?1.1 18.8?0.6 25.4?1.7* 33.6?4.9** 52.0?6.4*** 
ciprofloxacin E-M 
window 37.5?3.8 -4.3?1.3 -4.5?1.9 -7.0?2.0 -9.8?1.3 -12.4?4.0 
n=4 QTcB 367.5?13.7 4.0?1.0 9.7?9.6 8.5?9.3 12.5?10.5 22.0?10.5 
 
Table 1: Baseline values (actual units) and change from baseline for the E-M window and 
the QTcB interval after administration of various clinical reference drugs. Data show      
mean± SEM. A one-way ANOVA with Bonferoni post-hoc test was performed on the ‘change 
from baseline’ values, * P<0.05, ** P<0.01, *** P<0.001.  
 
7.3.6 Occurrence of Arrhythmias 
 
None of the reference drugs evoked episodes of TdP. Isolated ventricular premature 
contractions (VPCs) and an atrial premature contraction (APC) were observed in 8 
and 1 out of 45 animals respectively. Most of these VPC’s were observed during 
replacement of the catheters and were not observed in later experiments where the 
catheters were appropriately fixated.  Right bundle branch block (r-BBB) was 
reported after administration of diltiazem (1 of 4), terfenadine (4 of 4), haloperidol  
(1 of 3), thioridazine (2 of 5) and amiodarone (1 of 4). Furthermore atrio-ventricular 
block (AVB) was observed after treatment with diltiazem (3 of 4 animals), 
terfenadine (1 of 4), haloperidol (1 of 3) and dofetilide (2 of 4). Finally, diltiazem 
caused complete cardiovascular collapse in all animals (starting from 3 mg/kg) 
eventually leading to death.  
 
 
195 
CHAPTER 7 
7.4 Discussion 
 
7.4.1 The Anaesthetized Guinea-Pig Model and the E-M Window 
Over the last years the anaesthetized guinea-pig model has received a great deal of 
attention as a useful tool for early in vivo cardiovascular safety screening. Guinea-
pigs have a cardiac electrophysiology that largely resembles human and the small 
size of the animals favors the use of this model for cardiovascular safety screening. 
Several anaesthesia regimens have been described for assessing QT prolongation in 
guinea-pigs 20, 21, 22 with the pentobarbital anaesthetized model being the most 
common and best documented 5 ,6, 7, 23. In addition to the ECG-derived information 
(QT interval, QRS interval and PQ interval) the anaesthetized guinea-pig model 
provides information on hemodynamics (heart rate, blood pressure, QA interval), 
cardiac performance (left ventricular pressure) and on the induction of spontaneous 
arrhythmias making it a versatile cardiovascular screening model (Figure 6). 
Recently, the E-M window has been proposed as a novel risk marker for TdP in        
a LQT1 dog model 12. The present work provides the first documented report of the 
E-M window as a general risk marker for TdP within an early screening model. 
 
Figure 6:  Figure shows a schematic overview of the anaesthetized guinea-pig model as a 
versatile early cardiovascular safety screening tool. At present, both pre-clinical (ICH S7B) 
and clinical (ICH E14) studies use the QTc interval as a surrogate marker for TdP risk in man. 
The E-M window provides a new risk marker for TdP risk in man that might eventually be 
implemented in clinical research. APC, atrial premature contraction; VPC, ventricular 
premature contraction; BBB, bundle branch block (left or right). 
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7.4.2 Drugs with High TdP Risk are Selectively Flagged 
 
Drugs with documented high TdP risk 24, 25 consistently decreased the E-M window. 
Quinidine, domperidone, haloperidol and dofetilide caused a negative E-M window 
that might form a substrate for the development of TdP. Due to a large 
repolarization reserve in guinea-pigs 26, 27 IKr blockade by itself did not elicit TdP in 
the anaesthetized guinea-pig model.  
 
The results of terfenadine and thioridazine are less clear. Despite a substantial 
decrease of the E-M window, terfenadine and thioridazine did not cause negative    
E-M windows on their own. This might suggest that additional challenges on the 
repolarization reserve are required to trigger TdP with these agents. Terfenadine, for 
example, has been shown to be a multi-ion channel blocker, affecting both inward 
and outward currents, including the L-type calcium current (ICaL) and the slowly 
activating delayed rectifier potassium current (IKr),  which could be an explanation 
for the absence of a negative E-M window with this compound 28. Interestingly, 
terfenadine did not trigger TdP in a phenylephrine-sensitized rabbit model, whereas 
halofantrine and clofilium did lead to TdP 29.    
 
In the anaesthetized guinea-pig model a 5 % increase in the QTcB interval can be 
accurately detected 30 and a 10 % prolongation of the QTcB interval should           
be classified as important QT prolongation. Similarly, based on our current 
experience we suggest that a shortening of the E-M window below 20 ms warrants 
further evaluation, whereas a negative E-M window points directly to high TdP risk in 
man. Drugs with no TdP risk (nor the vehicle) had no effect on the E-M window 
demonstrating the selectivity of the new risk marker. 
 
7.4.3 Amiodarone 
 
The multi-target agent amiodarone has extremely complex electropharmacological 
actions, with effects on multiple ion ???????????????????????? 31, and is an interesting 
agent in the context of QT prolongation and TdP, despite causing a modest 
prolongation of the QT interval, it is an effective antiarrhthymic drug with a relatively 
low potential for TdP.  Amiodarone has been found safe in patients who had 
experienced TdP while taking other drugs 32, 33 and can be used to treat TdP 34, 
although it has various off target side effects which can limit chronic administration 
in a large cohort of patients. Furthermore, amiodarone showed relatively low 
potential for TdP in the canine chronic AV-block model, after both chronic 35 and 
acute dosing 36 and also in the Screenit rabbit model 37. In line with these reports, 
acute dosing of amiodarone did not elicit a negative E-M window in our experiments. 
Moreover, amiodarone increased the E-M window in anaesthetized guinea-pigs and 
prevented inversion of the E-M window by dofetilide. A similar protective effect of 
amiodarone has been described in a setting of sotalol-induced arrhythmias in dogs 38. 
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The mechanism of this protective effect might be the conservation of a positive E-M 
window, most likely due to the alterations in Ca2+ handling, although a reduction in 
heterogeneity of cardiac repolarization has been attributed to amiodarone as well 39. 
 
7.4.4 Moxifloxacin and Ciprofloxacin 
 
Fluoroquinolones antibiotics are all associated with some degree of QT    
prolongation 40, 41, but the different members of this therapeutic class have different 
torsadogenic profiles 42. Grepafloxacin (withdrawn from the market in 1999) and 
sparfloxacin have a high risk for induction of TdP in humans 43, whereas ciprofloxacin 
and moxifloxacin have a low risk for TdP in man. In agreement with the use of 
moxifloxacin as a positive control in thorough QT studies 44; and consistent with 
published pre-clinical data moxifloxacin prolonged the QTcB interval 6, 45 the present 
study. Despite considerably prolonging the QTcB interval, moxifloxacin only caused a 
minor decrease in the E-M window in anaesthetized guinea-pig suggesting minimal 
risk for TdP at the maximal dose used in this study (10 mg/kg). In line with these 
results moxifloxacin (8 mg/kg) did not produce episodes of TdP in a canine chronic 
AV-block model 46. Whether higher doses of moxifloxacin would further compromise 
the E-M window is not known, but pharmacokinetics of moxifloxacin (400 mg, oral 
administration, once daily) are well-controlled which could explain why only few 
cases of moxifloxacin-related TdP have been reported. For ciprofloxacin no effect on 
the E-M window was observed. This favorable safety outcome in the anaesthetized 
guinea-pig model is in line with the frequent use of ciprofloxacin in clinical practice as 
a safe antibiotic.  
 
Taken together, the E-M window appears to classify drugs with high and low TdP risk 
correctly and might be a valuable addition to the classical QTc interval screening. 
 
7.4.5 Isoprenaline 
 
Isoprenaline transiently reduced the E-M window due to the different kinetics of      
its effect on the QT and QLVPend interval. The decrease of the E-M window by 
isoprenaline might explain the torsadogenic activity of isoprenaline in the LQT1    
dog model (with compromised IKs) 12. However, in anaesthetized guinea-pigs 
combined administration of IKr- (quinidine 10 mg/kg) and IKs-blockers             
(JNJ303 2 mg/kg) - resulting in large negative E-M windows (less than -50 ms) - did 
not result ??? ???????????? ??? ??? stimulation (isoprenaline 0.0125 mg/kg) induced 
TdP (unpublished data). As such, no direct association between a negative E-M 
window and initiation of TdP could currently be demonstrated in guinea-pigs. 
However, in the canine LQT1 model the necessity of a negative E-M window for the 
onset of TdP has been demonstrated 12.  
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7.4.6 Effect of Heart Rate and Body Temperature on the E-M Window 
 
The duration of the QT interval is dependent on several factors including heart rate, 
autonomic influences 47 and body temperature 48. Different correction formulas have 
been applied in an attempt to discriminate between heart rate dependent and heart 
rate independent changes of the QT interval. In anaesthetized guinea-pigs the 
Bazett’s formula is frequently applied to correct for heart rate 6, 20, and this correction 
has been shown to be the most effective in this model 22. The shortening of the 
QTcB interval with salbutamol in the present study, however, illustrates the 
limitations of Bazett’s formula. Interestingly, the E-M window hardly changed with 
salbutamol despite drastic increases in heart rate. Similarly, significant decreases in 
heart rate associated with diltiazem did not affect the E-M window either.   
The effect of temperature on the duration of the QT interval has been studied in 
detail in anaesthetized dogs 48. A similar temperature dependency of the QT interval 
was observed in anaesthetized guinea-pigs: -14.6 ms°C-1 (QTcB) in anaesthetized 
guinea-pigs versus -14 ms°C-1 (QTcVDW) in anaesthetized dogs.  However, the E-M 
window remained remarkably stable during cooling and even tended to increase 
slightly when cooling below 35.5°C.  
Taken together, the E-M window is, in contrast to the QTcB interval, a robust 
parameter that is minimally affected by changes in heart rate or body temperature. 
 
7.4.7 Limitations of the study 
 
No bio-analysis of plasma samples was performed, therefore results could not be 
presented as x-folds of therapeutic concentrations and subsequently no safety 
margins could be determined. In literature some data on plasma concentrations and 
QTcB prolongation of reference drugs in anaesthetized guinea-pigs and dogs have 
been published 6, 24, 45 that could be useful to put our results in perspective. The 
QTcB prolongations evoked by reference compounds observed in the current study 
are consistent with these previous reports. 
 
7.4.8 Conclusions 
 
The present work studied for the first time the E-M window in anaesthetized guinea-
pigs as a general risk marker for TdP in man. A decreased E-M window was 
consistently observed with drugs with high TdP risk, but not with drugs with low or 
no TdP risk. Furthermore, the E-M window was found to be a robust marker 
minimally affected by changes in heart rate or body temperature. These results 
suggest that the E-M window in anaesthetized guinea-pigs is an alternative risk 
marker for TdP in man that complements the traditional QT interval screening. 
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8.1 General Discussion 
 
Over the last decades, drug-induced cardiac arrhythmias, including Torsades de 
Pointes (TdP) have become a major issue in drug development. Although 
(documented) episodes of TdP have a high impact for the individual patient, the 
estimated incidence is as low as 1 per 100,000 per year 1, 2.  In 2005, the regulatory 
document ICH S7B was introduced with guidelines for a non-clinical testing strategy 
to assess the potential of a test substance to delay ventricular repolarization. These 
guidelines recommended the use of an ion-channel screen to investigate the effects 
of the test substance on the rapid component of the delayed-rectifier potassium 
channel (IKr-channel), as well as an in-vivo QT study in animals such as monkey, 
swine, dog, rabbit, ferret or guinea pig. The data obtained in these studies should 
then be combined and used to make an integrated risk assessment of the possible 
proarrhythmic capability of a test compound. In addition, these guidelines 
encouraged interested parties to develop proarrhythmic models and indices of 
proarrhythmic activity. 
 
Although the current preclinical strategy, together with its clinical counterpart ICH 
E14, has been relatively successful in the attrition of unsafe drug candidates, 
cardiovascular safety remains one of the major reasons for the failure of compounds 
to reach the market. This is due to the fact that the mechanisms underlying TdP 
arrhythmia are not yet fully understood and the potential spectrum of side-effects of 
many drugs, including non-arrhythmic side-effects, is still incompletely explored. In 
addition, in the case of certain drugs post-marketing problems have occurred. For 
example, the COX2 inhibitor Vioxx, a non-steroidal anti-inflammatory drug (NSAID) 
that was approved by the FDA in May 1999 for a number of indications (including 
relief of the signs and symptoms of osteoarthritis, management of acute pain in 
adults, and for the treatment of menstrual symptoms) was voluntarily withdrawn by 
the manufacturer in 2004 due to safety concerns of an increased risk of 
cardiovascular events (including heart attack and stroke). 
 
The major aim of this thesis was to provide further insights into the mechanisms of 
TdP arrhythmia. Further understanding of such mechanisms should lead to improved 
methods to distinguish safe medications from those that may lead to TdP and 
sudden cardiac death, and to improved prediction and prevention of this 
arrhythmia in the patient. Over the years numerous discussions have taken place to 
advance the field of cardiac safety pharmacology, with specific focus on reducing 
TdP risk 3, 4. In this thesis, a number of these issues have been addressed, including 
the use of proarrhythmia models to identify novel surrogate markers of TdP       
(e.g., temporal aspects of repolarization prolongation), and the role of myocardial 
Ca2+ handling in TdP induction. 
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8.2 Markers and Models for TdP 
 
Beat-to-beat variability of repolarization (BVR) has been proposed as a more 
predictive marker of TdP arrhythmia than repolarization duration alone 5. BVR has 
previously been shown to be increased in a number of in-vivo preclinical 
proarrhythmic models, including the chronic-AV-block (CAVB) dog 6 and the 
methoxamine-sensitized rabbit 7. Additionally, increases in BVR have been observed 
in other experimental studies when animals were exposed to compounds that are 
known to cause TdP 8, 9. Increases in BVR have also been seen in specific patient 
groups with an augmented arrhythmia risk 10, 11. Interestingly, a recent study also 
showed an increase of BVR in professional football players 12. Although this study 
does not directly relate these increases to augmented arrhythmia propensity in this 
group, it is well known that strenuous exercise training is accompanied by ventricular 
hypertrophy, and this may be a substrate for sudden cardiac death in a small subset 
of these athletes 13, who could be genetically predisposed.  
 
One of the major aims of this thesis was to understand the underlying mechanisms 
of BVR, as until now these have remained largely elusive. In Chapter 2 we show 
that isolated canine myocytes can be used to examine the cellular 
electrophysiological effects of proarrhythmic compounds by using various techniques 
that are outlined in this chapter. We then use these techniques in Chapters 3     
and 4 to delineate specific mechanisms of BVR, especially in the setting of intense          
?-adrenergic ????????????? stimulation (see section 8.3). 
 
A recent interesting study from Nalos et al. 14 tested various IKr blockers, with 
different clinical proarrhythmic outcomes in five test systems, regarding cellular 
markers of arrhythmia prediction. In contrast to other published reports 15, they 
conclude that isolated myocytes lack the specificity to identify proarrhythmic 
compounds. Nalos et al. 14 show that in both remodeled ventricular myocytes from 
CAVB dogs and in unremodeled rabbit myocytes, moxifloxacin, a compound that has 
a relatively low proarrhythmic risk, can cause early afterdepolarizations (EADs). As a 
number of studies have indicated differential responses, at least in Purkinje fibres, 
between dog and rabbit preparations 16, 17 further investigation of these differences at 
the single myocyte level is warranted. Unfortunately, moxifloxacin has not been 
previously tested in isolated unremodeled canine myocytes and it would be of 
interest to see if moxifloxacin would cause EADs in this test system. These findings 
illustrate the importance of selecting the in-vitro test model that will have the most 
reliable translational outcome. 
 
Despite the fact that the single canine myocyte may not be ideal for predicting 
arrhythmia in-vivo, this cell type can be used to provide major mechanistic insights, 
as has been carried out in this thesis, to aid in developing better arrhythmia 
prediction algorithms in vivo. 
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The CAVB dog has been used as a model for proarrhythmic screening for a number 
of years, and as part of the work in this thesis we extend this by investigating the 
proarrhythmic capabilities of the combined ion-channel blocker AZD1305 (Chapter 
6). AZD1305 was in clinical development for the termination of persistent atrial 
fibrillation.  Apart from blocking IKr, this compound also inhibited INaLate and ICaL and 
by having this profile it had shown promise in a number of preclinical assays 18, 19. 
For example in the methoxamine-sensitized rabbit model, AZD1305 was devoid of 
any proarrhythmic actions despite causing large increases in repolarization times 18. 
In our study we show that AZD1305 was much less proarrhythmic than the pure IKr 
blocker dofetilide, despite causing similar ventricular repolarization prolongation. 
When TdP did occur, the arrhythmia(s) arose early during the 30-min infusion phase, 
when AZD1305 plasma concentrations were still rising. When no TdP arrhythmias 
were seen, BVR remained low, further illustrating the superiority of this parameter 
over QT prolongation alone. The road of clinical development of AZD1305 was 
unfortunately halted due to the fact that, as in the CAVB dog model, this compound 
led to TdP in a number of patients in a phase II clinical study 20. We believe that if a 
compound shows more balanced ion-channel potencies than those of AZD1305    
(i.e. similar inhibition of both inward and outward currents), the strategy of blocking 
these currents with a single agent could hold great therapeutic promise against 
cardiac arrhythmias without leading to TdP arrhythmia. These data highlight the 
importance of using sensitive proarrhythmic models such as the CAVB dog, before 
commencing costly clinical trials. 
 
As the heart is an electrically-driven muscular pump, the link between its electrical 
and mechanical activity is of vital importance. An unsuspected abnormality in the 
ventricular contraction pattern of patients with prolonged repolarization due           
to congenital long QT syndrome (LQTS) and an association with syncope and  
cardiac arrest was demonstrated over 20 years ago 21. However, only recently 
mechanical factors have been taken into consideration when discussing drug-induced 
arrhythmia 22. Previously, Gallacher et al. 8 elegantly demonstrated that in a canine 
model of long-QT1 (LQT1) syndrome, left-ventricular (LV) aftercontractions observed 
preceded the induction of TdP. After that study, van der Linde et al. 23 showed that 
in anesthetized dogs under baseline conditions the difference between the end of the 
QT interval and the end of the mechanical activity of the heart (assessed on the LV-
pressure signal) was positive, indicating that the heart was still in systole when the 
electrical activity had ceased (a positive electro-mechanical (E-M) window). 
Interestingly, under conditions of combined IKs ????????? ???? ???? stimulation, and 
prior to TdP arrhythmias in these animals, this relationship was reversed with 
completion of electrical activity taking substantially longer than the mechanical 
activity (negative E-M window). Furthermore, prevention of TdP with either the Ca2+ 
channel blocker verapamil, or the ???? blocker atenolol, led to less negative E-M 
windows.  In addition to these findings the disconnect between changes in the QT 
interval and the LV-pressure signal were illustrated when either heart rate or 
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temperature were altered. These data demonstrated, for the first time, the possibility 
of using the E-M window for the prediction of drug-induced TdP, and its advantages 
over looking at alterations in QT time alone. 
 
In Chapter 7 we extend the findings of van der Linde 23 to an anesthetized guinea-
pig model. Using a number of clinical-reference compounds with varying degrees of 
torsadogenic potential, we show that even though TdP was not induced in this 
model, the E-M window was able to discriminate compounds with known 
torsadogenic potential from compounds found to be safe, despite the fact that some 
of the latter agents alter repolarization times.  Due to the cardiac electrophysiology 
of the guinea pig, with its strong ‘repolarization reserve’ due to slow deactivation of 
IKs 24, 25, no TdP arrhythmias were actually seen in this study with one agent alone, 
and therefore a direct link between TdP and negative E-M windows could not be 
established. A more recent study 26, employing a strategy of a combined 
pharmacological assault, could however induce TdP arrhythmias in this model. This 
study illustrated that large negative E-M windows are a prerequisite for TdP induction 
in the anesthetized guinea pig. Taken together these findings are a first step in 
validation of this novel marker beyond the canine LQT1 model.  
 
Since the publication of van der Linde et al. 23, a number of groups have looked 
further into the E-M window, both in preclinical assays and also in its applicability to 
the clinical situation. Interesting work in isolated heart preparations illustrated that 
IKs inhibition can lead to a reduction in the E-M window in isolated minipig hearts 27. 
In addition, E-M windows remained more positive in mini-pig hearts than dog hearts, 
which may correlate with the resistance of the mini-pig heart to TdP arrhythmias. 
Finally, in dogs with chronic AV block from our own laboratory, preliminary 
experiments show that the E-M window is drastically reduced when compared to 
sinus-rhythm animals and this is further exaggerates before the induction of TdP 
(Figure 1). Further investigation of these changes is clearly warranted. 
 
  
Figure 1: Changes in the E-M window after remodeling due to chronic AV block, and in the 
same animal just before dofetilide-induced aftercontractions and TdP are seen.  
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Clinical data is also emerging that in patients with the congenital LQT syndrome, 
mean E-M windows were significantly more negative than in control patients (-60±59 
ms versus 4±27 ms) 22. In addition, patients that were symptomatic had even more 
negative E-M windows when compared with asymptomatic LQT patients (-75±68 ms 
versus -39±36 ms). 
 
It appears therefore that negative E-M windows can set the stage for arrhythmia 
under certain conditions. Although it is likely that it is not the negative E-M window 
per se that is arrhythmogenic, it is likely that a negative window (meaning a situation 
with a long mechanical diastole during prolonged electrical systole) allows for 
arrhythmogenic aftercontractions to occur, which may provide a substrate for TdP, 
as demonstrated by Gallacher et al. 8. Although the exact mechanisms linking 
negative E-M windows to arrhythmia generation are still unclear, they possibly 
involve a ‘window of opportunity’ for spontaneous SR Ca2+ release to occur             
in myocardium susceptible to Ca2+ overload, and/or the (re)activation of          
inward currents such as window ICaL, Na+-Ca2+ exchange (NCX) current or stretch-
activated currents. In this context, it will be interesting to ultimately determine 
whether aftercontractions are the consequence of spontaneous or Ca2+-induced Ca2+ 
release, and whether they activate inward mechano-sensitive currents to prolong 
repolarization further. With regard to the latter, a number of stretch-activated ion 
channels operate in the cardiac myocyte including INa 28. A recent study 29 
interestingly showed that ranolazine, a drug with antianginal and antiarrhythmic (via 
(late) INa) properties, also inhibits the mechanosensitivity of the Na+ channel. 
Whether this property plays a role in this ranolazine’s electropharmacological profile 
remains to be seen. Other stretch-activated channels are also operative in the 
cardiac myocyte 22.  
 
Further understanding of the presumed mechano-electrical feedback in TdP 
generation is crucial to establish novel antiarrhythmic strategies and for the 
development of safer medicinal compounds by pharmaceutical companies. 
 
8.3 Cellular Determinants of BVR 
 
One of the major themes of this PhD thesis is the investigation of the mechanistic 
basis of BVR and how alterations in this parameter may be arrhythmogenic, 
especially under conditions of sympathetic stimulation. BVR of the single myocyte 
most likely contributes to variability at the whole-heart level, although this is not the 
only governing factor 30, 31. 
 
Under normal conditions the sympathetic nervous system is involved in mediating the 
so-called ‘fight or flight’ response. Under conditions of physiological stress the activity 
of this system is increased, and amongst effects on other organ systems, leads to 
profound increases of the contractile and electrical function of the heart. The link 
between altered sympathetic tone and arrhythmogenesis has long been established. 
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For example, a study by Priori et al. 32 showed that electrical stimulation of the left 
stellate ganglion (part of the intrinsic sympathetic nervous system) led to the 
formation of delayed afterdepolarizations (DADs) in the LV of anesthetized cats (see 
also Volders (2010) 33 ). As BVR is an important marker of arrhythmia. It is important 
to improve insights into how sympathetic stimulation affects this marker, which may 
increase our understanding of the antiarrhythmic actions of beta blockers 34, 35 and 
left cardiac sympathetic denervation 36, 37. 
 
In Chapter 3 our initial findings in single myocytes show that when IKs is intact, 
sympathetic stimulation can rescue increased BVR induced by interventions that 
undermine ‘repolarization reserve’. It has been demonstrated that this reserve 
consists, at least partly, of ???-induced increases in IKs 38 - 40. Challenges to IKs may 
thus undermine the repolarization reserve. For instance, as shown in   Figure 2, the 
rescue of ATX-II-induced repolarization instability by isoproterenol (ISO) is 
undermined during IKs blockade with HMR1556. Taken together, these data highlight 
the role of IKs in repolarization reserve.    
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
 
 
 
Figure 2: Inhibition of IKs by HMR1556 rev??????????????????????? stimulation on ATX-II-
induced repolarization instability. 
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Furthermore, in Chapter 3 we show that when IKs is abolished pharmacologically 
and BVR increased ?????????????? ????? ??? stimulation, this was followed by the 
generation of both DADs and early afterdepolarizations (EADs). Interestingly, 
intracellular Ca2+ chelation with BAPTA or inhibition of the NCX current reduced the 
BVR increase that was observed under these conditions, indicating that Ca2+-
dependent currents were responsible. These studies were expanded in Chapter 4.  
In this chapter a combined experimental and computational approach was used to 
illustrate that increased BVR caused by the combination of IKs blockade and            
??? stimulation was largely due to interspersed action-potential prolongation due to 
the generation of presystolic DADs. We then went on to show that this phenomenon 
was caused by differences in Ca2+-dependent inactivation of the L-type Ca2+ current 
after presystolic spontaneous Ca2+ release. We showed that this interspersed action-
potential prolongation was also seen in an in-vivo canine model of LQT1, albeit on 
monophasic action potentials,  and this contributed to increased dispersion of 
repolarization, measured by Tpeak-Tend intervals, which may ultimately play a role in 
arrhythmogenesis.  
 
As BVR appears to be a better proarrhythmic marker than repolarization duration 
alone it is also important to understand the relationships between action-potential 
duration (APD) and BVR, because it may be hypothesized that when APD increases, 
BVR is also augmented. Figure 3 illustrates the relationships between these two 
parameters after different interventions. 
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Figure 3: Relationship of BVR and action potential duration (APD) under baseline conditions 
and after various interventions in single canine myocytes. Left panel, baseline conditions; 
Middle panel, after APD prolongation by either IKr blockade or late INa augmentation. Finally, 
the right panel indicates that after various interventions that alter cellular Ca2+ handling this 
relationship can be substantially altered. The red ‘cloud’ indicates cells that were exposed to 
IKs inhib?????? ????????? ????? ??? stimulation (where BVR values are higher than would be 
expected for the given APD). The blue ‘cloud’ indicates cells that were exposed to agents that 
reduce Ca2+ loading, for example BAPTA and ryanodine (after exposure to IKs inhibition and 
??? stimulation). Under these conditions BVR is lower than would be predicted from the APD 
values. 
 
As can be seen in Figure 3, under baseline conditions the relationship between APD 
and BVR appears to be linear (R2=0.55), with BVR increasing at the same pace as 
APD. However when various interventions are applied to cause excessive 
prolongation of APD, for example during IKr blockade, this relationship can be more 
reliably correlated with an exponential function (R2=0.72 for an exponential fit versus 
R2=0.67 for a linear fit). These data indicate that under ‘normal’ conditions, the 
major influence on BVR is indeed APD, however when APD prolongation becomes 
excessive, disproportionate increases in BVR can be seen. When interventions are 
applied that directly alter Ca2+ handling within the myocytes and cause spontaneous 
Ca2+ releases, for example after IKs ????????????? stimulation, this balance is altered, 
with high levels of BVR observed despite the fact that the average APD is relatively 
low. On the other hand, when Ca2+ releases are completely blocked, for example with 
ryanodine, the relationship is tipped in the other direction, with large APDs being 
seen with relatively low BVR. Interestingly, similar data have been accrued from cells 
isolated from dogs with CAVB. In these cells the exponential relationship that was 
seen between APD and BVR could be linearized by using high doses of caffeine to 
cause complete block of the ryanodine receptor (Antoons et al., personal 
communication).  
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Taken together, these data indicate that Ca2+ handling within the myocytes has a 
significant influence on alterations in BVR, and also suggest that there are 
possibilities to prolong APD without increasing BVR, should the correct balance be 
found. This has important implications for the proarrhythmic safety of medicinal 
compounds. 
 
Recent computer simulations of BVR (Heijman et al., PhD thesis, Maastricht 
University, 2012) also support the notion that BVR is not only driven by APD and that 
stochastic gating strongly contributes to BVR. In that study an adapted computer 
model was developed to include such stochastic channel gating. This was achieved 
by stimulating individual channels and considering the probability of state transition, 
or by including specific Langevin terms in differential equations of 13 major ion 
channels and transporters. One of the major findings of this study was that APD 
prolongation strongly increased BVR, but this was not the only determinant of the 
exaggerated BVR seen under various conditions.  
 
The results described in this PhD thesis also give important insights into other 
potential antiarrhythmic strategies. For example, an agent that can specifically 
prevent diastolic spontaneous Ca2+ release without affecting systolic Ca2+ release 
may have great utility under conditions of increased Ca2+ loading.  Such an agent 
would also preserve systolic function, conserving cardiac output.   
 
Altering Ca2+ handling has been found to reduce arrhythmic events in various 
models, including the CAVB dog, with a number of these indicating that reduced BVR 
plays an important role. In the CAVB dog model, the susceptibility to triggered 
arrhythmias has been related to a diminished repolarization reserve and to SR Ca2+ 
overload, due to electrical and structural remodeling 41 - 44. Verduyn et al. 45 showed 
that both flunarizine and ryanodine could prevent IKr-block-induced TdP. 
Furthermore, a recent study by Oros et al. 46 probed the antiarrhythmic mechanisms 
of flunarizine under these conditions and showed that this agent prevented 
dofetilide-induced TdP in these animals, which was also paralleled by BVR. This study 
went on to show that flunarizine decreased myocyte BVR and prevented the 
occurrence of EADs. In the same study, verapamil was also tested for its 
antiarrhythmic properties. Similarly to flunarizine, verapamil could prevent dofetilide-
induced TdP, but interestingly neither a decrease in QT times nor (monophasic) APD 
was seen with this agent, despite a reduction in BVR. These data further support the 
idea that under certain conditions the relationship between BVR and APD can be 
dissociated. Perhaps suprisingly, Stams et al. 47 has reported that K201, an agent 
that has been shown to reduce the amount of Ca2+ leak from the SR 48, and that is 
under development for the prevention of atrial fibrillation, could neither suppress nor 
prevent dofetilide-induced TdP in the CAVB model. In fact, in the study of Stams et 
al. 47, high doses of this agent alone led to drug-induced TdP, and this was 
accompanied by an increase in BVR.  
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These findings may suggest that prevention of Ca2+ leak may not reduce BVR, 
however K201 not only inhibits Ca2+ leak but also inhibits multiple other ion channels 
which may influence the potential antiarrhythmic properties of this agent. 
Furthermore this agent prevents Ca2+ leak via a very specific mechanism, 
(stabilization of the ryanodine receptor via inhibition of calstabin2) and perhaps this 
intervention alone is not enough to prevent spontaneous Ca2+ release.  Further 
studies in other models of TdP, such as in the LQT1 dog, may give some important 
insights into the reasons why this agent does not seem to have antiarrhythmic 
properties, despite its apparent favorable profile. 
 
Interestingly, a number of studies have shown the applicability of CAMKII inhibition 
for prevention of arrhythmogenic EADs 49, 50. Recently, Bourgonje et al. 51 showed an 
increase in CaMKII phosphorylation in the proarrhythmic CAVB-dog model and a 
reduction of dofetilide-induced TdP after CAMKII inhibition with either W7 or KN-93. 
Work contained within this thesis provides further evidence that the strategy of 
CAMKII inhibition may be an alternative avenue for antiarrhythmic therapy, although 
clinically-safe specific inhibitors are not yet available to investigate this potential 
pharmacological breakthrough. 
 
Altering NCX activity has also been proposed as an attractive antiarrhythmic target. 
Inhibiting forward mode NCX is a modulator of EADs, especially under conditions of 
Ca2+ overload. Our data support this notion and we have illustrated the utility of the 
NCX inhibitor SEA0400 in preventing excessive BVR in LQT1 stimulated myocytes 
(Chapter 3).  Recent studies have substantiated these data in different models. 
Bourgonje et al. 52 illustrated that SEA0400 is capable of reducing dofetilide-induced 
BVR (from 65 to 23 ms) despite prolonged APD in single myocytes isolated from 
CAVB dogs, as well as abolishing EADs. Similarly, in-vivo this compound abolished 
dofetilide-induced TdP dose-dependently in these CAVB animals. Milberg et al. 53 
have shown that SEA0400 reduced proarrhythmia in a rabbit model of heart failure, 
although interestingly in this study, as opposed to the CAVB study, reductions in APD 
were observed. Currently, there is no definite answer as to how this strategy will fair 
in patients, and further research is warranted. However, these data are promising. 
 
In the studies contained in this thesis, in which cellular BVR was assessed, only LV 
myocytes were used. Interestingly, at the whole heart level, at least in the CAVB 
dog, only LV BVR appeared to be predictive of arrhythmia formation 30. In Chapter 
5 of this thesis we show that there are specific regional differences in the response 
?????? stimulation in the LV versus the right ventricle (RV).  We demonstrate that 
there is an enhanced responsiveness of th?????????AR stimulation which results from 
higher cAMP elevation in the cytoplasm due to a decreased degradation by PDE3 and 
PDE4 in the RV compared to the LV. We also demonstr???? ????? ????? ?????? ??? 
stimulation the pressures in the RV are still much lower than those in the LV. It is 
well known that in-vivo the LV operates at much higher pressures than the RV. If we 
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align this with other findings in this thesis, namely that spontaneous Ca2+ releases 
are one of the mechanisms behind increased BVR, we could speculate that the 
increased total Ca2+ loading in the LV contributes significantly to BVR in this ventricle. 
In the study of Gallacher et al. 8 EADs only appeared on the LV MAP recordings at 
the endocardial surface, and not on the LV epicardium or in the RV, which 
corroborates results from canine LV-wedge studies reported by Katra and Laurita 54 
showing a predominant endocardial origin of triggered activity model of drug-induced 
LQT1 syndrome plus ISO. Previous studies have illustrated that both IKs and ITO are 
larger in the RV when compared to the LV 55, and therefore this inferior 
‘repolarization reserve’ in the LV may be a determinant of exaggerated BVR in the 
LV.  Investigation of how alterations of non-ionic targets, such as specific PDEs, 
change BVR and proarrhythmic outcomes is clearly needed.  
 
8.4 Implications for Cardiac Safety Pharmacology and Future Directions 
 
Although it is well-known that inhibition of IKr is not the only reason why drug-
induced TdP can occur, the ICH S7B guideline only recommends screening 
compounds against this ion channel, together with an in-vivo QT assay. In the work 
presented in this thesis we have shown, in agreement with previous studies 30, 56 that 
safe prolongation of repolarization is possible and that that increases in repolarization 
times alone do not necessarily lead to the occurrence of afterdepolarizations and 
proarrhythmia. In addition, we have further validated the utility of BVR as a 
proarrhythmic marker in vivo and have given further insights into the mechanisms 
involved in BVR and arrhythmia g??????????????????????????????????stimulation and 
the importance of IKs in preventing excessive BVR. Previous work has clearly shown 
that under normal conditions IKs has minimal effects on repolarization times under 
baseline conditions 38, 39, however its role becomes prominent during sympathetic 
stimulation or when repolarization is impaired by other factors (e.g., IKr blockade 57). 
Recently, it has also been shown that this current has antiarrhythmic properties in a 
rabbit model of ischemia/reperfusion 58. Towart et al., 59 have also shown that a 
number of compounds that were thought to be safe from the IKr screen and other in-
vitro action potential assays, were actually highly proarrhythmic due to the fact that 
they had potent activity against IKs, and for this reason it is proposed that screening 
against this ion channel should be carried out in the early stage of drug discovery. 
Therefore, it is clear that potential effects on IKs should also be considered when 
assessing the propensity of new chemical entities to cause arrhythmia. Data 
contained within this thesis further illustrate the need for such screening programs. 
 
These data also bring into question the reasoning that the proarrhythmic screening 
of new compounds occurs only under baseline, normal healthy conditions. For 
example, APD assessment in-vitro is nearly always carried out in tissue from healthy 
animals using physiological salt solutions, and in QT assessments healthy animals are 
used.  Contrary to this, the majority of pharmaceuticals are given to patients that are 
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not healthy, meaning that their response to the drug may be altered. In addition, a 
number of other factors will also influence the proarrhythmic potential of novel 
agents in the clinical situation, including genetic disposition (either with regards to 
drug metabolism or (silent) mutations in cardiac proteins) and drug-drug 
interactions. For example, pharmacokinetic interactions with drugs known to inhibit 
cytochrome P450 isoenzymes (among them CYP3A4 and CYP2D6) may enhance the 
torsadogenic potential of agents normally metabolized by these enzymes CYP3A4 
activity itself can be inhibited by a wide variety of drugs including some macrolide 
antibiotics, ketoconazole and related antifungals, cimetidine, protease inhibitors, and 
amiodarone. In addition, other factors, including age, smoking, hepatic disease, 
genetic polymorphisms and even grapefruit juice may lead to CYP3A4 inhibition. 
 
It is therefore essential to examine the proarrhythmic potential of chemical entities in 
disease models and also at supratherapeutic doses. In this thesis we demonstrate 
that the proarrhythmic potential of AZD1305 could be detected in a proarrhythmic 
model, despite appearing safe from various preclinical assays. This compound did 
indeed cause TdP arrhythmias in selected patients.  In addition to the use of 
proarrhythmic models for screening, consideration should also be given to testing 
compounds under altered physiological conditions, for example during sympathetic 
stimulation or conditions of altered electrolytes 60. Over recent years development of 
patient-specific human induced pluripotent stem cells (iPSCs) and human embryonic 
stem cell-derived cardiomyocytes  (hESC-CM) have been introduced as new 
paradigm for modeling human disease and for individualizing drug testing 61, 62. 
However, a recent study from Jonsson et al. 63 has shown that the hESC-CM system 
has a number of weaknesses with regards to their electrophysiological phenotype, 
and consequently their potential as a safety pharmacology model. Therefore, much 
work remains to be done to fully understand the usefulness of stem-cell technology 
in cardiac safety pharmacology, and it will only be when these milestones have been 
reached before such systems will be widely adopted by the community. 
 
In addition, we present a novel marker of proarrhythmia, the E-M window, in a small 
animal model, which appears to be another more reliable marker of TdP than QT 
prolongation alone. Interestingly the detection of adverse effects on cardiac 
contractility is also emerging in safety-pharmacology studies 64. Various publications 
have described in-vitro 65 and in-vivo models 66 - 68 for assessing cardiac contractile 
parameters for safety assessment and in a number of pharmaceutical companies 
telemetry studies recording LV pressures during drug administration are routinely 
carried out.  The integration of both electrical and mechanical recordings in one 
model has some clear advantages, including reducing the number of animal 
experiments required for drug development. Furthermore the integration of such 
parameters in a small animal model, may mean that these studies can be carried out 
at an earlier stage of drug discovery to ensure only the safest drug candidates are 
pursued.   
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Finally, in Chapter 4 of this thesis, a combined experimental and computational 
approach is applied. Recently the use of computer modeling in safety pharmacology 
has received increasing attention, especially in the context of cardiac action potential 
modeling. A number of action potential models are currently available and these 
models are amongst some of the most detailed models in systems biology 69.  A 
recent example of such an approach in the safety pharmacology arena came from 
Davies et al. 70, who developed an in-silico canine AP model to provide an 
assessment of the effect of a compound on the myocyte APD using concentration-
???????????????????????????????????????????????????????????????????????????????????????
traces from 19 various in-vitro cellular experiments, with various ion-channel 
conductances, meaning that some variability was introduced into the model. In this 
model differential responses were seen in the 19 different ‘cells’ potentially 
explaining some of the observed variation in reaction to drugs. This work is a first 
step in developing and integrating multiple models to represent variability that may 
occur in patient populations. A number of other approaches have also been applied 
to integrate computer modeling into cardiac safety studies 71 - 73. In this thesis 
computer modeling was used primarily to direct our experiments in the ‘wet 
laboratory’ and in addition it allows us to specifically analyze multiple parameters 
simultaneously (e.g., IKs, ICaL and Ca2+ transients) which is not currently possible in 
an experimental set-up. In addition modeling allows for specific targeting of proteins 
or ion channels, which, due to compound specificity issues, is not always the case in 
an experimental set-up.  Over the next decades computer modeling will play an 
increasing role in providing such important information.  
 
One of the major questions remaining is how much validation of a novel arrhythmia 
marker is required before it is adopted by regulatory agencies, and ultimately 
pharmaceutical companies. For example, in-vivo BVR was proposed as a marker for 
proarrhythmia back in 2004. However, at least to our knowledge, it has not been 
commonly adopted as a routine screening strategy. Whether this will also be the 
case for other proarrhythmic markers such as the E-M window remains to be seen. 
Also, the question is raised whether guidelines, such as the ICH S7B, need to be 
updated in the light of recent data such as those contained in this thesis. There is 
still a need for intense clinical investigation of the link between such markers and 
arrhythmogenesis, which may aid in decision-making. Recently a large multicentre 
clinical study has been commenced that will investigate current shortcomings in 
sudden cardiac death risk stratification and answer several related research 
questions, including the utility of BVR. The initial patient recruitment is underway and 
was expected to be completed by July 2012, with follow-up expected to end in 
September 2014 74. The results of this trial and consequent actions are highly 
anticipated.  
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Summary 
 
The major function of the heart is to continuously pump blood through the 
circulatory system of the entire body and hence careful regulation of this activity is 
essential. Synchronous pump function is driven by electrical signals, called action 
potentials.  Under normal conditions these signals are generated and regulated by 
pacemaker cells within the sinoatrial (SA) node, which is located within right atrium. 
These electrical signals then enter the base of the ventricle at the Bundle of His and 
then follow the left and right bundle branches along the interventricular septum. The 
bundle branches then divide into an extensive system of Purkinje fibers that conduct 
the impulses at high velocity throughout the ventricles. This results in rapid 
depolarization of ventricular myocytes throughout both ventricles. In mammalian 
ventricular myocytes the action potential consists of a prolonged plateau phase 
where calcium ions can enter the myocytes of the ventricle, this triggers calcium 
induced calcium release, a process essential for excitation-contraction coupling. The 
global electrical signal of the heart is reflected in the electrocardiogram, and various 
parameters can be extrapolated from this signal, including the QT time which is 
utilized as a measure of repolarization duration. 
 
The normal cardiac rhythm is very regular, with minimal fluctuation allowing for 
continual blood flow, however it can be altered to meet the oxygen demand   by 
nervous impulses or by circulatory substances, including the adrenergic agonist 
adrenaline. Under certain conditions however the rhythm of the heart can become 
irregular, too fast (tachycardia) or too slow (bradycardia), or the beats of the atria 
and ventricle become unsynchronized. These arrhythmias can be caused by a 
multitude of both extrinsic and intrinsic factors, including genetic mutations (for 
example Long QT1 syndrome, catecholaminergic polymorphic ventricular tachycardia 
(CPVT)), cardiomyopathies and can also be drug-induced. 
 
Over recent years drug-induced arrhythmias have received increased attention, in 
particular drug-induced Torsades de Pointes (TdP). This arrhythmia is a polymorphic 
ventricular tachycardia that can deteriorate into ventricular fibrillation and ultimately 
sudden cardiac death, and is normally seen in the context of a prolonged QT interval 
on the ECG. Although regulatory guidelines are in place to prevent compounds 
causing such arrhythmias getting to market, various pharmacological agents have 
been shown to cause this arrhythmia, and this has led to the withdrawal of a number 
of compounds. Currently prolongation of the QT interval and inhibition of one of the 
major ionic currents (IKr) are used as surrogate markers that a compound may cause 
TdP, however this strategy can still lead to both false negatives and false positives, a 
situation that is detrimental to drug development. 
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The major aim of this thesis was to further understand mechanisms involved in the 
generation of this deadly arrhythmia, leading to improved prediction and 
prevention of this potentially deadly arrhythmia. 
 
Chapter 1 is a general introduction, in which a background to cellular cardiac 
electrophysiology is given, as is an overview of the problem of drug-induced TdP and 
the current strategies for dealing with this issue at the preclinical stage of drug 
development. It is in this chapter where the concepts of beat-to-beat variability of 
repolarization (BVR) and the electro-mechanical (E-M) window are introduced. Finally 
in this chapter the aims and goals of the thesis are formulated. 
 
In Chapter 2 we describe in detail a number of protocols for assessing changes in 
action potential duration in canine ventricular myocytes utilizing both optical imaging 
and electrophysiological techniques.  We also present a protocol for assessing the 
occurrence of after-depolarizations and BVR at the level of the single cell. Both of 
these protocols can be utilized in cardiac safety pharmacology studies to predict the 
proarrhythmic potential of novel chemical entities and we illustrate how these 
protocols can reliably detect the electrophysiological effects of a number of reference 
compounds. 
 
In Chapter 3 we use one of the techniques described in Chapter 2 to investigate how 
BVR can manifest itself at the single cell level. In this chapter isolated myocytes were 
????????????????????????? ?????????????-????????????????????????????? ????????????Ks 
in the rescue of excessive increases in BVR following IKr blockade and augmented 
late INa. We show that both increases in action potential durations either by IKr 
blockade or augmentation of late INa leads to increased BVR, and these increases can 
?????????????????????????? ????ion, most likely due to the concomitant increase in 
IKs. In addition we illustrate that an increased BVR corresponds with an increased 
occurrence of afterdepolarizations, further illustrating the usefulness of this 
parameter in prediction of arrhythmia. Interestingly we also show that under 
conditions of IKs ???????????????????? ??????????? ???????????????????????????????????
exacerbated and this is also accompanied by the occurrence of afterdepolarizations. 
Both the increase in BVR and the afterdepolarizations can be abolished by chelation 
of intracellular calcium or by inhibition of the Sodium-Calcium exchanger current 
illustrating the possible utility of this strategy as a preventative antiarrhythmic 
treatment. 
 
In Chapter 4 we further develop the findings in Chapter 3 by investigating the 
specific mechanisms of BVR under conditions of IKs ????????? ???? ???? ??? ?????????
Using a variety of techniques we show that under these conditions spontaneous 
calcium releases (SCR) drive the increase in BVR by causing interspersed action 
potential prolongation. We illustrate that this is due to alterations in the inactivation 
of the L-type calcium channel after such calcium releases. A number of strategies, 
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including CAMKII inhibition and treatment with magnesium were able to significantly 
reduce BVR, and hence we propose a number of preventative strategies in this 
chapter.  These findings were extended beyond the single cell by investigating this 
phenomenon in both a whole animal model of LQT1 and in multicellular computer 
models. The findings shown in the single cell, also have relevance in both of these 
models, illustrating the fact that these data have significant translational value. 
These data also illustrate the fact that delayed afterdepolarizations caused by SCRs 
can not only initiate arrhythmogenesis by causing triggered activity, but also 
contribute by increasing the temporal and spatial dispersion of repolarization.  
 
Data included in Chapter 5 shows that there are specific regional differences in the 
response to ???? ??? ???????? in the left versus the right ventricle (RV). We 
demonstrate that there is an enhanced responsiveness of the RV to ????stimulation 
caused by higher cAMP elevation in the cytoplasm due to a decreased degradation 
by PDE3 and PDE4 in the RV compared to the LV. These data further illustrate 
interventricular differences which may be utilized to specifically intervene under 
various arrhythmic conditions. Further studies should concentrate on how this 
balance is altered under pathogenic conditions, which may aid in development of 
safer agents for prevention of arrhythmia 
 
In Chapter 6 we move from the single cell to the whole animal .The chronic AV block 
dog model has been used for a number of years as a proarrhythmic model  as in 
these animals structural and electrophysiological remodeling render these animals 
highly susceptible for TdP. In this chapter we use the novel multi ion channel blocker 
AZD1305 to further investigate the utility of BVR as a proarrhythmic marker in vivo. 
We show that AZD1305 has a lower proarrhythmic potential than the pure IKr blocker 
dofetilide in this model, despite both agents causing similar degrees of repolarization 
prolongation. Interestingly BVR of the left ventricular monophasic action potential 
was only increased after administration of dofetilide, further indicating the superiority 
of this proarrhythmic marker in prediction of TdP arrhythmia. Although AZD1305 
did cause TdP in a subset of animals, these data further illustrate that the approach 
of inhibition of multiple (inward and outward) currents holds great promise as a safe 
antiarrhythmic strategy. 
 
Chapter 7  investigates the utility of the E-M window as a predictive marker of TdP 
occurrence in a guinea pig model. The E-M window has recently been proposed as a 
novel marker for the prediction of TdP in a dog model of LQT1, and takes into 
account the temporal difference between then end of mechanical and electrical 
systole. We illustrate that when anaesthetized guinea pigs are challenged with 
agents that are known torsadogens, the E-M window becomes negative, with the 
electrical activity lasting longer than the mechanical activity. Interestingly when the 
electrical activity was ‘safely’ prolonged the E-M window did not become negative, 
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illustrating the fact that this surrogate marker is superior and is more robust than 
looking at repolarization duration alone.  
 
In the final chapter of this thesis, Chapter 8, the main findings of this thesis are 
discussed together with both their possible significance for both drug development 
(prediction) and novel antiarrhythmic strategies (prevention) of drug induced 
TdP. 
 
In conclusion the data provided within this thesis illustrates the importance of factors 
other than repolarization duration prolongation and the influence of ????stimulation 
and calcium handling in the manifestation of drug-induced arrhythmias. Insights are 
given into possible novel markers to improve the prediction of arrhythmia as well as 
possible antiarrhythmic mechanisms to prevent drug induced TdP. 
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Samenvatting 
 
De functie van het hart is hoofdzakelijk om continue bloed door het vatensysteem 
van het gehele lichaam te pompen, waarvoor een nauwkeurige regulatie noodzakelijk 
is. Gelijkmatig rondpompen wordt aangestuurd door elektrische signalen die 
actiepotentialen heten. Under normale omstandigheden ontstaan deze signalen 
iedere hartslag in pacemaker cellen in de sinusknoop, gelegen aan de bovenkant van 
de rechterboezem van het hart. Daarvandaan spreidt het elektrische signaal over de 
rechter- en linkerboezem voor een gesynchroniseerde contractie. Vervolgens komt 
het signaal via de atrioventrikulare knoop en de bundel van His in het 
interventrikulaire septum, waarvandaan het elektrische signaal vervolgens verder 
geleidt wordt door de linker en rechter bundeltakken. Hierna geleidt een complex 
netwerk van Purkinjevezels de elektrische impulsen met grote snelheid door de 
hartkamers voor een snelle en homogene depolarisatie van de hartspiermassa.       
Er bestaat een sterke hiërarchie voor de pacemakerfuncties in het hart, waarin 
meerdere delen van het hart de pacemakerfunctie kunnen overnemen als superieure 
pacemakers niet functioneren. Onder normale omstandigheden domineert de sino-
atriale pacemaker het hartritme. Globale elektrische activiteit in het hart wordt 
weergegeven in het elektrocardiogram of hartfilmpje (ECG), waarin diverse 
parameters kunnen worden gemeten, zoals de QT tijd, die dient als maat voor de 
activatie- of repolarisatieduur van de hartkamers. Op het niveau van de hartspiercel 
wordt het elektrische signaal gedragen door transmembrane actiepotentialen. Deze 
hebben een verlengde plateaufase gedurende welke calcium ionen de cel 
binnengaan, die vervolgens weer leidt tot calcium-geïnduceerde calcium vrijgave, 
een proces dat essentieel is voor excitatie-contractie koppeling. 
 
Het normale cardiale ritme is regelmatig, met slechts weinig fluctuatie, wat ervoor 
zorgt dat een continue bloedstroom mogelijk is. Indien nodig is het mogelijk het 
ritme aan te passen door middel van prikkels uit het autonome zenuwstelsel of door 
neurohumorale factoren zoals catecholamines, om aan een vergrote zuurstofvraag te 
kunnen voldoen. Onder bepaalde omstandigheden kan het hartritme onregelmatig 
worden: te snel (tachycardie), te traag (bradycardie), of de ritmes van boezems en 
kamers worden ontkoppeld. Deze ritmestoornissen kunnen door diverse ex- en 
intrinsieke factoren ontstaan, waaronder genetische mutaties (bijvoorbeeld het lange 
QT syndroom en catecholaminerge polymorfe ventriculaire tachycardie) en 
structurele cardiomyopathiën, maar ook als ongewenste bijwerking van bepaalde 
medicijnen. 
 
Gedurende een aantal jaren hebben deze laatstgenoemde ritmestoornissen steeds 
meer aandacht gekregen, met name medicijn-geïnduceerde torsades de pointes 
(TdP). TdP is een polymorfe tachycardie die kan eindigen in kamerfibrilleren en 
vervolgens plotse hartdood, die veelal samen gaat met een verlenging van de QT tijd 
op het ECG. Welke mechanismen leiden tot TdP ritmestoornissen is nog steeds niet 
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volledig bekend en ondanks dat er regels bestaan die moeten voorkomen dat stoffen 
op de markt komen die deze ritmestoornissen kunnen veroorzaken, hebben helaas 
diverse pharmacologische stoffen aantoonbaar geleid tot pro-aritmische bijwerkingen 
waarna een aantal van deze stoffen van de markt gehaald moesten worden. Een 
onvolledig begrip van deze ritmestoornis maakt dat de huidige indicatoren die TdP 
moeten voorspellen (QT verlenging en blokkade van een belangrijke ion stroom, IKr), 
zoals opgelegd door de regelgevende autoriteiten, verre van ideaal zijn, waaruit blijkt 
dat de voorspelling van TdP ritmestoornissen een van de grootste uitdagingen is voor 
de cardiale veiligheids farmacoloog. Daarom is het centrale doel in dit proefschrift 
dan ook om het mechanistische begrip van TdP uit te breiden, wat moet leiden tot 
een verbeterde voorspelling en het voorkomen van deze potentieel dodelijke 
ritmestoornis. 
 
Hoofdstuk 1  is de algemene introductie waarin een achtergrond wordt gegeven van 
cardiale cellulaire elektrofysiologie en een overzicht van het probleem van medicijn-
geïnduceerde TdP. Ook de huidige strategieën die bestaan bij het preklinische deel 
van medicijn ontwikkeling worden besproken. In dit hoofdstuk worden verder de 
concepten van slag-op-slag variabiliteit van repolarisatie (BVR) en het elektro-
mechanische (E-M) “window” geïntroduceerd. Ten slotte worden de doelen van dit 
proefschrift geformuleerd. 
 
In Hoofdstuk 2 beschrijven we gedetailleerde methoden om veranderingen in 
actiepotentiaal duur in kamercellen uit hondenharten te bestuderen met 
elektrofysiologische en optische beeldvorming technieken. We presenteren 
vervolgens een protocol waarmee het optreden van na-depolarisaties en de mate 
van BVR op het niveau van de geïsoleerde hartspiercel kan worden bepaald. Beide 
methoden kunnen bij cardiale veiligheids farmacologie studies gebruikt worden om 
het pro-aritmische potentiaal van nieuwe chemische stoffen te voorspellen op 
hartspiercel niveau en we tonen aan hoe deze protocollen de electrofysiologsiche 
effecten van een aantal referentie stoffen betrouwbaar detecteren. 
 
In de studies voor Hoofdstuk 3  hebben we onderzocht hoe BVR zich manifesteert in 
ventriculaire hartspiercellen uit honden, gedurende medicijn-geïnduceerd lange QT 
type 1, 2 en 3 omstandigheden. Geïsoleerde hartspiercellen werden gebruikt om het 
belang van ?-adrenerge receptor (?AR) stimulatie van IKs gedurende bij het 
terugbrengen van overmatige toename van BVR, ontstaan door IKr blokkade en late 
INa toename, aan te tonen. We tonen aan dat een toegenomen BVR overeenkomt 
met een toegenomen incidentie van vroege na-depolarisaties, wederom wijzend op 
de bruikbaarheid van deze parameter bij het voorspellen van ritmestoornissen. We 
tonen verder aan dat onder omstandigheden van IKs blokkade en ?AR stimulatie, 
zoals tijdens het lange QT fenotype, BVR is toegenomen en dat deze toename samen 
gaat met het optreden van na-depolarisaties. Zowel de toename in BVR als het 
optreden van na-depolarisaties kan ongedaan gemaakt worden door chelatie van 
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intracellulair calcium of door remming van de natrium-calcium “exchanger” stroom, 
duidend op hun potentiaal als preventieve antiaritmische strategieën. 
 
In Hoofdstuk 4 onderzoeken we specifieke mechanismen van BVR gedurende IKs 
blokkade en ?AR stimulatie verder. Met behulp van verscheidene technieken tonen 
we aan dat onder deze omstandigheden spontane calcium vrijgave (SCR) zorgen 
voor de toename in BVR door wisselende actiepotentiaal verlenging. We tonen aan 
dat dit wordt veroorzaakt door wisselingen in de inaktivering van het L-type calcium 
kanaal na SCR. Diverse behandelingen, waaronder CaMKII inhibitie en toediening 
van magnesium, verminderden BVR. Vandaar dat we een aantal preventieve 
strategieën voorstellen gebaseerd op de resultaten uit dit hoofdstuk. We trekken 
onze resultaten door van de geïsoleerde hartspiercel naar het diermodel van LQT1 en 
multicellulaire computermodellen. We tonen aan dat late na-depolarisaties, 
veroorzaakt door SCR, niet alleen aritmieën kunnen veroorzaken via getriggerde 
activiteit, maar ook door temporele en spatiële dispersie van repolarisatie te 
vergroten. 
 
Data uit Hoofdstuk 5  tonen aan dat er regionale verschillen bestaan in de respons 
op ?AR stimulatie in de linker (LV) en rechter (RV) hartkamer. Toegenomen 
gevoeligheid van de RV op ?AR stimulatie wordt veroorzaakt door een hogere cAMP 
concentratie in de myoplasma vanwege een toegenomen afbraak door PDE3 en 
PDE4 in de RV vergeleken met de LV. We tonen aan dat PDE3 en PDE4 ervoor 
zorgen dat cAMP gekompartimentaliseerd wordt waardoor locatie-specifieke 
verschillen tussen  de hartkamers ontstaan bij ?AR stimulatie. Aangezien BVR alleen 
voorspellend is voor aritmieën wanneer deze gemeten wordt in de LV, kan deze 
kompartimentalisatie hier gedeeltelijk mee te maken hebben. Verder onderzoek is 
essentieel om het begrip over de mogelijke relaties tussen PDE’s, cAMP signalen en 
BVR te vergroten. Verder kunnen toekomstige studies zich richten op hoe de ?AR 
respons in de hartspiercel en de onderliggende verschillen in PDE verdeling 
veranderd worden onder pathologische cardiale omstandigheden, wat kan bijdragen 
tot verbeterd begrip van elektrische remodelering en de ontwikkeling van veiligere 
anti-aritmische medicijnen. 
 
In Hoofdstuk 6 gaan we van de geïsoleerde cel naar het hele dier. Het hondenmodel 
met chronisch compleet atrioventriculair blok wordt al tientallen jaren gebruikt als 
pro-aritmisch model omdat deze dieren vanwege structurele en elektrische 
remodelering, zeer gevoelig zijn voor TdP. We gebruikten de nieuwe multi-kanaal 
blokker AZD1305 om de bruikbaarheid van BVR als pro-aritmische marker in vivo te 
onderzoeken. We tonen aan dat AZD1305 in dit model een lager pro-aritmisch 
potentiaal heeft dan de pure IKr blokker dofetilide, ondanks dat beide stoffen een 
vergelijkbare verlenging van repolarisatie laten zien. Het is interessant te zien dat 
BVR van de LV monofasische actiepotentiaal alleen verlengt na toediening van 
dofetilide en dat dit, samen met andere kenmerken, verder wijst op de superioriteit 
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van deze pro-aritmische marker bij het voorspellen van TdP ritmestoornissen. 
Ondanks dat AZD1305 leidde tot TdP in een subgroep, tonen deze data nog steeds 
aan dat het blokkeren van meerdere (in- en uitwaartse) ionstromen, veelbelovend is 
als antiaritmische strategie. 
 
In Hoofdstuk 7  beschrijven we het gebruik van de E-M window als voorspellende 
marker voor het optreden van TdP in een cavia model. De E-M window werd 
recentelijk voorgesteld als nieuwe marker voor het voorspellen van TdP in een 
hondenmodel van LQT1 en het houdt rekening met het temporele verschil tussen het 
einde van de mechanische en elektrische systole. We tonen aan dat wanneer 
geanestheseerde cavia’s worden blootgesteld aan bekende TdP opwekkers, de E-M 
window negatief wordt, waarbij de elektrische activiteit vaak (veel) langer duurt dan 
de mechanische activiteit. Opvallend is dat wanneer de elektrische activiteit “veilig” 
verlengt, de E-M window niet negatief wordt, hetgeen aantoont dat deze alternatieve 
marker beter en meer robuust is dan alleen repolarisatie duur. 
 
In het laatste hoofdstuk van dit proefschrift, Hoofdstuk 8, worden de voornaamste 
bevindingen uit dit proefschrift bediscussieerd, samen met hun mogelijke belang 
voor medicijn-ontwikkeling en veiligheids farmacologie (voorspelling) en nieuwe 
anti-aritmische strategieën (preventie) bij medicijn-geïnduceerde TdP. 
 
Concluderend geven de resultaten uit dit proefschrift het belang aan van factoren 
anders dan verlenging van repolarisatie, de invloed van ?AR stimulatie en calcium 
verwerking in het optreden van medicijn-geïnduceerde ritmestoornissen. Er wordt 
inzicht gegeven in mogelijke, nieuwe markers die verbeterde voorspelling van deze 
ritmestoornis mogelijk maken, alsmede in mogelijke anti-aritmische mechanismen die 
medicijn-geïnduceerde TdP kunnen voorkomen. 
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